,PageNo,Text
0,page_1,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Study Protocol', 'gsk', 'Sponsor:', 'GlaxoSmithKline Biologicals', ""Rue de l'institut 89,"", '1330 Rixensart, Belgium', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Date of protocol', 'Final Version 1: 02 March 2014', 'Date of protocol', 'Amendment 1 Final: 13 February 2017', 'amendment', 'Amendment 2 Final: 20 October 2017', 'Amendment 3 Final: 19 October 2018', 'Title', 'Occurrence of potential bacterial and viral pathogens', 'in stable chronic obstructive pulmonary disease', '(COPD) and during acute exacerbations of COPD', '(AECOPD), in Asia Pacific.', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'PPD', 'Co-ordinating author', 'Scientific Writer', ',', 'Contributing authors', 'PPD', ', Epidemiologist', 'PPD', 'Clinical Research and', 'Development Lead', 'PPD', 'Clinical Research', ',', 'and Development Lead', 'PPD', 'Senior Epidemiology Expert', 'PPD', 'Vaccine Development Leader', 'PPD', 'Biostatistician', 'PPD', 'Lead', 'statistician', 'PPD', 'Project', 'Delivery Lead', 'PPD', 'Study Delivery Lead', 'PPD', 'Study Delivery Manager,', '(External Consultant [Freelance]for GSK', 'Biologicals)', 'PPD', 'Senior', 'Manager, Oversight Data Management', '19-OCT-2018', '1', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
1,page_2,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Contributing authors', 'PPD', 'Study Data Manager', 'PPD', 'Vaccine Supply', 'Coordinator (CVO Europe, for GSK Biologicals)', 'PPD', 'Clinical Readout Team', 'Leader, Clinical Laboratory Sciences', 'PPD', 'Study Manager, GVCL', '(Business & Decision Life sciences, for GSK', 'Biologicals), PPD', 'Study Manager,', 'Clinical Laboratory Sciences', 'PPD', 'Global', 'Regulatory Lead and', 'PPD', 'Global', 'Regulatory Affairs representative', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'Clinical Safety Representatives', 'PPD', 'Expert Scientist, Clinical', 'Laboratory Sciences', 'PPD', 'Study Data Manager (Business &', 'Decision Life Sciences, for GSK Biologicals)', 'Dr. PPD', ', University of Sydney Head,', 'Respiratory Trials, Contributing author from The', 'George Institute for Global Health, Australia', ""GSK Biologicals' Protocol DS v15.0"", 'C 2014-2018 GSK group of companies or its licensor.', '19-OCT-2018', '2', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
2,page_3,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Protocol Amendment 3 Sponsor Signatory Approval', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Date of protocol amendment', 'Amendment 3 Final: 19 October 2018', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Sponsor signatory', 'Ashwani Kumar Arora', 'Clinical and Epidemiology Project Lead', 'Signature', 'Date', 'For internal use only', 'Checksum', '!Ver.!Created On -', '-', '15661ebdab2e949f7alflbc2071b9dec72aceccf2.0 10/25/2018 6:16:52 PM - -', '19-OCT-2018', '3', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
3,page_4,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Protocol Amendment 3 Rationale', 'Amendment number:', 'Amendment 3', 'Rationale/background for changes:', 'The protocol has been amended to implement the following changes:', 'Removal of all STGG (Skim Milk-Tryptone-Glucose-Glycerol) wording', 'throughout the protocol. STGG product not being available, it has been decided to', 'replace it with cryobeads for storage of bacterial isolates. PCR testing on samples', 'stored in cryobeads was shown to be as efficient as for samples stored in STGG.', 'Besides, this decision has been taken for alignment with other COPD studies,', 'where STGG solutions are no longer used.', 'Clarification of technique used for target identification. For the primary endpoint,', 'various viral pathogens will be identified but not quantified. Along this line, the', 'wording ""and by HRV quantitative RT-PCR"" has been removed from primary', 'endpoint to avoid confusion as HRV viral load data will be reported as part of the', 'tertiary endpoints.', 'Clarification in exclusion criteria section (4.3). Administration of antibiotics', 'before study entry, where study entry is meant to be Visit 1.', 'Clarification in study procedure section (6.3) and in the section for recording', 'current medication (6.4.2.10) during scheduled visits, where it has been specified', 'that recording of any current medication is applicable for any disease not only', 'COPD-related. Moreover, a footnote referring to Table 10 ""Reporting period for', 'SAE and AEs leading to withdrawal"" has been added for further clarification, both', 'in Table 4 and 5.', 'Addition of a section (actual 6.4.2.6) for Pregnancy test for Visit 1, Visit 2 and', 'Visit 3. A Pregnancy test section for Screening Visit was included during Protocol', 'Amendment 1: to be consistent, same wording has been included for the', 'subsequent visits.', 'Clarification of reporting of severe AECOPDs. Two sentences have been added in', 'sections 7.1.1 and 7.2.2.1 for making clear that severe AECOPD events are not to', 'be reported as SAE as they are meant as disease-related outcomes.', 'Rewording in the table concerning reporting period for SAE and AEs leading to', 'withdrawal for better clarification (Table 10).', 'Addition of a new outsourced laboratory (DDL).', 'To correct some typographical errors.', '19-OCT-2018', '4', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
4,page_5,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Protocol Amendment 3 Investigator Agreement', 'I agree:', 'To conduct the study in compliance with this protocol, any mutually agreed future', 'protocol amendments or protocol administrative changes, with the terms of the study', 'agreement and with any other study conduct procedures and/or study conduct', 'documents provided by GlaxoSmithKline (GSK) Biologicals.', 'To assume responsibility for the proper conduct of the study at this site.', ""That I am aware of, and will comply with, 'Good Clinical Practice' (GCP) or other"", 'applicable guidelines and all applicable regulatory requirements.', 'To ensure that all persons assisting me with the study are adequately informed about', 'study-related duties and functions as described in the protocol.', 'To acquire the reference ranges for laboratory tests performed locally and, if required', ""by local regulations, obtain the laboratory's current certification or Quality"", 'Assurance procedure manual.', 'To ensure that no samples (including serum samples) are retained onsite or elsewhere', 'without the approval of GSK Biologicals and the express written informed consent of', ""the subject and/or the subject's legally acceptable representative."", 'To perform no other biological assays on the samples except those described in the', 'protocol or its amendment(s).', 'To co-operate with a representative of GSK Biologicals in the monitoring process of', 'the study and in resolution of queries about the data.', 'That I have been informed that certain regulatory authorities require the sponsor to', ""obtain and supply, as necessary, details about the investigator's ownership interest in"", 'the sponsor, and more generally about his/her financial ties with the sponsor. GSK', 'Biologicals will use and disclose the information solely for the purpose of complying', 'with regulatory requirements.', 'Hence I:', 'Agree to supply GSK Biologicals with any necessary information regarding', 'ownership interest and financial ties (including those of my spouse and dependent', 'children).', 'Agree to promptly update this information if any relevant changes occur during the', 'course of the study and for one year following completion of the study.', 'Agree that GSK Biologicals may disclose any information it has about such', 'ownership interests and financial ties to regulatory authorities.', 'Agree to provide GSK Biologicals with an updated Curriculum Vitae and other', 'documents required by regulatory agencies for this study.', '19-OCT-2018', '5', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
5,page_6,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Date of protocol amendment', 'Amendment 3 Final: 19 October 2018', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Investigator name', 'Signature', 'Date', 'For internal use only', 'Checksum-', '!Ver.!Created On -', '-', '15661ebdab2e949f7alflbc2071b9dec72acecef2.0 10/25/2018 6:16:52 PM - -', '19-OCT-2018', '6', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
6,page_7,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Sponsor Information', 'Sponsor', 'GlaxoSmithKline Biologicals', ""Rue de l'Institut 89"", '1330 Rixensart, Belgium', 'Sponsor Medical Expert for the Study', 'Refer to the local study contact information document.', 'Sponsor Study Monitor', 'Refer to the local study contact information document.', 'Study Contact for Reporting of a Serious Adverse Event (SAE)', 'GSK Biologicals Central Back-up Study Contact for Reporting SAEs: refer to protocol', 'Section 7.3.2.', 'Study Contact for Reporting SAEs: refer to the local study contact information', 'document.', '19-OCT-2018', '7', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
7,page_8,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'SYNOPSIS', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort study to', 'assess the occurrence of potential bacterial and viral', 'pathogens in stable chronic obstructive pulmonary disease', '(COPD) and during acute exacerbations of COPD', '(AECOPD), in moderate to very severe COPD patients, in', 'Asia Pacific.', 'Objectives', 'Primary', 'To estimate the proportion of potential bacterial and viral', 'pathogens (overall and by species) detected in sputum of', 'stable COPD patients and during AECOPD, using', 'respectively bacteriological methods and viral PCR, over the', 'course of 1 year.', 'Secondary', 'To evaluate the concordance between PCR and', 'bacteriological methods data in sputum for potential', 'bacterial pathogens.', 'To estimate the proportion of potential bacterial and viral', 'pathogens (overall and by species) detected in sputum of', 'stable COPD patients, by GOLD grade.', 'To estimate the proportion of potential bacterial and viral', 'pathogens (overall and by species) detected in sputum', 'during AECOPD, by severity of AECOPD.', 'To estimate the incidence rate of all-cause AECOPD,', 'overall and by GOLD grade.', 'To describe the severity and duration of all-cause', 'AECOPD, overall and by GOLD grade.', 'To assess the impact of all-cause AECOPD on HRQOL.', 'To assess the impact of all-cause AECOPD on lung', 'function.', 'To assess the impact of all-cause AECOPD on healthcare', 'utilisation.', '19-OCT-2018', '8', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
8,page_9,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Tertiary', 'To assess the use of EXACT-PRO for determining the', 'end date of AECOPD.', 'To evaluate the load of bacterial and viral pathogens in', 'stable COPD and during AECOPD.', 'To collect biological specimens for future respiratory', 'disease-related testing:', '-', 'Aliquots of sputum samples for assay development', 'and microbiome analysis at stable visits and during', 'exacerbation.', '-', 'Blood sampling for potential', 'identification/quantification of biomarkers at Visit 1', 'and Visit 3.', 'Rationale for the', 'Because the infectious aetiology of AECOPD has been', 'study', 'suggested to vary according to geographical region, the', 'primary purpose of this study (which will be conducted in', 'several countries in Asia Pacific) is to evaluate the occurrence', 'of potential bacterial and viral pathogens in the sputum of', 'stable COPD patients and at the time of AECOPD. Given the', 'increasing and projected burden of COPD in the Asia Pacific', 'region, this study will also evaluate the frequency, severity', 'and duration of AECOPD, as well as the impact of AECOPD', 'on health-related quality of life (HRQOL), healthcare', 'utilisation and lung function.', 'In addition, both PCR and bacteriological methods will be', 'used for characterisation (quantification in some cases) of', 'bacteria in sputum. To date, identification of bacteria and', 'assessment of bacterial load is done in the vast majority of', 'cases by culture. However, the few studies that have', 'compared culture with PCR demonstrated that PCR is more', 'discriminatory at detecting typical airway bacteria [Curran,', '2007; Singh 2014]. Moreover, in a multi-centre study, PCR', 'has the advantage that it can be performed on stored sputum', 'samples, and can therefore be done centrally, whereas culture', 'has to be performed on fresh sputum samples, which can lead', 'to variable results due to variability in testing methods', 'between laboratories.', '19-OCT-2018', '9', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
9,page_10,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Study design', 'Type of design: Prospective, epidemiological,', 'interventional, multi-country, cohort study.', 'Study population: A stable cohort of approximately 200', 'moderate to very severe COPD patients with at least 1', 'documented moderate or severe AECOPD in the year', 'before enrolment.', 'Type of study: self-contained.', 'Data collection: Electronic Case Report Form (eCRF)', 'and electronic diary cards.', 'Primary completion Date: Visit 3 (Month 12). Refer to', 'glossary of terms for the definition of PCD.', 'End of Study (EoS): Last testing results released of', 'samples collected at Visit 3.', 'Duration of the study: The study will last approximately', '1 year for each subject.', 'Note: Screening visit should ideally occur not more than', '6 weeks before visit 1.', 'Epoch 001: Prospective data collection starting at', 'Screening Visit (Pre-Month 0) and ending at Visit 3', '(Month 12).', 'Synopsis Table 1', 'Study groups and epochs foreseen in the study', 'Number of', 'Epoch', 'Study Groups', 'Age (Min/Max)', 'subjects', 'Epoch 001', 'Prospective', 'Approx 200', '> 40 years', 'X', 'Discussion of study', 'The primary objective of this study is to prospectively', 'design', 'investigate the prevalence and distribution of bacteria and', 'viruses isolated from sputum samples from moderate to very', 'severe COPD patients and at the time of AECOPD, in Asian', 'populations. In order to increase the chance that the patients', 'will exacerbate during the study, only patients with a', 'documented history of at least 1 moderate or severe AECOPD', 'in the previous year will be recruited, as this is known to be', 'the best predictor of AECOPD [Hurst, 2010]. Therefore, this', 'study will permit an estimation of incidence of AECOPD in a', 'COPD population at increased risk of exacerbation. It will not', 'provide a true population-based incidence of AECOPD.', 'In order to study factors affecting disease progression in Asia', 'Pacific, prospective data from a relatively large cohort of', 'COPD patients is essential. The use of electronic Diary Cards', 'to detect changes in the respiratory symptoms that define an', 'AECOPD, the standardised questionnaires and spirometry', '19-OCT-2018', '10', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
10,page_11,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'assessments will allow robust conclusions to be drawn about', 'the effects of exacerbations on decline in lung function and', 'HRQOL.', 'EXACT PRO will be used to assess breathlessness, cough and', 'presence of sputum, chest symptoms, difficulty bringing up', 'sputum, feeling tired or weak, sleep disturbance, and feeling', 'scared or worried about their condition. Advantages to this', 'approach include standardised data, reduced recall bias, and', 'the potential to identify events and determine resolution based', 'on a predefined scoring algorithm [Leidy, 2011]. Standardised', 'questionnaires completed during study visits include the', 'SGRQ-C and the CAT. The SGRQ-C is designed to assess', 'HRQOL, current health and does not specify a recall period.', 'The CAT is a simple, short, patient-completed instrument', 'to', 'assess HRQOL and symptom burden in patients with COPD.', 'The CAT has good internal consistency and test-retest', 'reliability, correlates strongly with the SGRQ-C, and is able to', 'distinguish between stable patients and those undergoing an', 'AECOPD [Jones, 2012].', 'Number of subjects', 'The target is to enrol approximately 200 eligible moderate to', 'very severe COPD patients.', 'Enppoints', 'Primary (Amended on 19 October 2018)', 'Occurrence of potential bacterial and viral pathogens in', 'sputum of stable COPD patients and during AECOPD,', 'over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological', 'methods, including (but not necessarily limited to) H.', 'influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii.', '-', 'Viral pathogens, as identified by PCR, including (but', 'not necessarily limited to) RSV, parainfluenza virus,', 'enterovirus/HRV, metapneumovirus, influenza', 'virus, adenovirus, bocavirus and coronavirus.', '19-OCT-2018', '11', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
11,page_12,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Secondary', 'Occurrence of potential bacterial pathogens in sputum of', 'stable COPD patients and during AECOPD, as measured', 'by real-time qualitative PCR/ quantitative PCR and', 'compared to data from bacteriological methods, over the', 'course of 1 year:', '-', 'Including (but not necessarily limited to)', 'H. influenzae, M. catarrhalis, S. pneumoniae,', 'S. aureus and P. aeruginosa.', 'Occurrence of potential bacterial and viral pathogens', '(overall and by species) in sputum of stable COPD', 'patients by GOLD grade, over the course of 1 year.', 'Occurrence of potential bacterial and viral pathogens', '(overall and by species) in sputum during AECOPD by', 'severity of AECOPD, over the course of 1 year.', 'Incident rate (per subject per year) of AECOPD, overall', 'and by GOLD grade, over the course of 1 year.', 'Severity of AECOPD, overall and by GOLD grade, over', 'the course of 1 year.', 'Duration of AECOPD, overall and by AECOPD severity,', 'over the course of 1 year.', 'CAT score in stable COPD patients and during', 'AECOPD, over the course of 1 year.', 'SGRQ-C score in stable COPD patients, over the course', 'of 1 year.', 'FEV1% of predicted normal value in stable COPD', 'patients, at Pre-Month 0 and Month 12.', 'Healthcare utilisation, over the course of 1 year.', 'Tertiary', 'EXACT-PRO scores in stable COPD patients and during', 'AECOPD, over the course of 1 year.', 'Bacterial load measured by both culture and PCR in', 'COPD and during AECOPD.', 'HRV load measured by PCR in COPD and during', 'AECOPD.', '19-OCT-2018', '12', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
12,page_13,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'TABLE OF CONTENTS', 'PAGE', 'SPONSOR INFORMATION', '7', 'SYNOPSIS', '8', 'LIST OF ABBREVIATIONS (AMENDED 19 OCTOBER 2018)', '20', 'GLOSSARY OF TERMS', '22', 'TRADEMARKS', '26', '1. INTRODUCTION', '27', '1.1.', 'Background', '27', '1.2.', 'Rationale for the study', '30', '2. OBJECTIVES', '30', '2.1.', 'Primary objective', '30', '2.2.', 'Secondary objectives', '30', '2.3.', 'Tertiary objective(s)', '31', '3.', 'STUDY DESIGN OVERVIEW', '32', '3.1.', 'Discussion of study design', '34', '3.1.1.', 'Detection of AECOPD', '35', '3.1.1.1.', 'Date of onset and end date of AECOPD', '36', '3.1.1.2.', 'Guideline for assessing AECOPD that increase', 'in severity', '36', '4. STUDY POPULATION', '37', '4.1.', 'Number of subjects/ centres', '37', '4.1.1.', 'Recruitment of study centres', '37', '4.2.', 'Inclusion criteria for enrolment', '37', '4.3.', 'Exclusion criteria for enrolment (Amended 19 October 2018)', '38', '5.', 'CONDUCT OF THE STUDY', '40', '5.1.', 'Regulatory and ethical considerations, including the informed', 'consent process', '40', '6. DETAILED STUDY PROCEDURES (AMENDED 19 OCTOBER 2018)', '41', '6.1.', 'Subject identification', '41', '6.2.', 'General study aspects', '41', '6.3.', 'Outline of study procedures', '41', '6.4.', 'Detailed description of study procedures', '44', '6.4.1.', 'Procedures during the Screening Visit', '44', '6.4.1.1.', 'Informed consent', '44', '6.4.1.2.', 'Check inclusion and exclusion criteria', '44', '6.4.1.3.', 'Record demographic data', '44', '6.4.1.4.', 'Record medical history', '44', '6.4.1.5.', 'Record AECOPD history within the previous', 'year', '44', '19-OCT-2018', '13', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
13,page_14,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.1.6.', 'Smoking exposure history (ATS-DLD-78A', 'questionnaire)/biomass exposure history (At', 'screening visit only)', '44', '6.4.1.7.', 'Smoking status', '45', '6.4.1.8.', 'Physical examination', '45', '6.4.1.9.', 'Pregnancy test', '45', '6.4.1.10.', 'Measure/ record height and weight', '45', '6.4.1.11.', 'Pre- and post-bronchodilator spirometry', '45', '6.4.1.12.', 'Chest X-ray', '46', '6.4.1.13.', 'Train subjects on the use of electronic Diary', 'Card and assign electronic Diary Card to', 'subject', '46', '6.4.1.14.', 'Sputum sampling (Amended 19 October 2018)', '46', '6.4.1.15.', 'Recording of AE/SAEs', '47', '6.4.1.16.', 'Screening conclusion', '47', '6.4.2.', 'Procedures during Visit 1, Visit 2 and Visit 3', '47', '6.4.2.1.', 'Check inclusion and exclusion criteria', '47', '6.4.2.2.', 'Record intercurrent comorbidities', '47', '6.4.2.3.', 'Vaccination History', '47', '6.4.2.4.', 'Smoking status', '47', '6.4.2.5.', 'Physical examination', '47', '6.4.2.6.', 'Pregnancy test (Amended 19 October 2018)', '48', '6.4.2.7.', 'Measure/ record height and weight', '48', '6.4.2.8.', 'Pre- and post-bronchodilator spirometry', '48', '6.4.2.9.', ""Record subject's COPD status"", '48', '6.4.2.10.', 'Record current medication (Amended 19', 'October 2018)', '48', '6.4.2.11.', 'Record healthcare resource utilisation', '48', '6.4.2.12.', 'Additional treatments prescribed by primary', 'and secondary care physician', '49', '6.4.2.13.', 'Train subjects on the use of electronic Diary', 'Card and assign electronic Diary Card to', 'subject', '49', '6.4.2.14.', 'Return the electronic diary card', '49', '6.4.2.15.', 'Sputum sampling (Amended 19 October 2018)', '49', '6.4.2.16.', 'Blood Sampling', '50', '6.4.2.17.', 'HRQOL questionnaires', '50', '6.4.2.18.', 'Recording of AE/SAEs', '50', '6.4.2.19.', 'Study conclusion', '50', '6.4.3.', 'Procedures during AECOPD visit', '51', '6.4.3.1.', 'Record date of visit', '51', '6.4.3.2.', 'Physical examination', '51', '6.4.3.3.', 'Pregnancy Test', '51', '6.4.3.4.', 'Chest X-rays/pneumonia confirmation', '51', '6.4.3.5.', 'Confirm AECOPD and record start date', '52', '6.4.3.6.', 'Record current medication for AECOPD', '52', '6.4.3.7.', 'Record healthcare resource utilisation', '52', '6.4.3.8.', 'Additional COPD treatments prescribed by', 'primary and secondary care physician', '52', '6.4.3.9.', 'Sputum sampling (Amended 19 October 2018)', '52', '6.4.3.10.', 'HRQOL questionnaires', '53', '19-OCT-2018', '14', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
14,page_15,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.3.11. Record AECOPD severity and AECOPD end', 'date', '53', '6.4.3.12.', 'Recording of AE/SAEs', '53', '6.4.4.', 'Sampling', '53', '6.4.4.1.', 'Sputum Sampling', '53', '6.4.4.2.', 'Blood Sampling', '54', '6.4.5.', 'Health Related Quality of Life questionnaires', '54', '6.4.6.', 'Recording of AEs/SAEs', '54', '6.4.7.', 'Study conclusion', '54', '6.5.', 'Biological sample handling and analysis', '54', '6.5.1.', 'Use of specified study materials', '55', '6.5.2.', 'Biological samples', '55', '6.5.3.', 'Laboratory assays (Amended 19 October 2018)', '56', '7. SAFETY', '59', '7.1.', 'Safety definitions', '59', '7.1.1.', 'Definition of an adverse event (Amended 19 October', '2018)', '59', '7.1.2.', 'Definition of a serious adverse event', '59', '7.1.3.', 'Clinical laboratory parameters and other abnormal', 'assessments qualifying as AEs or SAEs', '60', '7.2.', 'Detecting and recording AEs, SAEs', '61', '7.2.1.', 'Time periods for detecting and recording AEs and SAEs', '61', '7.2.2.', 'Evaluation of SAEs (Amended 19 October 2018)', '62', '7.2.2.1.', 'Active questioning to detect SAEs', '62', '7.2.2.2.', 'Assessment of causality', '62', '7.2.2.3.', 'Assessment of outcomes', '63', '7.3.', 'Reporting of SAEs', '63', '7.3.1.', 'Prompt reporting of SAEs related to study participation to', 'GSK', '63', '7.3.2.', 'Contact information for reporting SAEs to GSK', '63', '7.3.3.', 'Completion and transmission of SAEs reports related to', 'study participation to GSK', '64', '7.3.3.1.', 'Back-up system in case the electronic reporting', 'system does not work', '64', '7.3.4.', ""Updating of SAE after freezing of the subject's eCRF"", '64', '7.3.5.', 'Regulatory reporting requirements for SAEs', '64', '7.4.', 'Treatment of AEs', '65', '8.', 'SUBJECT COMPLETION AND WITHDRAWAL', '65', '8.1.', 'Subject completion', '65', '8.2.', 'Subject withdrawal', '65', '9.', 'STATISTICAL METHODS', '66', '9.1.', 'Endpoints', '66', '9.1.1.', 'Primary endpoint (Amended 19 October 2018)', '66', '9.1.2.', 'Secondary endpoints', '66', '9.1.3.', 'Tertiary endpoints', '67', '9.2.', 'Determination of sample size', '67', '9.3.', 'Cohorts for Analyses', '68', '9.3.1.', 'All screened Set', '68', '9.3.2.', 'All Enrolled Set', '68', '19-OCT-2018', '15', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
15,page_16,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '9.3.3.', 'Full Analysis Set', '69', '9.4.', 'Analysis of demographics', '69', '9.5.', 'Analysis of primary objective', '69', '9.6.', 'Analysis of secondary objectives', '70', '9.7.', 'Analysis of tertiary objectives', '71', '9.8.', 'Conduct of analyses', '71', '9.8.1.', 'Sequence of analyses', '71', '9.8.2.', 'Statistical considerations for interim analyses', '71', '10. ADMINISTRATIVE MATTERS', '72', '10.1.', 'Electronic Case Report Form instructions', '72', '10.2.', 'Study monitoring by GSK Biologicals', '72', '10.3.', 'Record retention', '73', '10.4.', 'Quality assurance', '73', '10.5.', 'Posting of information on publicly available registers and publication', 'policy', '74', '10.6.', 'Provision of study results to investigators', '74', '10.7.', 'Data Sharing', '74', '11. COUNTRY SPECIFIC REQUIREMENTS', '74', '12. REFERENCES', '75', '19-OCT-2018', '16', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
16,page_17,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF TABLES', 'PAGE', 'Table 1', 'Classification of severity of airflow limitation in COPD (based on', 'post-bronchodilator FEV1)', '27', 'Table 2', 'Classification of severity of AECOPD', '29', 'Table 3', 'Study groups and epochs foreseen in the study', '33', 'Table 4', 'List of study procedures for scheduled visits', '41', 'Table 5', 'List of study procedures for AECOPD visits', '43', 'Table 6', 'Intervals between study visits', '43', 'Table 7', 'Biological samples', '55', 'Table 8', 'Microbiology', '57', 'Table 9', 'Planned assays on serological samples', '58', 'Table 10', 'Reporting period for SAE and AEs leading to withdrawal', '(Amended 19 October 2018)', '61', 'Table 11', 'Timeframes for submitting SAEs related to study participation to', 'GSK', '63', 'Table 12', 'Exact 95% confidence intervals of the percentage of occurrence', 'of a specific bacterium from sputum collected during AECOPD', '67', 'Table 13', '95% confidence intervals of AECOPD incidence rates with', 'different overdispersion values', '68', 'Table 14', ""GSK Biologicals' laboratories"", '78', 'Table 15', 'Outsourced Laboratories', '78', '19-OCT-2018', '17', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
17,page_18,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF FIGURES', 'PAGE', 'Figure 1', 'The refined ABCD assessment tool', '27', 'Figure 2', 'Study design overview', '32', '19-OCT-2018', '18', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
18,page_19,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF APPENDICES', 'PAGE', 'APPENDIX A CLINICAL LABORATORIES (Amended 19 October 2018)', '78', 'APPENDIX B AMENDMENT TO THE PROTOCOL', '79', '19-OCT-2018', '19', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
19,page_20,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF ABBREVIATIONS (Amended 19 October 2018)', 'A. baumannii', 'Acinetobacter baumannii', 'AE', 'Adverse Event', 'AECOPD', 'Acute exacerbation of COPD', 'ATS-DLD-78A', 'American Thoracic Society-Division of Lung Diseases-', '78A', 'CAT', 'COPD assessment test', 'CI', 'Confidence Interval', 'CLS', 'Clinical Laboratory Sciences', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'DTT', 'Dithiothreitol', 'eCRF', 'electronic Case Report Form', 'EoS', 'End of Study', 'ER', 'Emergency Room', 'EXACT-PRO', 'Exacerbations of Chronic Pulmonary Disease Tool -', 'Patient Reported Outcome', 'FAS', 'Full Analysis Set', 'FEV1', 'Forced expiratory volume in 1 second', 'FVC', 'Forced vital capacity', 'GCP', 'Good clinical practice', 'GOLD', 'Global Initiative for Chronic Obstructive Lung Disease', 'GP', 'General Practitioner', 'GSK', 'GlaxoSmithKline', 'H. influenzae', 'Haemophilus influenzae', 'HRQOL', 'Health-related quality of life', 'HRV', 'Human Rhinovirus', '19-OCT-2018', '20', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
20,page_21,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'ICD', 'International Classification of Diseases', 'ICF', 'Informed Consent Form', 'ICH', 'International Conference on Harmonisation', 'IEC', 'Independent Ethics Committee', 'IRB', 'Institutional Review Board', 'K. pneumoniae', 'Klebsiella pneumoniae', 'LAR', 'Legally Acceptable Representative', 'M. catarrhalis', 'Moraxella catarrhalis', 'OTC', 'Over-the-counter', 'P. aeruginosa', 'Pseudomonas aeruginosa', 'PCD', 'Primary Completion Date', 'PCR', 'Polymerase chain reaction', 'RSV', 'Respiratory syncytial virus', 'RT-PCR', 'Reverse transcription polymerase chain reaction', 'S. aureus', 'Staphylococcus aureus', 'S. pneumoniae', 'Streptococcus pneumoniae', 'SAE', 'Serious Adverse Event', 'SGRQ-C', ""St. George's Respiratory Questionnaire for COPD"", 'patients', 'SPM', 'Study Procedures Manual', 'USA', 'United States of America', '19-OCT-2018', '21', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
21,page_22,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'GLOSSARY OF TERMS', 'Adverse event:', 'Any untoward medical occurrence in a subject,', 'temporally associated with the use of a medicinal product,', 'whether or not considered related to the medicinal', 'product, or temporally associated with a study procedure.', 'An adverse event (AE) can therefore be any unfavourable', 'and unintended sign (including an abnormal laboratory', 'finding), symptom, or disease (new or exacerbated)', 'temporally associated with the use of a medicinal product.', 'For marketed medicinal products, this also includes', 'failure to produce expected benefits (i.e., lack of', 'efficacy), abuse or misuse.', 'Anonymised data:', 'Information about an individual that GSK or a third party', 'cannot reasonably attribute to the individual, or could', 'only attribute to the individual by expending a', 'disproportionate amount of time, effort or expense (e.g.', 'de-identified or aggregated information). For the purpose', 'of this policy, Key-Coded personally identifiable', 'information shall not be considered Anonymised', 'Information', 'Current smoker', 'A person who is currently smoking or who stopped', 'smoking within the past 6 months.', 'Cohort study:', 'A form of epidemiological study where subjects in a', 'study population are classified according to their', 'exposure status/disease and followed over time', 'prospective/ retrospective) to ascertain the outcome(s).', 'Eligible:', 'Qualified for enrolment into the study based upon strict', 'adherence to inclusion/exclusion criteria.', 'Epidemiological study:', 'An observational or interventional study without', 'administration of medicinal product(s) as described in a', 'research protocol.', '19-OCT-2018', '22', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
22,page_23,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'End of Study', 'For studies without collection of human biologicals', 'samples or imaging data EoS is the Last Subject Last', '(Synonym of End of', 'Visit (LSLV).', 'Trial)', 'For studies with collection of Human Biologicals', 'Samples or imaging data, EoS is defined as the date of the', 'last testing/reading released of the Human Biological', 'Samples or imaging data, related to primary and', 'secondary endpoints. EoS must be achieved no later than', '8 months after LSLV.', 'Epoch:', 'An epoch is a set of consecutive timepoints or a single', 'timepoint from a single protocol. Epochs are defined to', 'support a main purpose which either to draw conclusions', 'on subject participation or to draw a complete conclusion', 'to define or precise the targeted label of the product.', 'Supporting means that data collected at the timepoints', 'included in an epoch must be sufficient to fulfil the', 'purpose of the epoch.', 'Typical examples of epochs are screening', 'immunogenicity follow-up, safety follow-up, ESFU,', 'follow-up.', 'eTrack:', ""GSK Biologicals' tracking tool for clinical/"", 'epidemiological trials.', 'Evaluable:', 'Meeting all eligibility criteria, complying with the', 'procedures defined in the protocol (see Section 9.3 for', 'details on criteria for evaluability).', 'Former smoker', 'A person who stopped smoking for at least 6 months.', 'GOLD grade:', 'The spirometric classification of airflow limitation in', '(classification of severity', 'COPD patients is based on post-bronchodilator FEV1 and', 'of airflow limitation in', 'can be divided into four GOLD grades [GOLD, 2013]:', 'COPD patients)', 'GOLD grade', 'In patients with FEV1 FVC < 0.70:', 'GOLD 1: Mild', 'FEV1 80% predicted', 'GOLD 2: Moderate', '50% FEV1 < 80% predicted', 'GOLD 3: Severe', '30% FEV1 < 50% predicted', 'GOLD 4: Very Severe', 'FEV1 < 30% predicted', '19-OCT-2018', '23', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
23,page_24,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Interventional Human', 'Studies in which participants are administered medical', 'Subject Research:', 'care, medicinal products and/or medical/scientific', 'procedures as described in a research protocol.', 'Non-interventional', 'Studies where medicinal products, should they be', '(observational) Human', 'administered, are prescribed in normal (routine) medical', 'Subject Research:', 'practice. No medical care or medical/scientific procedures', 'as required in a research protocol are administered to', 'participants except as part of routine medical care.', 'Pack-years of smoking:', 'Pack-years is a quantification of cigarette smoking, a way', 'to measure the total amount a person has smoked in the', 'course of his/her lifetime. The number of pack-years is', 'calculated as follows:', '(average number of cigarettes smoked per day X', 'number of years smoked)/20', 'E.g. a smoking history of 10 pack-years means having', 'smoked 20 cigarettes per day for 10 years, or having', 'smoked 10 cigarettes per day for 20 years.', 'Note: For the purpose of this study, pipe and/or cigar use', 'should not be used to calculate pack year history.', 'Research protocol:', 'A document that describes the objective(s), design,', 'methodology, statistical considerations, and organisation', 'of a study. The protocol usually also gives the', 'background and rationale for the study, but these could be', 'provided in other protocol referenced documents.', 'Prospective study:', 'A study in which the subjects/cases are identified and', 'then followed forward in time in order to address one or', 'more study objectives.', 'Protocol amendment:', 'The International Conference on Harmonisation (ICH)', 'defines a protocol amendment as: ""A written description', 'of a change(s) to or formal clarification of a protocol.', 'GSK Biologicals further details this to include a change', 'to an approved protocol that affects the safety of subjects,', 'scope of the investigation, study design, or scientific', 'integrity of the study.', 'Primary completion', 'The date that the final subject was examined or received', 'date:', 'an intervention for the purpose of final collection of data', 'for all primary outcomes, whether the clinical trial/', 'pharmaco-epidemiological study was concluded', 'according to the pre-specified protocol or was terminated.', '19-OCT-2018', '24', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
24,page_25,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Self-contained study:', 'Study with objectives not linked to the data of another', 'study.', 'Site Monitor:', 'An individual assigned by the sponsor who is responsible', 'for assuring the proper conduct of epidemiological studies', 'at one or more investigational sites.', 'Study population:', 'Sample of population of interest.', 'Subject:', 'Term used throughout the protocol to denote an', 'individual who has been contacted in order to participate', 'or participates in the epidemiological study or a person', 'about whom some medical information has been recorded', 'in a database.', 'Subject number:', 'A unique number identifying a subject, assigned to each', 'subject consenting to participate in the study.', '19-OCT-2018', '25', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
25,page_26,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'TRADEMARKS', 'The following trademarks are used in the present protocol.', 'Trademarks of the GSK group of', 'Generic description', 'companies', 'COPD Assessment test (CAT)', 'Questionnaire to measure the impact of', 'COPD on wellbeing and daily life', 'EXACT-PRO', 'Exacerbations of Chronic Pulmonary', 'Disease Tool - Patient Reported Outcome', 'SGRQ-C', ""St. George's Respiratory Questionnaire for"", 'COPD patients', '19-OCT-2018', '26', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
26,page_27,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '1.', 'INTRODUCTION', '1.1.', 'Background', 'Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable', 'disease characterised by persistent airflow obstruction which is not fully reversible and', 'which is usually progressive in the long term. The classification of COPD severity is', ""done based on the patient's spirometric classification according to [GOLD, 2013]. The"", 'airflow limitation in COPD patients can be classified into GOLD grades as shown in', 'Table 1 [GOLD, 2013]. In this study, additional parameters are going to be collected in', 'order to allow for a combined assessment that could be used for future evaluation, as', 'detailed in Figure 1 [GOLD,', '2017].', 'Table 1', 'Classification of severity of airflow limitation in COPD (based on', 'post-bronchodilator FEV1)', 'GOLD grade', 'In patients with FEV1/ FVC < 0.70:', 'GOLD 1: Mild', 'FEV1 80% predicted', 'GOLD 2: Moderate', '50% FEV1 < 80% predicted', 'GOLD 3: Severe', '30% FEV1 < 50% predicted', 'GOLD 4: Very Severe', 'FEV1 < 30% predicted', 'GOLD = Global Initiative for Chronic Obstructive Lung Disease; FEV1 = forced expiratory volume in 1 second;', 'FVC = forced vital capacity', 'Figure 1', 'The refined ABCD assessment tool', 'Spirometrically', 'Assessment of', 'Assessment of', 'confirmed', 'symptoms/risk of', 'airflow limitation', 'diagnosis', 'exacerbations', 'Exacerbation', 'history', 'FEV,', '2', '(% predicted)', 'or', 'Post-bronchodilator', 'GOLD 1', '80', '1 leading', 'c', 'D', 'FEV,/FVC < 0.7', 'to hospital', 'GOLD 2', '50-79', 'admission', 'GOLD 3', '30-49', '0 or 1', 'GOLD 4', '< 30', '(not leading', 'to hospital', 'A', 'B', 'admission)', 'mMRC 0-1', 'mMRC 2', 'CAT < 10', 'CAT 10', 'Symptoms', 'GOLD = Global Initiative for Chronic Obstructive Lung Disease; CAT = COPD assessment test; FEV1 = forced', 'expiratory volume in 1 second; FVC = forced vital capacity; mMRC = Modified British Medical Research Council', 'Questionnaire', '19-OCT-2018', '27', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
27,page_28,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'In addition to the airflow limitation, number of exacerbation per year and number of', 'hospitalizations per year and CAT score will be collected at the enrollment in order to', 'allow for the classification according to the [GOLD, 2017]:', 'Patient Group A - Low Risk, Less Symptoms Typically GOLD 1 or GOLD 2 (Mild', 'or Moderate airflow limitation); and/or 0-1 exacerbation per year and no', 'hospitalization for exacerbation; and CAT score < 10 or mMRC grade 0-1', 'Patient Group B - Low Risk, More Symptoms Typically GOLD 1 or GOLD 2 (Mild', 'or Moderate airflow limitation); and/or 0-1 exacerbation per year and no', 'hospitalization for exacerbation; and CAT score > 10 or mMRC grade > 2', 'Patient Group C - High Risk, Less Symptoms Typically GOLD 3 or GOLD 4', '(Severe or Very Severe airflow limitation); and/or > 2 exacerbations per year or', '>', '1', 'with hospitalization for exacerbation; and CAT score < 10 or mMRC grade 0-1', 'Patient Group D - High Risk, More Symptoms Typically GOLD 3 or GOLD 4', '(Severe or Very Severe airflow limitation); and/or > 2 exacerbations per year or >', '1', 'with hospitalization for exacerbation; and CAT score > 10 or mMRC grade > 2.', 'The airflow limitation in COPD is associated with an enhanced and chronic inflammatory', 'response to noxious particles and gases in the airways and the lungs [Hogg, 2004]. The', 'most important environmental risk factor for COPD is tobacco smoking. However,', 'long-term exposure to traffic pollution and biomass smoke are also important', 'contributors. Indoor air pollution (generated largely by inefficient and poorly ventilated', 'stoves burning biomass fuels such as wood, crop waste and dung, or coal) for instance', 'accounts for the high prevalence of COPD among non-smoking women in parts of the', 'Middle East, Africa and Asia [WHO, 2013].', 'COPD is the fifth leading cause of mortality worldwide, accounting for 6% of all deaths', 'globally [WHO, 2015]. A recent study reported high overall morbidity and mortality rates', 'due to COPD in the Asia Pacific region. The prevalence of moderate to severe COPD in', 'adults aged 30 years or above was estimated to be 5.9% in South Korea, 5.4% in Taiwan,', '4.7% in Australia and 3.5% in Hong Kong [Tan, 2009]. The overall estimated prevalence', 'COPD in Asia-Pacific was estimated to be 6.2% with 19.1% having severe COPD [Lim,', '2015]. The prevalence and burden of COPD are projected to continue to increase in the', 'coming decades due to continued exposure to risk factors and the changing age structure', ""of the world's population [Mathers, 2006]. In Asia, urbanisation is expected to play a"", 'major role in the increase of the number of prevalent cases of COPD between 2010 and', '2020 [Tan, 2009]. In terms of the number of deaths, the burden of disease is higher in the', 'Asia-Pacific region when compared to the industrialised western countries. It was', 'estimated through mathematical modelling that 56.6 million people aged > 30 years had', 'moderate to severe COPD with a prevalence rate of 6.3% [Ko, 2008].', 'The morbidity and mortality of COPD is substantially contributed to by acute', 'exacerbations of COPD (AECOPD). An AECOPD is defined as ""a clinical diagnosis of', 'exclusion, made when a patient with COPD experiences an acute worsening in', 'respiratory symptoms (typically dyspnoea, cough, sputum quantity and/or sputum', 'purulence), and in whom no alternative specific cause for that deterioration has been', '19-OCT-2018', '28', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
28,page_29,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'identified by clinical examination and/or corroborative testing. The worsening in', 'respiratory symptoms may or may not warrant a change in underlying therapy and the', 'symptoms will typically resolve over a period of days to weeks"" [ERS/ATS Draft Task', 'Force Recommendations, Major Symposium, ERS Scientific Congress Barcelona 2013].', 'AECOPD are often associated with concurrent deteriorations in pulmonary function and', 'increases in both local and systemic inflammation. Higher exacerbation rates have been', 'related to a faster decline in lung function and are known to have a negative effect on the', ""patient's quality of life. Moreover, frequent exacerbations are associated with significant"", 'mortality, particularly if they require hospitalisation. Between 40 - 60% of medical', 'expenditure for COPD is a direct consequence of AECOPD [Cazzola, 2008]. The severity', 'of AECOPD can be graded according to the intensity of medical intervention required', '(see Table 2) [Wedzicha, 2007].', 'Table 2', 'Classification of severity of AECOPD', 'Grade', 'Intensity of medical intervention', 'Mild', 'Controlled with an increase in dosage of regular medications', 'Moderate', 'Requires treatment with systemic corticosteroids and/ or antibiotics', 'Severe', 'Requires hospitalisation', 'Bacteria, viruses and environmental pollution are also thought to be important causes of', 'AECOPD [Sapey, 2006]:', 'The lungs are not sterile and are known to be colonised with different strains of', 'bacteria [Charlson, 2011; Erb-Downward, 2011; Mons√≥, 1995]. It has been', 'suggested that the bronchial bacterial load increases during AECOPD [Miravitlles,', '2002; Wilkinson, 2006]. Based on a recent literature review, the most frequent', 'bacterial pathogens identified during AECOPD in European countries and in the', 'USA were Haemophilus influenzae (H. influenzae), Streptococcus pneumoniae', '(S. pneumoniae), Moraxella catarrhalis (M. catarrhalis), Pseudomonas aeruginosa', '(P. aeruginosa) and Staphylococcus aureus (S. aureus) [Mapi Research Trust-', 'literature review for GlaxoSmithKline (GSK) Biologicals]. However, it has been', 'suggested that the infectious aetiology of AECOPD can vary according to', 'geographical region. In Asia, a rise in infections caused by P. aeruginosa and the', 'Gram-negatives Klebsiella pneumoniae (K. pneumoniae) and Acinetobacter', 'baumannii (A. baumannii) has been reported in several countries [Hui, 2011; Ye,', '2013]. In addition, the infectious aetiology of AECOPD has also been suggested to', 'vary according to the severity of the illness, with P. aeruginosa being particularly', 'common in patients with advanced disease [Domenech, 2013; Ko, 2007].', 'The most commonly detected viruses during AECOPD are Human Rhinoviruses', '(HRV), RSV, coronaviruses, influenza, parainfluenza and adenoviruses [De Serres,', '2009; Sapey, 2006]. It has also been shown that viruses can be present in the airways', 'of stable COPD patients, suggesting that some respiratory viruses may cause', 'persistent low-grade infection contributing to the pathogenesis of disease [Mohan,', '2010].', 'Mixed bacterial and viral co-infections occur in 8-58% of exacerbations [De Serres,', '2009; Hutchinson, 2007; Papi, 2006; Perotin, 2013; Wilkinson, 2006].', '19-OCT-2018', '29', '75661ebdab2e949f7a1f1bc2071b9dec72acecc']"
29,page_30,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'AECOPD is sudden worsening of COPD symptoms. Many studies have attempted to', 'measure the burden of bacterial or viral infections in patients with AECOPD, but very', 'few have investigated the presence of mixed viral and bacterial infections both in stable', 'COPD patients and during AECOPD.', '1.2.', 'Rationale for the study', 'Because the infectious aetiology of AECOPD has been suggested to vary according to', 'geographical region, the primary purpose of this study (which will be conducted in', 'several countries in Asia Pacific) is to evaluate the occurrence of potential bacterial and', 'viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.', 'Given the increasing and projected burden of COPD in the Asia Pacific region, this study', 'will also evaluate the frequency, severity and duration of AECOPD, as well as the impact', 'of AECOPD on health-related quality of life (HRQOL), healthcare utilisation and lung', 'function.', 'In addition, both PCR and bacteriological methods will be used for characterisation and', '(quantification in some cases) of bacteria in sputum. To date, identification of bacteria', 'and assessment of bacterial load is done in the vast majority of cases by culture.', 'However, the few studies that have compared culture with PCR demonstrated that PCR is', 'more discriminatory at detecting typical airway bacteria [Curran, 2007;Singh, 2014].', 'Moreover, in a multi-centre study, PCR has the advantage that it can be performed on', 'stored sputum samples, and can therefore be done centrally, whereas culture has to be', 'performed on fresh sputum samples, which can lead to variable results due to variability', 'in testing methods between laboratories.', '2.', 'OBJECTIVES', '2.1.', 'Primary objective', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum of stable COPD patients and during AECOPD, using', 'respectively bacteriological methods and viral PCR, over the course of 1 year.', 'Refer to Section 9.1.1 for the definition of the primary endpoint.', '2.2.', 'Secondary objectives', 'To evaluate the concordance between PCR and bacteriological methods data in', 'sputum for potential bacterial pathogens.', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum of stable COPD patients, by GOLD grade.', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum during AECOPD, by severity of AECOPD.', 'To estimate the incidence rate of all-cause AECOPD, overall and by GOLD grade.', '19-OCT-2018', '30', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
30,page_31,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'To describe the severity and duration of all-cause AECOPD, overall and by GOLD', 'grade.', 'To assess the impact of all-cause AECOPD on HRQOL.', 'To assess the impact of all-cause AECOPD on lung function.', 'To assess the impact of all-cause AECOPD on healthcare utilisation.', 'Refer to Section 9.1.2 for the definition of the secondary endpoints.', '2.3.', 'Tertiary objective(s)', 'To assess the use of EXACT-PRO for determining the end date of AECOPD.', 'To evaluate the load of bacterial and viral pathogen in stable COPD and during', 'AECOPD.', 'To collect biological specimens for future respiratory disease-related testing:', '- Aliquots of sputum samples for assay development and microbiome analysis at', 'stable visits and during exacerbation.', '-', 'Blood sampling for potential identification/quantification of biomarkers at Visit', '1 and Visit 3.', '-', 'Bacterial isolates for further strain characterisation.', 'Refer to Section 9.1.3 for the definition of the tertiary endpoints.', '19-OCT-2018', '31', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
31,page_32,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '3.', 'STUDY DESIGN OVERVIEW', 'Protocol waivers or exemptions are not allowed unless necessary for the management of', 'immediate safety concerns. Therefore, adherence to the study design requirements,', 'including those specified in the outline of study procedures (Section 6), are essential and', 'required for study conduct.', 'Figure 2 presents an overview of the study design.', 'Figure 2', 'Study design overview', 'Moderate to very severe', 'COPD patients', '3 40 years', 'Scheduled', 'Screening Visit', 'V1', 'V2', 'V3', '(stable) visits', '(Pre-month 0)', 'MO', 'M6', 'M12', '(V1,V2,V3)', '-', 'Spiro, Chest X-Ray,', 'e-DC, SP', 'SP', 'Spiro SP', 'for all subjects', 'e-DC, SP, ATS-DLD-078,', 'CAT,SGRQ-C', 'CAT, SGRQ-C', 'CAT, SGRQ-C,', 'Biomass exposure', 'BS', 'BS', 'AECOPD visit during', 'AECOPD and follow-up', 'AECOPD', 'Follow -up', 'phone call(s)', 'visit', 'phone call(s)', '-', 'SP *,CAT', 'for each AECOPD', 'Epoch 001', 'V = Visit; M = Month; SP = sputum sample; e-DC: Training and use of electronic Diary card; CAT = COPD', ""assessment test; SGRQ- = St. George's Respiratory Questionnaire for COPD patients; spiro = spirometry ;"", 'BS = Blood Sampling; AECOPD = acute exacerbation of COPD; ATS-DLD-078 = American Thoracic Society', 'and National Heart and Lung Institute-Division of Lung Disease Respiratory Questionnaire', '* The sputum samples during AECOPD should preferably be obtained before administration of the first dose of', 'antibiotics to treat the AECOPD (if applicable). Self collection of the sputum sample will be allowed in specific', 'cases, where the first dose of antibiotics absolutely needs to be taken before an AECOPD visit can take place.', 'This is not allowed at scheduled visits when subject should be in stable condition.', 'Follow- up phone calls will take place at least every 2 weeks, until the AECOPD has resolved', 'Type of design: Prospective, epidemiological, interventional, multi-country, cohort study.', 'Study population: A cohort of approximately 200 moderate to very severe COPD', 'patients with at least 1 documented moderate or severe AECOPD in the year before', 'enrolment.', 'Type of study: self-contained.', 'Data collection: Electronic Case Report Form (eCRF) and electronic diary cards.', 'Primary completion Date: Visit 3 (Month 12). Refer to glossary of terms for the', 'definition of PCD.', 'End of Study (EoS): Last testing results released of samples collected at Visit 3.', 'Duration of the study: The study will last approximately 1 year for each subject from', 'screening visit up to study conclusion.', '19-OCT-2018', '32', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
32,page_33,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Note: Screening visit should ideally occur not more than 6 weeks before visit 1.', '-', 'Epoch 001: Prospective data collection starting at Screening Visit (Pre-month 0)', 'and ending at Visit 3 (Month 12).', 'Table 3', 'Study groups and epochs foreseen in the study', 'Number of', 'Epoch', 'Study Groups', 'Age', 'subjects', 'Epoch 001', 'Prospective', 'Approx 200', '40 years', 'X', 'Study visits/contacts:', '- Screening visit.', '- Three scheduled (stable) study visits occurring at 6 months intervals.', '-', 'For each AECOPD: AECOPD visit (within 96 hours of the onset of the', 'symptoms) and follow-up phone call(s) (at least every 2 weeks until the', 'AECOPD has resolved). Follow-up phone contacts will define end of AECOPD.', 'COPD symptoms', 'Subjects will be asked to record their COPD symptoms in an electronic Diary Card', 'on a daily basis:', '-', 'Daily in the morning throughout the study: Morning symptoms questionnaire.', '- Daily at bedtime throughout the study: EXACT-PRO (EXAcerbations of Chronic', 'Pulmonary Disease Tool - Patient Reported Outcome) questionnaire.', 'Biological samples:', '-', 'Sputum samples collected at site (spontaneous or induced, as per investigator', 'judgement) will be collected at each study visit at the site (scheduled [stable]', 'visits and AECOPD visits) if, in the opinion of the investigator, it is safe for the', 'subject.', 'Or', ""- Sputum sample collected at subject's home (spontaneous). Self-collection of"", 'the sputum sample will be allowed in specific cases, where the first dose of', 'antibiotics absolutely needs to be taken before an AECOPD visit can take place.', 'This is not allowed at scheduled visits when subject should be in stable condition.', 'Note: The sputum samples collected during AECOPD should preferably be obtained', 'before administration of the first dose of antibiotics to treat the AECOPD (if applicable).', '-', 'Blood samples for biomarker testing will be collected at Visit 1 (M0) and Visit', '3 (M12).', '19-OCT-2018', '33', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
33,page_34,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'HRQOL assessments', '- Subjects will be asked to complete the COPD assessment Test (CAT) at each', 'study visit (scheduled [stable] visits and AECOPD visits).', ""- Subjects will be asked to complete the St. George's Respiratory Questionnaire"", 'for COPD patients (SGRQ-C) at each scheduled (stable) study visit (Visit 1', '[Month 0], Visit 2 [Month 6] and at Visit 3 [Month 12]).', 'Pre- and post-bronchodilator spirometry assessments will be done for all subjects at', 'Screening Visit (pre-Month 0) and at Visit 3 (Month 12).', '3.1.', 'Discussion of study design', 'The primary objective of this study is to prospectively investigate the prevalence and', 'distribution of bacteria and viruses isolated from sputum samples from moderate to very', 'severe COPD patients and at the time of AECOPD, in Asian populations. In order to', 'increase the chance that the patients will exacerbate during the study, only patients with a', 'documented history of at least 1 moderate or severe AECOPD in the previous year will', 'be recruited, as this is known to be the best predictor of AECOPD [Hurst, 2010].', 'Therefore, this study will permit an estimation of incidence of AECOPD in a COPD', 'population at increased risk of exacerbation. It will not provide a true population-based', 'incidence of AECOPD.', 'In order to study factors affecting disease progression in Asia Pacific, prospective data', 'from a relatively large cohort of COPD patients is essential. The use of electronic Diary', 'Cards to detect changes in the respiratory symptoms that define an AECOPD, the', 'standardised questionnaires and spirometry assessments will allow robust conclusions to', 'be drawn about the effects of exacerbations on decline in lung function and HRQOL.', 'EXACT PRO will be used to assess breathlessness, cough and presence of sputum, chest', 'symptoms, difficulty bringing up sputum, feeling tired or weak, sleep disturbance, and', 'feeling scared or worried about their condition. Advantages to this approach include', 'standardised data, reduced recall bias, and the potential to identify events and determine', 'resolution based on a predefined scoring algorithm [Leidy, 2011]. Standardised', 'questionnaires completed during study visits include the SGRQ-C and the CAT. The', 'SGRQ-C is designed to assess HRQOL, current health and does not specify a recall', 'period. The CAT is a simple, short, patient-completed instrument to assess HRQOL and', 'symptom burden in patients with COPD. The CAT has good internal consistency and', 'test-retest reliability, correlates strongly with the SGRQ-C, and is able to distinguish', 'between stable patients and those undergoing an AECOPD [Jones, 2012].', '19-OCT-2018', '34', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
34,page_35,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '3.1.1.', 'Detection of AECOPD', 'Occurrence of potential AECOPD will be monitored by means of electronic Diary Cards', 'which the subject will use to record his/ her morning symptoms on a daily basis. The', 'electronic Diary Cards will be programmed as to detect potential AECOPD as follows', '(based on the Anthonisen criteria [Anthonisen, 1987]):', 'Worsening of two or more of the following major symptoms for at least two', 'consecutive days: dyspnoea, sputum volume, sputum purulence (colour), OR', 'Worsening of any major symptom together with any of the following minor', 'symptoms for at least two consecutive days: sore throat, colds (nasal discharge', 'and/or nasal congestion), fever (oral temperature 37.5¬∞C) without other cause,', 'increased cough, increased wheeze.', 'Note that: The same two symptoms do not have to be present on both days as long as at', 'least one major symptom is present on both days.', 'Each time a potential AECOPD is detected via the electronic Diary Card, the device will', 'alert the subject to contact the study site, and at the same time an alert will be sent to the', 'site so that the investigator or medically qualified individual contacts the subject to', 'determine if the alert is an AECOPD or not, and if an AECOPD visit is warranted. In', 'addition, the site should proactively follow-up all data received via the electronic Diary', 'Card and contact the subject whenever deemed necessary.', 'During the contact with the subject, the investigator or medically qualified individual will', 'determine whether the subject might actually be experiencing an AECOPD (e.g.', 'notifications that can be explained solely by increased physical activity will not be', 'considered):', 'If the investigator or medically qualified individual concludes that the subject is not', 'experiencing an AECOPD, this should be documented/ reported in the electronic', 'Diary website (StudyWorks). Please refer to study procedures manual (SPM) for', 'more details on how to perform this.', 'If the investigator or medically qualified individual concludes that the subject may be', 'experiencing an AECOPD, an AECOPD visit will be scheduled as soon as possible', 'after the onset of AECOPD symptoms as recorded in the electronic Diary Card or', 'confirmed by the subject (maximum 96 hours after onset of symptoms and, if', 'applicable, preferably before starting treatment with antibiotics). The AECOPD', 'onset date will be captured in the eCRF and additional information about severity', 'will be also collected.', '-', 'In case the AECOPD is confirmed but no AECOPD visit can take place, the site', 'should record the information in the medical records subject files, and in the', 'eCRF in medical records section and obtain all relevant information regarding', 'the AECOPD (hospital record, medical record etc.) and record this in the eCRF.', 'If the investigator concludes the subject is experiencing/continuing with the same', 'event for which a visit has been performed already, an AECOPD visit should not', 'take place. Medical treatment should be foreseen according to standard medical', 'practice outside of the study.', '19-OCT-2018', '35', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
35,page_36,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'During the AECOPD visit, the investigator will confirm the occurrence of the AECOPD', 'based on clinical and medical judgement and based on the Anthonisen criteria and will', 'record its date of onset. The end date of the AECOPD and its severity will be determined/', 'confirmed by the investigator/delegate during (a) follow-up phone call(s), which will take', 'place at least every 2 weeks until the AECOPD has resolved.', 'If an AECOPD occurs at the time when one of the scheduled [stable] study visits is', 'planned, it should be handled and recorded as an AECOPD visit, with all relevant', 'AECOPD visit study procedures performed and, if possible, the stable study visit should', 'be re-scheduled to a later date, when the subject is stable again and within the time', 'window specified in the protocol.', 'The investigator/site must engage their best efforts to reach the patients, however, if the', 'site does not succeed in contacting the patient, the reason should be recorded and an', 'explanation given about what occurred. For example, the subject could be hospitalized or', 'could visit a different physician (and in that case medical record should be obtained), or', 'the subject is on holidays or not able to go the site.', '3.1.1.1.', 'Date of onset and end date of AECOPD', 'The date of onset is the first day (of at least 2 consecutive days) of worsening symptoms', 'of COPD, as determined by the Investigator according to the Anthonisen criteria.', 'The end date should be based on when the investigator determines that the AECOPD', 'symptoms have resolved. In determining this end date, consideration should be given to', 'symptoms recorded in the electronic Diary Card and subject assessment during the phone', 'calls.', 'Both start and end date of each confirmed AECOPD occurring from the screening visit to', 'study conclusion will be recorded in the eCRF.', '3.1.1.2.', 'Guideline for assessing AECOPD that increase in severity', 'If an exacerbation starts off as mild, but becomes moderate or severe or starts off as', 'moderate and becomes severe, the exacerbation should be captured as one exacerbation', 'and classified by its highest level of severity.', '19-OCT-2018', '36', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
36,page_37,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '4.', 'STUDY POPULATION', 'This will be a multi-country study to be conducted in Asia Pacific.', '4.1.', 'Number of subjects/ centres', 'The target is to enrol approximately 200 eligible moderate to very severe COPD patients.', 'Refer to Section 9.2 for a detailed description of the criteria used to estimate the sample', 'size.', '4.1.1.', 'Recruitment of study centres', 'Centres will be selected for study participation based on the following criteria:', 'Experience with patients with respiratory disorders.', 'Able to perform microbiology testing. Please refer to SPM for details on the', 'requirements to be met for microbiology testing.', 'No limitations on the quantity of export of biological samples to GSK Biologicals or', 'to designated laboratories.', '4.2.', 'Inclusion criteria for enrolment', 'Deviations from inclusion criteria are not allowed because they can potentially jeopardise', 'the scientific integrity of the study and regulatory acceptability of the study or subject', 'safety. Therefore, adherence to the criteria as specified in the protocol is essential.', 'All subjects must satisfy ALL the following criteria at study entry:', 'Subjects who, in the opinion of the investigator, can and will comply with the', 'requirements of the protocol (e.g., completion of electronic Diary Card, sputum', 'sampling, pre- and post-bronchodilator spirometry, return for follow-up visits).', 'Written informed consent obtained from the subject.', 'Male or female aged 40 years or older at the time of enrolment.', 'Confirmed diagnosis of moderate to very severe COPD based on post-bronchodilator', 'spirometry (i.e. forced expiratory volume in 1 second [FEV1] over forced vital', 'capacity [FVC] ratio [FEV1/FVC] <0.7 and FEV1 < 80% predicted [GOLD grades', '2, 3 and 4].', 'Stable COPD patient* with documented history** (e.g. medical record verification)', 'of at least 1 moderate or severe AECOPD within the 12 months before study entry.', '* Patient for whom the last episode of AECOPD is resolved for at least 30 days at', 'the time of study entry.', '**Note: A documented history of a COPD exacerbation (e.g., medical record', 'verification) is a medical record of worsening COPD symptoms that required', 'systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or', '19-OCT-2018', '37', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
37,page_38,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not', 'qualify as an exacerbation history unless the use was associated with treatment of', 'worsening symptoms of COPD, such as increased dyspnea, sputum volume, or', 'sputum purulence (color). Subject verbal reports are not acceptable.', 'Refer to the SPM for details on what is accepted as documented history of AECOPD.', 'Refer to Table 2 for the definitions of moderate and severe AECOPD.', 'Current or former tobacco smoker (cigarette) with a smoking history of > 10 pack-', 'years OR a subject exposed to biomass smoke for > 20 years [Guoping Hu, 2010]', 'Refer to the glossary of terms for the definitions of pack-years, current and former', 'smoker.', 'Able to provide a sputum sample at Screening Visit.', '4.3.', 'Exclusion criteria for enrolment (Amended 19 October 2018)', 'Deviations from exclusion criteria are not allowed because they can potentially jeopardise', 'the scientific integrity and regulatory acceptability of the study or subject safety.', 'Therefore, adherence to the criteria as specified in the protocol is essential.', 'The following criteria should be checked at the time of study entry. If ANY exclusion', 'criterion applies, the subject must not be included in the study:', 'Diagnosed with a respiratory disorder other than COPD (such as sarcoidosis, active', 'tuberculosis or receiving tuberculosis treatment, clinically significant bronchiectasis,', 'lung fibrosis, pulmonary embolism, pneumothorax, lung cancer diagnosed within the', 'previous 5 years, current primary diagnosis of asthma in the opinion of the', 'investigator), or chest X-ray revealing evidence of clinically significant', 'abnormalities not believed to be due to the presence of COPD* Subjects with', 'allergic rhinitis do not need to be excluded and may be enrolled at the discretion of', 'the investigator.', '* A chest X-ray must be taken at Screening Visit, if no chest X-ray taken within the', 'previous 3 months is available.', 'Diagnosis of a-1 antitrypsin deficiency as the underlying cause of COPD.', 'Undergone or has had lung surgery 12 months before, or plans to have lung surgery', '12 months after, study entry.', 'Any confirmed or suspected immunosuppressive or immunodeficient condition,', 'based on medical history and physical examination (no laboratory testing required).', 'Received chemotherapy within the 12 months before study entry.', 'Concurrently participating in another clinical study, at any time during the study', 'period, in which the subject has been or will be exposed to an investigational or a', 'non-investigational vaccine/product (pharmaceutical product or device).', '19-OCT-2018', '38', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
38,page_39,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Administration of antibiotics within 1 month of study entry OR continuous', 'administration of antibiotics (defined as more than 30 days in total) within 90 days', 'before study entry*', '*Study entry is Visit 1. If this exclusion criteria is met during Screening Visit the', 'patient can enter the study and this exclusion criteria will be reassessed during', 'Visit 1.', 'Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive', 'days within 90 days prior to informed consent.', 'Contraindication for spirometry testing (such as recent eye surgery, recent thoracic or', 'abdominal surgery procedures, unstable cardiovascular status, recent myocardial', 'infarction or pulmonary embolism).', 'Psychiatric illness or any other condition that interferes with the ability to understand', 'the study procedures.', 'Pregnant female.', '19-OCT-2018', '39', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
39,page_40,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '5.', 'CONDUCT OF THE STUDY', '5.1.', 'Regulatory and ethical considerations, including the', 'informed consent process', 'The study will be conducted in accordance with the ICH Guideline for Good Clinical', 'Practice (GCP) or other applicable guidelines, all applicable subject privacy requirements', 'and the guiding principles of the Declaration of Helsinki.', 'GSK will obtain favourable opinion/approval to conduct the study prior to a site initiating', 'the study in that country or will document that neither a favourable opinion nor an', 'approval to conduct the study is needed.', 'Conduct of the study includes, but is not limited to, the following:', 'Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and', 'favourable opinion/approval of study protocol and any subsequent amendments.', 'Subject informed consent.', 'Investigator reporting requirements as stated in the protocol.', 'GSK Biologicals will provide full details of the above procedures to the investigator,', 'either verbally, in writing, or both.', 'Freely given and written informed consent must be obtained from each subject, as', 'appropriate, prior to participation in the study.', 'GSK Biologicals will prepare a model Informed Consent Form (ICF) which will embody', 'the applicable ICH GCP or other applicable guidelines, and GSK Biologicals required', 'elements. While it is strongly recommended that this model ICF be followed as closely as', 'possible, the informed consent requirements given in this document are not intended to', 'pre-empt any local regulations which require additional information to be disclosed for', 'informed consent to be legally effective. Clinical judgement, local regulations and', 'requirements should guide the final structure and content of the local version of the ICF.', 'The investigator has the final responsibility for the final presentation of the ICF,', 'respecting the mandatory requirements of local regulations. The ICF generated by the', ""investigator with the assistance of the sponsor's representative must be acceptable to"", 'GSK Biologicals and be approved (along with the protocol, and any other necessary', 'documentation) by the IRB/IEC.', '19-OCT-2018', '40', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']"
40,page_41,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.', 'DETAILED STUDY PROCEDURES (AMENDED 19', 'OCTOBER 2018)', '6.1.', 'Subject identification', 'Subject numbers will be assigned sequentially to subjects consenting to participate,', 'according to the range of subject numbers allocated to each study centre.', '6.2.', 'General study aspects', 'Supplementary study conduct information not mandated to be present in this protocol is', 'provided in the accompanying Study Procedures Manual (SPM). The SPM provides the', 'investigator and the site personnel with administrative and detailed technical information', 'that does not impact the safety of the subjects.', '6.3.', 'Outline of study procedures', 'Table 4 presents the study procedures involved during scheduled [stable] visits.', 'Table 4', 'List of study procedures for scheduled visits', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Informed consenta', 'Check inclusion/exclusion criteriaa', 'O', 'Record demographic data', 'Record medical history', 'Record history of AECOPD within the previous yearb', 'Record intercurrent comorbidities', 'O', 'Record history of pneumococcal and influenza', 'O', 'vaccination', 'Smoking exposure history (ATS-DLD-78A questionnaire)/', 'biomass exposure history (Biomass Exposure', 'O', 'questionnaire)', 'Smoking status', 'Physical examination including vital signsh', 'O', 'O', 'O', 'Urine Pregnancy Test', 'Measure/recoro height and weightd', 'Pre-and post-bronchodilator spirometrye', 'Chest X-rayf', ""Record subject's COPD status (stable, recovered or not"", 'recovered)', 'Record current medication', 'Record healthcare resource utilisation', 'Record additional treatments prescribed by primary and', 'secondary care physicians', 'Train subject on use of electronic Diary Card and assign', 'O', 'O', 'electronic Diary Card to the subject', 'Return electronic Diary Card', 'O', 'Sputum sampling', '19-OCT-2018', '41', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
41,page_42,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Blood samples for biomarkers', 'Record Adverse Events (AEs)*', 'A', 'Record serious adverse events (SAEs)', 'A', 'Screening conclusion', 'Study conclusion', 'HRQOL questionnaires:', 'CAT', 'O', 'O', 'O', 'SGRQ-C', 'O', 'O', 'O', 'is used to indicate a study procedure that requires documentation in the individual eCRF.', 'O is used to indicate a study procedure that does not require documentation in the individual eCRF.', 'a For non-eligible subjects, only informed consent, inclusion/ exclusion criteria, demographic data and SAEs related to', ""study participation that occurred after signing the informed consent pages need to be completed in the subject's eCRF."", 'For other activities, ""not done\' can be indicated.', 'b', 'Record both documented and self-reported, non-documented AECOPD. Subjects need documentation for at least', '1', 'moderate or severe AECOPD within the previous year to be eligible for study participation.', 'C', 'Significant comorbidities include weight loss, cardiovascular disease, hypertension, gastro-oesophageal reflux', 'disease, osteoporosis/ osteopenia, skeletal muscle wasting and dysfunction, anxiety/ depression and diabetes.', 'd To be recorded in the ""Physical examination\' section of the eCRF.', 'e Only study certified site staff can perform spirometry assessment.', 'f Only if no chest X-ray is taken within the previous 3 months.', 'g Sputum can be collected spontaneously or can be induced, as per investigator judgement. Sputum sampling should', 'only be done if, in the opinion of the investigator, it is safe for the subject.', '* Non-serious AEs will be recorded in the eCRF and will not be entered into the safety database.', '^ Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'h Physical examination (Visit1-3) should be done only if necessary by the investigator or delegate.', '19-OCT-2018', '42', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
42,page_43,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 5 presents the list of study procedures for AECOPD visits.', 'Table 5', 'List of study procedures for AECOPD visits', 'Type of contact', 'AECOPD Visit', 'End of AECOPD phone call(s)', 'Time point', 'within 96 hours of onset', 'at least every 2 weeks as of', 'AECOPD visit until AECOPD', 'symptoms', 'has resolvedi', 'Record date of visit', 'Physical examination', 'Urine Pregnancy Test', 'Chest X-rays/pneumonia confirmationi', 'Confirm AECOPD and record its start date', 'Record current medication for AECOPD', 'Record healthcare resource utilisation', 'Record additional COPD treatments prescribed by', 'primary and secondary care physicians', 'Sputum samplingk', 'HRQOL questionnaire:', 'CAT', 'O', 'Record AECOPD severitym', 'Record AECOPD end date', 'Record Adverse Events (AEs)*', 'Record serious adverse events (SAEs)^', 'is used to indicate a study procedure that requires documentation in the individual eCRF.', 'i', 'End of AECOPD phone calls/ visits should be scheduled at least every 2 weeks, until the AECOPD has resolved. Only', 'the last phone call will be recorded in the eCRF as the end of the AECOPD phone call. All intermediate calls should be', 'recorded on source documentation.', 'j', 'Only if clinically indicated to exclude another cause of worsening of symptoms (e.g. pneumonia). If a chest X-ray is', 'clinically indicated but a chest X-ray/ CT scan has already been taken for that AECOPD as part of medical care before', 'the study AECOPD visit takes places, the results of that chest X-ray/ CT scan can be used. All cases of pneumonia', '(including all signs and symptoms assessed to confirm pneumonia) should be documented in the eCRF.', 'k', 'Sputum can be collected spontaneously or can be induced, as per investigator judgement. Sputum sampling should', 'only be done if, in the opinion of the investigator, it is safe for the subject.', 'I Physical examination should be done only if necessary by the investigator or delegate.', 'm AECOPD severity grading as indicated in Table 2.', '* Non-serious AEs will be recorded in the eCRF and will not be entered into the safety database.', '^ Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'Table 6 presents the intervals between study visits.', 'Table 6', 'Intervals between study visits', 'Interval', 'Optimal length of interval', 'Allowed interval¬π', 'Screening Visit (pre-Month 0)', 'Visit 1', '+ 14 days', '<42 days before Visit 1', 'Scheduled study visits', 'Visit 1 (Month 0)', 'Visit 2 (Month 6)', '182 days', '175 203 days', 'Visit 2 (Month 6)', 'Visit 3 (Month 12)', '182 days', '175 203 days', 'AECOPD-driven study visit(s) and/or phone contacts', 'Onset AECOPD symptoms', 'AECOPD Visit', 'max 96 hours¬≤', '1 If an AECOPD occurs at the time one of the scheduled study visits is planned, the stable study visit should be re-', 'scheduled to a later date, when the subject is stable again and within the time window specified. In consultation with', 'GSK, the concluding visit (Visit 3, Month 12) may however exceptionally be conducted outside of the allowed interval if', 'necessary by the investigator.', '2 AECOPD visits will be scheduled as soon as possible after the onset of AECOPD symptoms as recorded in the', 'electronic Diary Card or confirmed by the subject (maximum 96 hours after and, if applicable, preferably before starting', 'treatment with antibiotics).', '19-OCT-2018', '43', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
43,page_44,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.', 'Detailed description of study procedures', '6.4.1.', 'Procedures during the Screening Visit', '6.4.1.1.', 'Informed consent', 'The signed informed consent of the subject must be obtained before study participation', 'during the screening visit. Refer to Section 5.1 for the requirements on how to obtain', 'informed consent.', '6.4.1.2.', 'Check inclusion and exclusion criteria', 'All applicable inclusion and exclusion criteria as described in Sections 4.2 and 4.3 will be', 'checked before enrolment.', '6.4.1.3.', 'Record demographic data', 'Demographic data such as date of birth, gender, geographic ancestry will be recorded in', ""the subject's eCRF."", '6.4.1.4.', 'Record medical history', ""The subject's medical history will be obtained by review of the subject's medical records."", 'Prior to study participation, any pre-existing conditions or signs and/or symptoms present', 'in a subject will be recorded.', '6.4.1.5.', 'Record AECOPD history within the previous year', 'Documented, self-reported and non-documented AECOPD should be recorded in the', 'eCRF. However, for study participation the subject should have had at least one', 'documented moderate or severe AECOPD episode within the previous year.', '6.4.1.6.', 'Smoking exposure history (ATS-DLD-78A questionnaire)/biomass', 'exposure history (At screening visit only)', 'The subject will be asked to complete the smoking history questionnaire (which is a', 'shortened version of the American Thoracic Society-Division of Lung Diseases-78A', '[ATS-DLD-78A] questionnaire) by himself/herself. The subject will have to provide', 'information about his/ her smoking history, including duration (number of years) and', 'number of cigarettes smoked. Subject years exposed to biomass will be assessed from', 'information obtained on indoor exposure to fuels such as wood, crop waste and dung, or', 'coal.', 'From the information obtained via the questionnaire, calculation of the pack-years will be', 'done for inclusion into the study. Please refer to the SPM for details on how to calculate', 'pack years using this questionnaire and for guidance on administration of the exposure', 'history questionnaire.', '19-OCT-2018', '44', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']"
44,page_45,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.1.7.', 'Smoking status', ""The subject's smoking status (current or former smoker) will be recorded in the eCRF."", 'Refer to the glossary of terms for the definitions of current and former smoker.', '6.4.1.8.', 'Physical examination', 'At the screening visit, a complete physical examination of the subject will be performed', 'which will include vital signs after at least 10 minutes of rest (systolic/ diastolic blood', 'pressure, heart rate, respiratory rate). Collected information will be recorded in the eCRF.', 'Treatment of any abnormality observed during a physical examination has to be', 'performed according to local medical practice outside this study or by referral to an', 'appropriate health care provider.', '6.4.1.9.', 'Pregnancy test', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to any', 'study procedure. Note: The urine pregnancy test must be performed even if the subject is', 'menstruating at the time of the study visit. The test should be carried out before', 'performing chest x-ray. If the test is positive, the chest X- ray should not be performed', 'and the subject should be withdrawn from the study.', '6.4.1.10. Measure/ record height and weight', ""The height and weight of the subject will be measured and recorded in the 'Physical"", ""examination' section of the eCRF."", '6.4.1.11. Pre- and post-bronchodilator spirometry', 'Pre- and post-bronchodilator spirometry should be performed during the screening visit.', 'Only study-certified staff can perform spirometry assessment for this study. Spirometry', 'will be performed following the eResearch Technology (ERT) instructions for use', 'FlowScreen manual and following all safety requirements.', 'A good quality spirometry should be obtained, and will be confirmed by the spirometry', 'provider. If during the Screening Visit a good quality spirometry was not obtained, the', ""spirometry can be repeated, as per investigator's medical judgement. If a repeat"", 'spirometry is elected, the site should make all possible efforts to repeat the spirometry', 'preferably within 7 days of the previous spirometry. The data will be directly transferred', 'from the provider to GSK Biologicals.', 'Treatment of any abnormality observed during spirometry has to be performed according', 'to local medical practice outside this study or by referral to an appropriate health care', 'provider.', '19-OCT-2018', '45', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
45,page_46,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.1.12.', 'Chest X-ray', 'Screening - Baseline test', 'A posterior to anterior (PA) chest X-ray must be performed at the screening visit if no', 'chest X-ray/ CT scan is available within the last 3 months.', 'Subjects with evidence of clinically significant abnormalities not believed to be due to the', 'presence of COPD will not be eligible for study participation.', '6.4.1.13. Train subjects on the use of electronic Diary Card and assign electronic', 'Diary Card to subject', 'From screening visit to visit 1, subjects will be trained on how to use their electronic', 'Diary Card. At visit 1, the investigator should evaluate whether or not the subject', 'will be able to comply with the daily completion of the electronic Diary Card', 'throughout the study. Compliance with electronic Diary Card completion implies', 'that subject learns how to translate his/ her respiratory symptoms in answers to the', 'questions as well as acquiring the technical expertise to use the device. Refer to the', 'SPM for recommendations on what is considered adequate compliance.', 'The site staff will follow electronic Diary Card completion closely and should', 'provide timely input/guidance to ensure that the subject correctly completes the', 'eDiary Card both AM & PM as per protocol.', 'In addition, site staff will pro-actively monitor electronic Diary Card compliance', 'throughout the study and provide the necessary input to maintain compliance.', '6.4.1.14. Sputum sampling (Amended 19 October 2018)', 'Sputum samples will be collected during the screening visit if, in the opinion of the', 'investigator, it is safe for the subject. If it is not safe, the sputum sample will not be', 'collected and the subject will not be included in the study.', 'Sputum samples can be either spontaneous or induced, as per investigator judgement.', 'Internal standard operating procedures should be put in place to ensure proper', 'sputum collection, sample tracking and subject safety at study collection site.', 'At home, sputum collection will not be permitted.', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing.', 'Remaining DTT-sputum will be aliquoted as such. These samples will be kept at', '-70/80¬∞C until shipment to GSK or GSK designated lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', '19-OCT-2018', '46', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
46,page_47,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.1.15.', 'Recording of AE/SAEs', 'Recording of AE/SAEs', 'Refer to Section 7.2 for procedures for the investigator to record AE/SAEs. Refer to', 'Section 7.3 for guidelines on how to submit SAE reports to GSK Biologicals.', 'The subjects will be instructed to contact the investigator immediately should they', 'manifest any signs or symptoms they perceive as serious.', '6.4.1.16. Screening conclusion', 'The investigator will review all the data collected during the screening visit to ensure', 'accuracy and completeness.', '6.4.2.', 'Procedures during Visit 1, Visit 2 and Visit 3', '6.4.2.1.', 'Check inclusion and exclusion criteria', 'At visit 1, all applicable inclusion and exclusion criteria as described in Sections 4.2 and', '4.3 will be checked before enrolment.', '6.4.2.2.', 'Record intercurrent comorbidities', 'Significant comorbidities include, but is not limited to, weight loss, cardiovascular', 'disease, hypertension, gastro-oesophageal reflux disease, osteoporosis/osteopenia', 'skeletal muscle wasting and dysfunction, anxiety/ depression and diabetes.', '6.4.2.3.', 'Vaccination History', 'Record in the eCRF whether the subject received any influenza vaccination within the', 'previous 12 months or has ever received any pneumococcal vaccination (including date', 'of vaccination as detailed as possible]).', '6.4.2.4.', 'Smoking status', ""The subject's smoking status (current or former smoker) will be recorded in the eCRF."", 'Refer to the glossary of terms for the definitions of current and former smoker.', '6.4.2.5.', 'Physical examination', 'Physical examination at each study visit (Visit 1, Visit 2 and Visit 3) will be performed', 'only if deemed necessary by the investigator or delegate.', '19-OCT-2018', '47', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
47,page_48,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.2.6.', 'Pregnancy test (Amended 19 October 2018)', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to any', 'study procedure. Note: The urine pregnancy test must be performed even if the subject is', 'menstruating at the time of the study visit.', '6.4.2.7.', 'Measure/ record height and weight', 'The height and weight of the subject will be measured at Visit 3 and recorded in the', ""'Physical examination' section of the eCRF."", '6.4.2.8.', 'Pre- and post-bronchodilator spirometry', 'Pre- and post-bronchodilator spirometry should be performed during Visit 3 as detailed in', 'Table 4. Only study-certified staff can perform spirometry assessment for this study.', 'Spirometry will be performed following the eResearchTechnology (ERT) instructions for', 'use FlowScreen manual and following all safety requirements.', 'A good quality spirometry should be obtained, and will be confirmed by the spirometry', 'provider. If during Visit 3 a good quality spirometry was not obtained, the spirometry can', ""be repeated, as per investigator's medical judgement. If a repeat spirometry is elected, the"", 'site should make all possible efforts to repeat the spirometry preferably within 7 days of', 'the previous spirometry. The data will be directly transferred from the provider to GSK', 'Biologicals.', 'Treatment of any abnormality observed during spirometry has to be performed according', 'to local medical practice outside this study or by referral to an appropriate health care', 'provider.', '6.4.2.9.', ""Record subject's COPD status"", ""The subject's COPD status (stable/recovered or not recovered) will be recorded in the"", 'eCRF.', '6.4.2.10.', 'Record current medication (Amended 19 October 2018)', 'At each study visit/contact, the investigator should question the subject about any', 'medications taken.', 'All medications administered will be recorded in the eCRF.', '6.4.2.11. Record healthcare resource utilisation', ""Healthcare use will be obtained through review of the subject's medical record (aided by"", 'subject self-reporting). Healthcare utilisation includes all unscheduled visits to a', 'physician office, visits to urgent care, visits to emergency department, and', 'hospitalizations. Healthcare use should be recorded in eDiary Card and reported in the', '19-OCT-2018', '48', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
48,page_49,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'eCRF at study visit. Refer to the SPM for more details and guidance on recording of', 'healthcare use.', '6.4.2.12. Additional treatments prescribed by primary and secondary care', 'physician', 'All treatments prescribed by the primary and secondary healthcare physician will be', 'recorded in the eCRF.', '6.4.2.13.', 'Train subjects on the use of electronic Diary Card and assign electronic', 'Diary Card to subject', 'From screening visit to visit 1, subjects will be trained on how to use their electronic', 'Diary Card. At visit 1, the investigator should evaluate whether or not the subject', 'will be able to comply with the daily completion of the electronic Diary Card', 'throughout the study. Compliance with electronic Diary Card completion implies', 'that subject learns how to translate his/ her respiratory symptoms in answers to the', 'questions as well as acquiring the technical expertise to use the device. Refer to the', 'SPM for recommendations on what is considered adequate compliance.', 'The site staff will follow electronic Diary Card completion closely and should', 'provide timely input/guidance to ensure that the subject reaches the targeted learning', 'curve.', 'In addition, site staff will pro-actively monitor electronic Diary Card compliance', 'throughout the study and provide the necessary input to maintain compliance.', '6.4.2.14. Return the electronic diary card', 'On the last visit (Visit 3), the site staff will pro-actively check with the subjects on', 'whether he/she has returned the electronic Diary Card.', '6.4.2.15.', 'Sputum sampling (Amended 19 October 2018)', 'Sputum samples will be collected during the scheduled visits, if in the opinion of the', 'investigator, it is safe for the subject.', 'Sputum samples can be either spontaneous or induced, as per investigator judgement.', 'Internal standard operating procedures should be put in place to ensure proper', 'sputum collection, sample tracking and subject safety at study collection site.', 'At home, sputum collection will not be permitted.', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing', 'Remaining DTT-sputum will be aliquoted as such. These samples will be kept at', '-70/80¬∞C until shipment to GSK or GSK designated lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', '19-OCT-2018', '49', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
49,page_50,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.2.16.', 'Blood Sampling', 'Blood samples for biomarker analysis will be taken at the scheduled visits; Visit 1', '(M0) and Visit 3 (M12), including:', '-', 'Hematology profile, including differential cell counts', 'Approximately 2.0 mL of whole blood will be collected for hematology', 'assessment. These samples should be kept at room temperature and shipped', 'on the day of collection, ambient.', '-', 'Specific biomarkers will include serum hsCRP, CXCL10 (IP-10) and plasma', 'fibrinogen, may include other biomarkers based on results of ongoing disease', 'understanding research.', 'Approximately 8.5 mL of whole blood will be collected and processed to', 'serum for hsCRP & CXCL10 (IP-10) assessment. After processing, these', 'samples should be kept at - -70/-80¬∞C until shipment.', 'Approximately 4.5 mL of whole blood (Na Citrate) will be collected and', 'processed to plasma for fibrinogen assessment. After processing, these', 'samples should be kept at - -70/-80¬∞C until shipment.', 'Approximately 6.0 mL of whole blood (EDTA) will be collected and', 'processed to plasma for other biomarker assessment. After processing, these', 'samples should be kept at - -70/-80¬∞C until shipment.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on the collection, handling, and processing of blood samples.', '6.4.2.17. HRQOL questionnaires', 'The subject will be asked to complete the HRQOL questionnaires by himself/herself,', 'during specified study visits directly in the electronic Diary Card as detailed in Table', '4 and Table 5.', 'Refer to the SPM for more details and guidance on the HRQOL questionnaires.', '6.4.2.18.', 'Recording of AE/SAEs', 'Refer to Section 7.2 for procedures for the investigator to record AE/SAEs. Refer to', 'Section 7.3 for guidelines on how to submit SAE reports to GSK Biologicals.', 'The subjects will be instructed to contact the investigator immediately should they', 'manifest any signs or symptoms they perceive as serious.', '6.4.2.19.', 'Study conclusion', 'The investigator will:', 'Review all the data collected to ensure accuracy and completeness', 'Complete the Study Conclusion screen in the eCRF.', '19-OCT-2018', '50', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
50,page_51,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.3.', 'Procedures during AECOPD visit', '6.4.3.1.', 'Record date of visit', 'If', 'an AECOPD occurs at of the scheduled study visits, the date of visit should be', 'document in the eCRF.', '6.4.3.2.', 'Physical examination', 'Physical examination at the AECOPD visit will be performed only if deemed necessary', 'by the investigator or delegate.', 'Treatment of any abnormality observed during a physical examination has to be', 'performed according to local medical practice outside this study or by referral to an', 'appropriate health care provider.', '6.4.3.3.', 'Pregnancy Test', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to any', 'study procedure. Note: The urine pregnancy test must be performed even if the subject is', 'menstruating at the time of the study visit. The test should be carried out before', 'performing chest x-ray. If the test is positive, the chest X- ray should not be performed', 'and the subject should be withdrawn from the study.', '6.4.3.4.', 'Chest X-rays/pneumonia confirmation', 'AECOPD visit test', 'A chest X-ray should be performed at the AECOPD visit if it is clinically indicated to', 'exclude another cause of worsening of symptoms (e.g. new infiltrate for pneumonia', 'cases).', 'All suspected pneumonias will require confirmation as defined by the presence of new', 'infiltrate(s) on chest x-ray AND at least 2 of the following signs and symptoms:', 'Increased cough,', 'Increased sputum purulence (colour) or production,', 'Auscultatory findings of adventitious sounds (e.g., egophony, bronchial breathing', 'sounds, rales, etc),', 'Dyspnea or tachypnea,', 'Fever (oral temperature > 37.5 ¬∞C),', 'Elevated WBC (>10,000/mm3 or >15% immature forms),', 'Hypoxemia (HbO2 saturation <88% or at least 2% lower than baseline value),', 'All incidences of pneumonia must be captured on the pneumonia page of the eCRF.', '19-OCT-2018', '51', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
51,page_52,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'The investigators and site staff should remain vigilant for the possible development of', 'pneumonia in patients with COPD as the clinical features of such infections overlap with', 'the symptoms of COPD exacerbations. For all suspected cases of pneumonia,', 'investigators are strongly encouraged to confirm the diagnosis (this includes obtaining a', 'chest x-ray) and to initiate appropriate therapy as promptly as possible.', 'Please refer to SPM for details on what should be considered for pneumonia', 'confirmation.', '6.4.3.5.', 'Confirm AECOPD and record start date', 'The investigator should confirm the AECOPD based on his/her medical judgement. The', 'date of onset of AECOPD will be determined as detailed in Section 3.1.1.1 and will be', 'documented in the eCRF.', '6.4.3.6.', 'Record current medication for AECOPD', 'At each study visit/contact, the investigator should question the subject about any', 'medications administered for treatment of AECOPD.', 'All medications administered for treatment of AECOPD will be recorded in the', 'eCRF.', '6.4.3.7.', 'Record healthcare resource utilisation', ""Healthcare use will be obtained through review of the subject's medical record (aided by"", 'subject self-reporting). Healthcare utilisation includes all unscheduled visits to a', 'physician office, visits to urgent care, visits to emergency department, and', 'hospitalizations. Healthcare use should be recorded in the eDiary Card and reported in the', 'eCRF at study visit. Refer to the SPM for more details and guidance on recording of', 'healthcare use.', '6.4.3.8.', 'Additional COPD treatments prescribed by primary and secondary care', 'physician', 'All treatments prescribed by the primary and secondary healthcare physician will be', 'recorded in the eCRF.', '6.4.3.9.', 'Sputum sampling (Amended 19 October 2018)', 'Sputum samples during AECOPD should preferably be obtained before', 'administration of the first dose of antibiotics to treat the AECOPD (if applicable).', 'Sputum can be collected spontaneously or can be induced, as per investigator', 'judgement. Sputum sampling should only be done if, in the opinion of the', 'investigator, it is safe for the subject.', '19-OCT-2018', '52', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
52,page_53,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', ""Sputum sample collected at subject's home (spontaneous): Self-collection of the"", 'sputum sample will be allowed in specific cases, where the first dose of antibiotics', 'absolutely needs to be taken before an AECOPD visit can take place. This is not', 'allowed at scheduled visits when subject should be in stable condition.', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing.', 'Remaining DTT-sputum will be aliquoted as such. These samples will be kept at', '-70/80¬∞C until shipment to GSK or GSK designated lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', '6.4.3.10. HRQOL questionnaires', 'The subject will be asked to complete the HRQOL questionnaire (CAT only) by', 'himself/herself directly in the electronic Diary Card, during the AECOPD visit as', 'detailed in Table 5.', 'Refer to the SPM for more details and guidance on the HRQOL questionnaires.', '6.4.3.11. Record AECOPD severity and AECOPD end date', 'The severity and end date of each confirmed AECOPD will be recorded in the eCRF. The', 'AECOPD severity will be assessed using the AECOPD severity scale (refer Table 2) and', 'the AECOPD end date will be determined as detailed in Section 3.1.1.1 and Section', '3.1.1.2.', '6.4.3.12. Recording of AE/SAEs', 'Refer to Section 7.2 for procedures for the investigator to record AE/SAEs. Refer to', 'Section 7.3 for guidelines on how to submit SAE reports to GSK Biologicals.', 'The subjects will be instructed to contact the investigator immediately should they', 'manifest any signs or symptoms they perceive as serious.', '6.4.4.', 'Sampling', '6.4.4.1.', 'Sputum Sampling', 'Sputum sampling: Refer to section 6.4 for description of the sampling procedure.', 'Full details for obtaining sputum samples are provided in the Module on Biospecimen', 'Management in the SPM and in the Central Laboratory Investigator Manual', 'accompanying this protocol.', '19-OCT-2018', '53', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
53,page_54,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.4.2.', 'Blood Sampling', 'Blood sampling: Refer to section 6.4 for the description of sampling procedure.', 'Full details for the collection, handling, and processing of blood samples are provided in', 'the Module on Biospecimen Management in the SPM and in the Central Laboratory', 'Investigator Manual accompanying this protocol.', '6.4.5.', 'Health Related Quality of Life questionnaires', 'Refer to section 6.4.2 for description of the Quality of Life (QoL) questionnaire. The', 'subject will be asked to complete the HRQOL questionnaires by himself/herself, during', 'specified study visits directly in the electronic Diary Card.', '6.4.6.', 'Recording of AEs/SAEs', 'Refer sections 6.4.1.15, 6.4.2.18 and 6.4.3.12 for recording of AEs/SAEs.', '6.4.7.', 'Study conclusion', 'Refer section 6.4.2.19 for study conclusion.', '6.5.', 'Biological sample handling and analysis', 'Please refer to the SPM and the Central Laboratory Investigator Manual for details of', 'biospecimen management (handling, storage and shipment).', 'Samples will not be labelled with information that directly identifies the subjects but will', 'be coded with the identification number for the subject (subject number).', 'Collected samples will be used for protocol mandated research. In addition, these', 'samples may be used to perform research related to the improvement, development', 'and quality assurance of the laboratory tests described in this protocol. This may', 'include the management of the quality of these tests, the maintenance or', 'improvement of these tests, the development of new test methods, as well as making', 'sure that new tests are comparable to previous methods and work reliably.', 'It is also possible that future findings may make it desirable to use the samples', 'acquired in this study for future research, not described in this protocol. Therefore,', 'all subjects in countries where this is allowed will be invited to give another specific', 'consent to allow GSK or a contracted partner to use the samples for future research', 'including development of tests and their quality assurance. Future research will be', 'subject to the laws and regulations in the respective countries and will only be', 'performed once an independent Ethics Committee or Review Board has approved', 'this research.', 'Information on further investigations and their rationale can be obtained from GSK', 'Biologicals.', 'Any sample testing will be done in line with the consent of the individual subject.', '19-OCT-2018', '54', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
54,page_55,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Refer also to the Investigator Agreement, where it is noted that the investigator cannot', 'perform any other biological assays except those described in the protocol or its', 'amendment(s).', 'Collected samples will be stored for a maximum of 20 years (counting from when the last', 'subject performed the last study visit/contact), unless local rules, regulations or guidelines', 'require different timeframes or different procedures, which will then be in line with the', 'subject consent. These extra requirements need to be communicated formally to and', 'discussed and agreed with GSK Biologicals.', '6.5.1.', 'Use of specified study materials', 'When materials are provided by GSK Biologicals or the central laboratory, it is', 'MANDATORY that all samples be collected and stored exclusively using those materials', 'in the appropriate manner. The use of other materials could result in the exclusion of the', 'subject from the analysis. The investigator must ensure that his/her personnel and the', 'laboratory(ies) under his/her supervision comply with this requirement. However, when', 'GSK Biologicals or the central laboratory does not provide material for collecting and', ""storing samples, appropriate materials from the investigator's site must be used. Refer to"", 'the Module on Clinical Trial Supplies in the SPM and Central Laboratory investigator', 'manual.', '6.5.2.', 'Biological samples', 'Table 7 present the biological samples that will be collected for this study.', 'Table 7', 'Biological samples', 'Sample type', 'Quantity', 'Unit', 'Timepoints', 'Sub-cohort', 'Fresh Sputum', 'Maximum possible', 'ml', 'Screening visit (Pre-Month', 'All screened', '0)', 'subjects', 'Visit 1 (Month 0)', 'All enrolled', 'Visit 2 (Month 6)', 'subjects', 'Visit 3 (Month 12)', 'AECOPD visit (within', '96 hours of onset of', 'symptoms)', 'Blood for', '21', 'ml', 'Visit 1 (Month 0)', 'All enrolled', 'biomarkers', 'Visit 3 (Month 12)', 'subjects', '19-OCT-2018', '55', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
55,page_56,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.5.3.', 'Laboratory assays (Amended 19 October 2018)', 'Please refer to APPENDIX A for the address of the clinical laboratories used for sample', 'analysis.', ""The quality of sputum samples will be assessed at the investigator's institution and/ or at"", 'a laboratory designated by GSK Biologicals by gram staining.', 'Standard bacteriological methods (and semi-quantitative counts) will be performed on', ""fresh sputum samples at the investigator's institution and/or at a laboratory designated by"", 'GSK Biologicals. Identification of potential bacterial pathogens will be performed', 'according to agreed identification methods (potential pathogens including, but not', 'necessarily limited to, H. influenzae, S. pneumoniae, M. catarrhalis, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii). All results should be entered in the', 'eCRF.', 'Further bacterial characterization for H. influenzae isolates: Identified H. influenzae', ""isolates should be collected and stored in the investigator's institution and will undergo"", 'further species confirmation (i.e. confirmed H. influenzae) and when possible, further', ""differentiation (i.e., Hi/NTHi) at GSK Biologicals' laboratory or at a laboratory"", 'designated by GSK Biologicals using molecular techniques such as PCR. Identified', ""H. influenzae isolates might undergo further testing at GSK Biologicals' laboratory or at a"", ""laboratory designated by GSK Biologicals' using other molecular techniques such as"", 'PCR and sequencing.', ""Identified M. catarrhalis isolates should be collected and stored in the investigator's"", 'institution and might undergo further species confirmation (and when possible, further', ""differentiation) at GSK Biologicals' laboratory or at a laboratory designated by GSK"", 'Biologicals using molecular techniques such as PCR and sequencing.', ""Identified P. aeruginosa isolates should be collected and stored in the investigator's"", ""institution and might potentially undergo further testing at GSK Biologicals' laboratory or"", 'at a laboratory designated by GSK Biologicals.', 'Further bacterial pathogens identification (including, but not necessarily limited to, H.', 'influenzae, S. pneumoniae, M. catarrhalis, S. pyogenes, S. aureus and P. aeruginosa) and', 'quantification (for H. influenzae, S. pneumoniae, M. catarrhalis) on stored sputum', ""samples will be performed at GSK Biologicals' laboratory or a laboratory designated by"", 'GSK Biologicals using qualitative PCR and/or quantitative PCR.', 'Viral pathogens identification (including, but not necessarily limited to, RSV,', 'parainfluenza virus, enterovirus/ HRV, metapneumovirus, influenza virus, adenovirus,', 'bocavirus and coronavirus) on stored sputum samples will be performed at GSK', ""Biologicals' laboratory or a laboratory designated by GSK Biologicals using multiplex"", 'reverse transcription polymerase chain reaction (RT-PCR).', 'In addition, some respiratory viral pathogens (such as HRV) will be quantified in stored', ""sputum samples (or subset) using RT-PCR at GSK Biologicals' laboratory or at a"", 'laboratory designated by GSK Biologicals.', '19-OCT-2018', '56', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']"
56,page_57,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 8 present the methods that will be used for identification of bacterial and viral', 'pathogens.', 'Table 8', 'Microbiology', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution or', 'Central Laboratory Manual', 'semi-', 'GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', ""Investigator's institution"", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae', 'H. influenzae species', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'confirmation and when', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'possible Hi/NTHi', 'as differentiation', 'laboratory', 'plates', 'differentiation', 'PCR', 'Sample collection for', 'potential further', 'characterisation', 'Stored sputum', 'Respiratory bacterial', 'Multiplex PCR', 'Qualitative', 'GSK Biologicals', 'pathogens', 'and/ or quant', 'laboratory or', '(including H. influenzae,', 'itative', 'designated laboratory', 'S. pneumoniae,', 'M. catarrhalis, S. aureus and', 'P. aeruginosa,', 'Streptococcus pyogenes))', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex-PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'laboratory or', 'parainfluenza virus,', 'designated laboratory', 'enterovirus/ HRV,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', 'Respiratory viral pathogens', 'RT-PCR', 'Quantitative', 'GSK Biologicals', '(such as HRV)', 'laboratory* or designated', 'laboratory', '* GSK Biologicals laboratory refers to the Clinical Laboratory Sciences (CLS) in Wavre, Belgium; Rixensart, Belgium;', 'Marburg, Germany.', 'Stored frozen sputum samples (in dithiothreitol [DTT]) might be used for assay', 'development, such as assays for diagnostic purpose or for microbiome analysis and/or for', 'assay validation/characterization purpose and/or quality control.', '19-OCT-2018', '57', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
57,page_58,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Additional testing on stored sputum samples (such as, but not limited to, K. pneumoniae', 'and A. baumannii PCR detection, quantitative PCR for other bacterial and/or viral', 'pathogens, further characterisation of virus such as rhinovirus typing, pathogen', 'genome/gene sequencing, pathogen quantitative/qualitative serotype-specific PCR,', 'multilocus sequence typing, microarray typing, 16sRNA analysis) or on H. influenzae, M.', 'catarrhalis and P. aeruginosa bacterial isolates (such as agglutination assays, further', 'strain characterisation using new molecular biology tools) may be done during the study', 'or after study completion, should these data be required for accurate interpretation of the', 'study data and/ or for further research related to respiratory diseases and/ or should such', ""test(s) become available at GSK Biologicals' laboratory or a laboratory designated by"", 'GSK.', 'Table 9 present the planned assays on serological samples.', 'Table 9', 'Planned assays on serological samples', 'Sample type', 'Component', 'Method', 'Scale', 'Laboratory', 'Plasma', 'Fibrinogen', ""Per contract laboratory's"", 'Quantitative', 'GSK', 'procedures', 'Biologicals', 'Serum', 'hsCRP', ""Per contract laboratory's"", 'Quantitative', 'or GSK', 'procedures', 'designated', 'Serum', 'CXCL10 (IP-10)', ""Per contract laboratory's"", 'Quantitative', 'lab', 'procedures', 'Leukocytes (White', ""Per contract laboratory's"", 'Quantitative', 'Blood Cells)', 'procedures', 'Neutrophils *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Lymphocytes *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Eosinophils *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Whole blood', 'Basophils *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Monocytes *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Erythrocyte (Red', ""Per contract laboratory's"", 'Quantitative', 'Blood Cells)', 'procedures', 'Haemoglobin', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Platelets', ""Per contract laboratory's"", 'Quantitative', 'procedures', '*For white blood cell differential counts', 'Additional testing for biomarkers on stored serum/plasma may be done during the study', 'or after study completion, should these data be required for accurate interpretation of the', 'study data and/ or for further research related to respiratory diseases available at GSK', ""Biologicals' laboratory or a laboratory designated by GSK."", ""The GSK Biologicals' clinical laboratories have established a Quality System supported"", ""by procedures. The activities of GSK Biologicals' clinical laboratories are audited"", 'regularly for quality assessment by an internal (sponsor-dependent) but laboratory-', 'independent Quality Department.', '19-OCT-2018', '58', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
58,page_59,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '7.', 'SAFETY', 'The investigator or site staff is/are responsible during the study for the detection and', 'documentation of events meeting the criteria and definition of an SAE as provided in this', 'protocol.', 'Each subject will be instructed to contact the investigator immediately should they/the', 'subject manifest any signs or symptoms they perceive as serious.', '7.1.', 'Safety definitions', '7.1.1.', 'Definition of an adverse event (Amended 19 October 2018)', 'An AE is any untoward medical occurrence in a subject, temporally associated with the', 'use of a medicinal product, whether or not considered related to the medicinal product, or', 'temporally associated with a study procedure.', 'Examples of an AE include', 'Signs, symptoms, or the clinical sequelae of a suspected interaction.', 'Examples of an AE DO NOT include:', 'Medical or surgical procedures (e.g., endoscopy, appendectomy); the condition that', 'leads to the procedure is an AE.', 'Situations where an untoward medical occurrence did not occur (e.g., social and/or', 'convenience admission to a hospital, admission for routine examination).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Occurrence of a severe AECOPD, unless in the opinion of the Investigator this is', 'related to study procedure.', '7.1.2.', 'Definition of a serious adverse event', 'An SAE is any untoward medical occurrence that:', 'a.', 'Results in death,', 'b. Is life-threatening,', 'Note: The term ""life-threatening\' in the definition of \'serious\' refers to an event in', 'which the subject was at risk of death at the time of the event. It does not refer to an', 'event, which hypothetically might have caused death, had it been more severe.', '19-OCT-2018', '59', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']"
59,page_60,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'c.', 'Requires hospitalisation or prolongation of an existing hospitalisation,', 'Note: In general, hospitalisation signifies that the subject has been admitted at the', 'hospital or emergency ward for observation and/or treatment that would not have', ""been appropriate in the physician's office or in an out-patient setting."", 'Complications that occur during hospitalisation are also considered AEs. If a', 'complication prolongs hospitalisation or fulfils any other serious criteria, the event', 'will also be considered serious. When in doubt as to whether ""hospitalisation\'', 'occurred or was necessary, the AE should be considered serious.', 'Hospitalisation for elective treatment of a pre-existing condition (known or', 'diagnosed prior to informed consent signature) that did not worsen from baseline is', 'NOT considered an SAE.', 'd.', 'Results in disability/incapacity,', ""Note: The term disability means a substantial disruption of a person's ability to"", 'conduct normal life functions. This definition is not intended to include experiences', 'of relatively minor medical significance such as uncomplicated headache, nausea,', 'vomiting, diarrhoea, influenza like illness, and accidental trauma (e.g., sprained', 'ankle) which may interfere or prevent everyday life functions but do not constitute a', 'substantial disruption.', 'or', 'e.', 'Is a congenital anomaly/birth defect in the offspring of a study subject', 'Medical or scientific judgement should be exercised in deciding whether reporting is', 'appropriate in other situations, such as important medical events that may not be', 'immediately life-threatening or result in death or hospitalisation but may jeopardise', 'the subject or may require medical or surgical intervention to prevent one of the', 'other outcomes listed in the above definition. These should also be considered', 'serious. Examples of such events are invasive or malignant cancers, intensive', 'treatment in an emergency room or at home for allergic bronchospasm, blood', 'dyscrasias or convulsions that do not result in hospitalisation.', '7.1.3.', 'Clinical laboratory parameters and other abnormal assessments', 'qualifying as AEs or SAEs', 'In absence of diagnosis, abnormal laboratory findings (e.g., clinical chemistry,', 'haematology, urinalysis) or other abnormal assessments that are judged by the', 'investigator to be clinically significant will be recorded as AEs or SAEs if they meet the', 'definition of an AE or an SAE (refer to Sections 7.1.1 and 7.1.2). Clinically significant', 'abnormal laboratory findings or other abnormal assessments that are present at baseline', 'and significantly worsen following the start of the study will also be reported as AEs or', 'SAEs. However, clinically significant abnormal laboratory findings or other abnormal', 'assessments that are associated with the disease being studied, unless judged by the', ""investigator as more severe than expected for the subject's condition, or that are present"", 'or detected at the start of the study and do not worsen, will not be reported as AEs or', 'SAEs.', '19-OCT-2018', '60', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
60,page_61,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'The investigator will exercise his or her medical and scientific judgement in deciding', 'whether an abnormal laboratory finding or other abnormal assessment is clinically', 'significant.', '7.2.', 'Detecting and recording AEs, SAEs', '7.2.1.', 'Time periods for detecting and recording AEs and SAEs', 'AEs and SAEs related to study participation will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', 'In order to fulfil international reporting obligations, SAEs that are related to study', 'participation (i.e., protocol-mandated procedures, invasive tests, a change from existing', 'therapy) will be collected and recorded from the time the subject consents to participate', 'in the study/study start until she/he is discharged from the study.', 'AEs leading to withdrawal from the study, will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', 'An overview of the protocol-required reporting periods for SAEs and AEs leading to', 'withdrawal is given in Table 10.', 'Table 10', 'Reporting period for SAE and AEs leading to withdrawal (Amended', '19 October 2018)', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month', 'M 0', 'M 6', 'M 12', 'Within 96', '0', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'related to', 'study', 'participation*', 'AEs/SAEs', 'leading to', 'withdrawal', 'from the', 'study', '*Study participation: Specific procedures required by study participation.', '19-OCT-2018', '61', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
61,page_62,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '7.2.2.', 'Evaluation of SAEs (Amended 19 October 2018)', '7.2.2.1.', 'Active questioning to detect SAEs', 'Each subject/ will be instructed to contact the investigator immediately should the subject', 'manifest any signs and symptoms (s)he perceives/ they perceive as serious. However, an', 'occurrence of severe AECOPD is not defined as an SAE and therefore does not need to', 'be reported as such, unless in the opinion of the Investigator this is related to a study', 'procedure.', 'All SAEs either observed by the investigator or his/ her staff or reported by the subject', 'spontaneously or in response to a direct question will be evaluated by the investigator.', 'The nature of each event, date and time of onset, outcome, intensity and possible', 'relationship to the study procedures should be established.', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (e.g., hospital progress notes, laboratory and diagnostics reports) relative', 'to the event. The investigator will then record all relevant information regarding the', ""AE/SAE in the eCRF. The investigator is not allowed to send photocopies of the subject's"", 'medical records to GSK Biologicals instead of appropriately completing the eCRF.', 'However, there may be instances when copies of medical records for certain cases are', 'requested by GSK Biologicals. In this instance, all subject identifiers will be blinded on', 'the copies of the medical records prior to submission to GSK Biologicals.', 'The investigator will attempt to establish a diagnosis pertaining to the event based on', 'signs, symptoms, and/ or other clinical information. In such cases, the diagnosis should', 'be documented as the AE/SAE and not the individual signs/symptoms.', '7.2.2.2.', 'Assessment of causality', 'The investigator should assess the causality of each SAE. The investigator will use', 'clinical judgement to determine the relationship between the SAEs and study', 'participation. Alternative causes, such as natural history of the underlying diseases, other', 'concomitant therapy and other risk factors will be considered and investigated.', 'There may be situations when a SAE has occurred and the investigator has minimal', 'information to include in the initial report to GSK Biologicals. However, it is very', 'important that the investigator always makes an assessment of causality for every event', 'prior to submission of the SAE report to GSK Biologicals. The investigator may change', 'his/her opinion of causality in light of follow-up information and update the SAE', 'information accordingly.', 'If an event meets the criteria to be considered as ""serious\' (see section 7.1.2), additional', 'examinations/tests will be performed by the investigator in order to determine ALL', 'possibly contributing factors to each SAE.', '19-OCT-2018', '62', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
62,page_63,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Possibly contributing factors include:', 'Medical history.', 'Concomitant medication.', 'Protocol required procedure.', 'Other procedure not required by the protocol.', '7.2.2.3.', 'Assessment of outcomes', 'The investigator will assess the outcome of all AEs (including SAEs) recorded during the', 'study as:', 'Recovered/ resolved.', 'Recovering/resolving.', 'Not recovered/ not resolved.', 'Recovered with sequelae/ resolved with sequelae.', 'Fatal (SAEs only).', '7.3.', 'Reporting of SAEs', '7.3.1.', 'Prompt reporting of SAEs related to study participation to GSK', 'SAEs that occur in the time period defined in Section 7.2.1 will be reported promptly to', 'GSK within the timeframes described in Table 11 once the investigator determines that', 'the event meets the protocol definition of an SAE.', 'Table 11', 'Timeframes for submitting SAEs related to study participation to', 'GSK', 'Follow-up of relevant information', 'Initial reports', 'Type of event', 'on a previous report', 'Timeframe', 'Documents', 'Timeframe', 'Documents', 'SAEs related to study', '24 hours*', 'Electronic/', '24 hours*', 'Electronic/', 'participation', 'Expedited Adverse', 'Expedited Adverse Event Report', 'Event Report', '*', 'Timeframe allowed after receipt or awareness of the information.', '7.3.2.', 'Contact information for reporting SAEs to GSK', 'Back-up Study Contact for Reporting SAEs', '24/24 hour and 7/7 day availability:', 'GSK Biologicals Clinical Safety & Pharmacovigilance', 'Fax:', 'PPD', 'PPD', 'or', '19-OCT-2018', '63', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
63,page_64,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '7.3.3.', 'Completion and transmission of SAEs reports related to study', 'participation to GSK', 'Once an investigator becomes aware that an SAE has occurred in a study subject, the', 'investigator (or designee) must complete the information in the electronic Expedited', 'Adverse Event Report WITHIN 24 HOURS. The report will always be completed as', 'thoroughly as possible with all available details of the event. Even if the investigator does', 'not have all information regarding an SAE, the report should still be completed within 24', 'hours. Once additional information is received, the report should be updated WITHIN 24', 'HOURS.', 'The investigator will always provide an assessment of causality at the time of the initial', 'report.', '7.3.3.1.', 'Back-up system in case the electronic reporting system does not work', 'If the electronic reporting system does not work, the investigator (or designee) must', 'complete, then date and sign a paper Expedited Adverse Event Report and fax it to the', 'GSK Biologicals Clinical Safety and Pharmacovigilance department within 24 hours.', 'This back-up system should only be used if the electronic reporting system is not working', 'and NOT if the system is slow. As soon as the electronic reporting system is working', 'again, the investigator (or designee) must complete the electronic Expedited Adverse', 'Event Report within 24 hours. The final valid information for regulatory reporting will be', 'the information reported through the electronic reporting system.', '7.3.4.', ""Updating of SAE after freezing of the subject's eCRF"", ""When SAE information is received after freezing of the subject's eCRF, new or updated"", 'information should be recorded on a paper Expedited Adverse Event Report, with all', 'changes signed and dated by the investigator. The updated report should be faxed to the', 'GSK Biologicals Clinical Safety and Pharmacovigilance department or to the Study', 'Contact for Reporting SAEs (see the Sponsor Information) within the designated', 'reporting time frames specified in Table 11.', ""Note: For studies using INFORM, freezing of the subject's eCRF would mean removal of"", ""write access in the subject's eCRF."", '7.3.5.', 'Regulatory reporting requirements for SAEs', 'The investigator will promptly report all SAEs to GSK Biologicals in accordance with the', 'procedures detailed in Section 7.3.1. GSK Biologicals has a legal responsibility to', 'promptly notify, as appropriate, both the local regulatory authority and other regulatory', 'agencies about the safety of a product under epidemiological investigation. Prompt', 'notification of SAEs by the investigator to the Study Contact for Reporting SAEs is', 'essential so that legal obligations and ethical responsibilities towards the safety of other', 'subjects are met.', '19-OCT-2018', '64', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
64,page_65,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '7.4.', 'Treatment of AEs', 'Treatment of any AE is at the sole discretion of the investigator and according to current', 'good medical practice. Any medication administered for the treatment of a SAE (that are', 'required to be reported as per protocol should be recorded in the Expedited Adverse', ""Event Report of the subject's eCRF."", '8.', 'SUBJECT COMPLETION AND WITHDRAWAL', '8.1.', 'Subject completion', 'A subject who returns for the concluding visit foreseen in the protocol is considered to', 'have completed the study.', '8.2.', 'Subject withdrawal', 'Subjects who are withdrawn because of AEs or SAEs related to study participation must', 'be clearly distinguished from subjects who are withdrawn for other reasons.', 'From an analysis perspective, a ""withdrawal\' from the study refers to any subject who did', 'not come back for the concluding contact foreseen in the protocol.', 'All data collected until the date of withdrawal/last contact of the subject will be used for', 'the analysis.', 'A subject is considered a ""withdrawal\' from the study when no study procedure has', 'occurred, no follow-up has been performed and no further information has been collected', 'for this subject from the date of withdrawal/last contact.', 'Investigators will make an attempt to contact those subjects who do not return for', 'scheduled visits or follow-up. The mode of contact will be by telephone. Three phone', 'contacts will be made with an interval of one week between each phone call.', 'Information relative to the withdrawal will be documented in the eCRF. The investigator', 'will document whether the decision to withdraw a subject from the study was made by', 'the subject himself/herself or by the investigator, as well as which of the following', 'possible reasons was responsible for withdrawal:', 'SAE.', 'Non-serious AE.', 'Protocol violation (specify).', 'Consent withdrawal, not due to an AE*.', 'Moved from the study area.', 'Lost to follow-up.', 'Other (specify).', '19-OCT-2018', '65', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
65,page_66,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '*In case a subject is withdrawn from the study because he/she has withdrawn consent, the', 'investigator will document the reason for withdrawal of consent, if specified by the', 'subject in the eCRF.', '9.', 'STATISTICAL METHODS', '9.1.', 'Enpoints', '9.1.1.', 'Primary endpoint (Amended 19 October 2018)', 'Occurrence of potential bacterial and viral pathogens in sputum of stable COPD', 'patients and during AECOPD, over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological methods, including (but not', 'necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii.', 'Viral pathogens, as identified by PCR, including (but not necessarily limited to)', 'RSV, parainfluenza virus, enterovirus/ HRV, metapneumovirus, influenza virus,', 'adenovirus, bocavirus and coronavirus.', '9.1.2.', 'Secondary endpoints', 'Occurrence of potential bacterial pathogens in sputum of stable COPD patients and', 'during AECOPD, as measured by real-time qualitative PCR/ quantitative PCR and', 'compared to data from bacteriological methods, over the course of 1 year:', '-', 'Including (but not necessarily limited to) H. influenzae, M. catarrhalis, S.', 'pneumoniae, S. aureus and P. aeruginosa.', 'Occurrence of potential bacterial and viral pathogens (overall and by species) in', 'sputum of stable COPD patients by GOLD grade, over the course of 1 year.', 'Occurrence of potential bacterial and viral pathogens (overall and by species) in', 'sputum during AECOPD by severity of AECOPD, over the course of 1 year.', 'Incident rate (per subject per year) of AECOPD, overall and by GOLD grade, over', 'the course of 1 year.', 'Severity of AECOPD, overall and by GOLD grade, over the course of 1 year.', 'Duration of AECOPD, overall and by AECOPD severity, over the course of 1 year.', 'CAT score in stable COPD patients and during AECOPD, over the course of 1 year.', 'SGRQ-C score in stable COPD patients, over the course of 1 year.', 'FEV1% of predicted normal value in stable COPD patients, at Pre-Month 0 and', 'Month 12.', 'Healthcare utilisation, over the course of 1 year.', '19-OCT-2018', '66', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
66,page_67,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '9.1.3.', 'Tertiary endpoints', 'EXACT-PRO scores in stable COPD patients and during AECOPD, over the course', 'of 1 year.', 'Bacterial load measured by both culture and PCR in COPD and during AECOPD.', 'HRV load measured by PCR in COPD and during AECOPD.', '9.2.', 'Determination of sample size', 'The primary objective of this study is to describe the proportion of bacterial and viral', 'pathogens (overall and by species) detected in sputum in stable COPD and during', 'AECOPD.', 'Assuming around 90% of the All Enrolled Set participated in the study, on average 1', 'AECOPD visit and 80% of the above population set can provide an evaluable sputum', 'sample at AECOPD, for 240, 200, 160, and 50 enrolled subjects, one may expect around', '180, 140, 120, 40 sputum samples, respectively. Assuming that results from these sputum', 'samples are independent and that the between country variability is much smaller than the', 'within country variability, we would have the following 95% exact confidence interval', 'for different incidences in sputum samples from exacerbations (see Table 12).', 'Table 12', 'Exact 95% confidence intervals of the percentage of occurrence of a', 'specific bacterium from sputum collected during AECOPD', 'Number of evaluable sputum samples during AECOPD', '%', 'N=180', 'N=140', 'N=120', 'N=40', '5', '[', '2.3', ';', '9.3', ']', '[', '2.0', ';', '10.0', ']', '[', '1.9', ';', '10.6', ']', '[', '0.6', ';', '16.9', ']', '10', '[', '6.0', ';', '15.3', ']', '[', '5.6', ';', '16.2', ']', '[', '5.3', ';', '16.8', ']', '[', '2.8', '; 23.7 ]', '20', '[', '14.4', ';', '26.6', ']', '[', '13.7', ';', '27.6', ']', '[', '13.3', '; 28.3', ']', '[', '9.1', ';', '35.6', ']', '30', '[', '23.4', ';', '37.3', ']', '[', '22.6', ';', '38.3', ']', '[', '22.0', ';', '39.0', ']', '[', '16.6', ';', '46.5', ']', '40', '[', '32.8', ';', '47.6', ']', '[', '31.8', ';', '48.6', ']', '[', '31.2', ';', '49.3', ']', '[', '24.9', ';', '56.7', ']', '50', '[', '42.5', ';', '57.5', ']', '[', '41.4', ';', '58.6', ']', '[', '40.7', ';', '59.3', ']', '[', '33.8', ';', '66.2', ']', 'N = total number of evaluable sputum samples during AECOPD.', 'One of the secondary objectives is to estimate the incidence rate of all-cause AECOPDs', 'in the study population.', 'Assuming around 80% of the all enrolled set completed the study, for 240, 200, 160 and', '50 subjects enrolled, one would have at least 190, 160, 130 and 40 subjects evaluable', 'respectively. Assuming further that around 80% of the subjects can provide an evaluable', 'sputum sample at AECOPD, this would lead to around 150, 130, 100, 30 subjects (see', 'Table 13).', '19-OCT-2018', '67', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
67,page_68,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 13', '95% confidence intervals of AECOPD incidence rates with different', 'overdispersion values', 'Q 1', 'Q = 1.5', '$ =2', '0.2.EECOPD/subject/year', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '30', '6', '0.20', '0.04', '0.36', '0.00', '0.40', '-0.03', '0.43', '100', '20', '0.20', '0.11', '0.29', '0.09', '0.31', '0.08', '0.32', '130', '26', '0.20', '0.12', '0.28', '0.11', '0.29', '0.09', '0.31', '150', '30', '0.20', '0.13', '0.27', '0.11', '0.29', '0.10', '0.30', '1 AECOPD/ /subject/year', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '40', '40', '1.00', '0.69', '1.31', '0.62', '1.38', '0.56', '1.44', '130', '130', '1.00', '0.83', '1.17', '0.79', '1.21', '0.76', '1.24', '160', '160', '1.00', '0.85', '1.15', '0.81', '1.19', '0.78', '1.22', '190', '190', '1.00', '0.86', '1.14', '0.83', '1.17', '0.80', '1.20', '2 AECOPD/subject/year', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '40', '80', '2.00', '1.56', '2.44', '1.46', '2.54', '1.38', '2.62', '130', '260', '2.00', '1.76', '2.24', '1.70', '2.30', '1.66', '2.34', '160', '320', '2.00', '1.78', '2.22', '1.73', '2.27', '1.69', '2.31', '190', '380', '2.00', '1.80', '2.20', '1.75', '2.25', '1.72', '2.28', '3 AECOPD/subject/yeal', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '40', '120', '3.00', '2.46', '3.54', '2.34', '3.66', '2.24', '3.76', '130', '390', '3.00', '2.70', '3.30', '2.64', '3.36', '2.58', '3.42', '160', '480', '3.00', '2.73', '3.27', '2.67', '3.33', '2.62', '3.38', '190', '570', '3.00', '2.75', '3.25', '2.70', '3.30', '2.65', '3.35', '* Normal approximation with variance = Q n/T2, where Q is the overdispersion factor for a Poisson distribution', '(calculations performed in Microsoft Excel).', 'T = Total number of evaluable subjects; n =Total number of exacerbations; CI = confidence interval; LL = lower limit;', 'UL = upper limit.', '9.3.', 'Cohorts for Analyses', 'The following study cohorts will be evaluated.', '9.3.1.', 'All screened Set', 'The all screened set will include all screened patients.', '9.3.2.', 'All Enrolled Set', 'The all enrolled set will include all successfully screened subjects in the study.', '19-OCT-2018', '68', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
68,page_69,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '9.3.3.', 'Full Analysis Set', 'The Full Analysis Set (FAS) will include all enrolled patients except for those who', 'discontinued the study during Visit 1.', 'Study objectives will be assessed on the FAS. The population set for each analysis will', 'change according to the subjects evaluable for the specific endpoint.', 'Note: Subjects using antibiotics on a continual basis (defined as more than 1 month in', 'total) will be allowed to continue study participation, but may be eliminated from the', 'analyses.', '9.4.', 'Analysis of demographics', 'Demographic characteristics (age at enrolment, gender and geographical ancestry) and', 'cohort description will be summarised using descriptive statistics:', 'Frequency tables will be generated for categorical variable such as geographical', 'ancestry.', 'Mean, median, standard deviation, minimum and maximum will be provided for', 'continuous data such as age.', 'The distribution of subjects enrolled among the study sites will be tabulated.', 'Withdrawal status will be summarised according to the reason for withdrawal. The', 'number of withdrawn patients will be tabulated by study visit and overall.', 'All tables will also be generated by country.', '9.5.', 'Analysis of primary objective', 'The proportion of sputum samples obtained at each visit (confirmed stable visits* and', 'AECOPD visits and positive for specific bacterial/ viral pathogens by bacteriological', 'methods and PCR, respectively (overall and by bacterial/viral species) will be computed', 'with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled study visit for which the', 'investigator confirms in the eCRF that the subject is stable/ has recovered from a', 'previous exacerbation.', '19-OCT-2018', '69', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
69,page_70,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '9.6.', 'Analysis of secondary objectives', 'The proportion of sputum samples obtained at each visit (confirmed stable visits* and', 'AECOPD visits [any severity, mild, moderate and severe]) and positive for specific', 'bacterial pathogens by both bacteriological methods and PCR (overall and by bacterial', 'species) will be computed with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled study visit for which the', 'investigator confirms in the eCRF that the subject is stable / has recovered from a', 'previous exacerbation.', 'The proportion of sputum samples obtained at each stable visit and positive for specific', 'bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and', 'by bacterial/ viral species) will be computed with 95% confidence intervals, by GOLD', 'grade at enrolment.', 'The proportion of sputum samples obtained at each AECOPD visits and positive for', 'specific bacterial/ viral pathogens by bacteriological methods and PCR, respectively', '(overall and by bacterial/viral species) will be computed with 95% confidence intervals,', 'by AECOPD severity.', 'The proportion of sputum samples obtained at each confirmed stable/AECOPD visit with', 'previous administration of antibiotics or not and positive for specific bacterial/ viral', 'pathogens by bacteriological culture and PCR, respectively (overall and by bacterial/viral', 'species) will be computed with 95% confidence intervals.', 'The following incidence rates will be computed, with 95% confidence intervals (CI):', 'All-cause AECOPD.', 'AECOPD having sputum containing bacterial pathogens found by PCR or by', 'bacteriological methods or by both methods (overall and by, but not limited to, the', 'following bacterial species: H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'and P. aeruginosa).', 'The 95% CI of the incidence rate will be computed using a model which accounts for', 'repeated events. The Generalised linear model assuming the Negative Binomial', 'distribution for the response variable with logarithm as link function, and the logarithm of', 'time for follow-up as an offset variable will be used. The incidence rates described above', 'will also be computed for mild, moderate severe AECOPD and by GOLD grade at', 'enrolment and will be estimated by country.', 'The number of subjects that report at least 1 AECOPD will be tabulated and descriptive', 'statistics (median, mean, range, standard deviation, first and third quartiles) on the', 'number of days of AECOPD episodes will be presented, for any, mild, moderate and', 'severe AECOPD.', 'Descriptive statistics (median, mean, range, standard deviation, first and third quartiles)', 'on the CAT and SGRQ-C scores will be tabulated at each respective visit.', '19-OCT-2018', '70', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
70,page_71,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Summary statistics (mean, median, standard deviation, maximum and minimum) on', 'post-bronchodilator FEV1% of predicted normal value will be tabulated at each', 'respective visit.', 'Descriptive summaries on healthcare use will be provided.', '9.7.', 'Analysis of tertiary objectives', 'Descriptive statistics (median, mean, range, standard deviation, first and third quartiles)', 'on the end date of AECOPD as provided by the investigator or estimated by', 'EXACT-PRO (via a specific algorithm which will be detailed in the Statistical Analysis', 'Plan) will be presented.', 'Descriptive summaries of the quantity of specific bacteria at each scheduled [stable] and', 'exacerbation visit will be provided for both culture and PCR analysis.', 'Descriptive summaries of the quantity of specific viruses at each scheduled [stable and', 'exacerbation visit will be provided for PCR analysis.', 'A conditional logistic model will be fitted to estimate the odds ratio of being in a stable', 'state vs. an exacerbation state given the presence or not of several bacterial pathogens', 'found by bacteriological culture and by country. The same model will also be performed', 'for bacterial and viral pathogens found by PCR.', '9.8.', 'Conduct of analyses', 'Any deviation(s) or change(s) from the original statistical plan outlined in this protocol', 'will be described and justified in the final study report.', '9.8.1.', 'Sequence of analyses', 'An interim analysis of the bacterial primary objective will be performed when at', 'least 40 AECOPD sputum samples are available. The rate of positive samples will be', 'computed for Hi, NTHi and Mcat together and per pathogen. No study report will be', 'written at this stage.', 'A final analysis of all objectives will be performed after the last subject last visit of', 'the entire study. A final study report will be written at this stage.', '9.8.2.', 'Statistical considerations for interim analyses', 'All analyses are exploratory and will be conducted on final data and therefore no', 'statistical adjustment for interim analyses is required.', '19-OCT-2018', '71', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
71,page_72,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '10.', 'ADMINISTRATIVE MATTERS', 'To comply with ICH GCP or other applicable guidelines, administrative obligations', 'relating to data collection, monitoring, archiving data, audits, confidentiality, ownership,', 'public disclosure requirements and publications must be met.', '10.1.', 'Electronic Case Report Form instructions', 'A validated GSK defined electronic data collection tool will be used as the method for', 'data collection.', 'In all cases, subject initials will not be collected nor transmitted to GSK. Subject data', 'necessary for analysis and reporting will be entered/transmitted into a validated database', 'or data system. Clinical data management will be performed in accordance with', 'applicable GSK standards and data cleaning procedures.', ""While completed eCRFs are reviewed by a GSK Biologicals' Site Monitor at the study"", 'site, omissions or inconsistencies detected by subsequent eCRF review may necessitate', 'clarification or correction of omissions or inconsistencies with documentation and', 'approval by the investigator or appropriately qualified designee. In all cases, the', 'investigator remains accountable for the study data.', 'Once the database is archived and the clinical study report is complete and approved by', 'all parties, each participating investigator will be provided with a CD-ROM of the final', 'version of the data generated at his/her investigational site.', '10.2.', 'Study monitoring by GSK Biologicals', 'GSK will monitor the study to verify that, amongst other items, the:', 'Data are authentic, accurate, and complete.', 'Safety and rights of subjects are being protected.', 'Study is conducted in accordance with the currently approved protocol, any other', 'study agreements, GCP and all applicable regulatory requirements.', 'The investigator and the head of the medical institution (where applicable) agrees to', 'allow the monitor direct access to all relevant documents.', 'The investigator must ensure provision of reasonable time, space and qualified personnel', 'for monitoring visits.', 'Direct access to all study-site related and source data is mandatory for the purpose of', 'monitoring review. The monitor will perform a eCRF review and a Source Document', 'Verification (SDV). By SDV we understand verifying eCRF entries by comparing them', 'with the source data that will be made available by the investigator for this purpose.', 'The Source Documentation Agreement Form describes the source data for the different', 'data in the eCRF. This document should be completed and signed by the site monitor and', '19-OCT-2018', '72', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
72,page_73,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', ""investigator and should be filed in the investigator's study file. Any data item for which"", 'the eCRF will serve as the source must be identified, agreed and documented in the', 'source documentation agreement form.', 'Upon completion or premature discontinuation of the study, the monitor will conduct site', 'closure activities with the investigator or site staff, as appropriate, in accordance with', 'applicable regulations, GCP, and GSK procedures.', '10.3.', 'Record retention', 'Following closure of the study, the investigator must maintain all site study records', '(except for those required by local regulations to be maintained elsewhere) in a safe and', 'secure location. The records must be easily accessible, when needed (e.g., audit or', 'inspection), and must be available for review in conjunction with assessment of the', 'facility, supporting systems, and staff. Where permitted by applicable laws/regulations or', 'institutional policy, some or all of these records can be maintained in a validated format', 'other than hard copy (e.g., microfiche, scanned, electronic); however, caution needs to be', 'exercised before such action is taken. The investigator must ensure that all reproductions', 'are legible and are a true and accurate copy of the original and meet accessibility and', 'retrieval standards, including re-generating a hard copy, if required. Furthermore, the', 'investigator must ensure that an acceptable back-up of the reproductions exists and that', 'there is an acceptable quality control procedure in place for making these reproductions.', 'GSK will inform the investigator/institution of the time period for retaining these records', 'to comply with all applicable regulatory requirements. The minimum retention time will', 'meet the strictest standard applicable to a particular site, as dictated by ICH GCP or other', 'applicable guidelines, any institutional requirements or applicable laws or regulations, or', 'GSK standards/procedures otherwise, the minimum retention period will default to 25', 'years after completion of the study report.', 'The investigator/institution must notify GSK of any changes in the archival', 'arrangements, including, but not limited to, archival at an off-site facility and transfer of', 'ownership of the records in the event the investigator leaves the site.', '10.4.', 'Quality assurance', 'To ensure compliance with GCP or other applicable guidelines and all applicable', 'regulatory requirements, GSK may conduct a quality assurance audit. Regulatory', 'agencies may also conduct a regulatory inspection of this study. Such audits/inspections', 'can occur at any time during or after completion of the study. If an audit or inspection', 'occurs, the investigator and institution agree to allow the auditor/inspector direct access', 'to all relevant documents and to allocate his/her time and the time of his/her staff to the', 'auditor/inspector to discuss findings and any relevant issues.', '19-OCT-2018', '73', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
73,page_74,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '10.5.', 'Posting of information on publicly available registers and', 'publication policy', 'GSK assures that the key design elements of this protocol will be posted on the GSK', 'website and in publicly accessible database(s) such as clinicaltrials.gov, in compliance', 'with the current regulations.', 'GSK also assures that results of this study will be posted on the GSK website and in', 'publicly accessible regulatory registry(ies) within the required time-frame, in compliance', 'with the current regulations.', 'Studies that do not evaluate vaccines/products are progressed for publication in the', 'scientific literature when the results provide important scientific or medical knowledge or', 'are relevant for patient care, and will be considered for disclosure on the GSK website', 'and in publicly accessible regulatory registry(ies).', '10.6.', 'Provision of study results to investigators', 'Where required by applicable regulatory requirements, an investigator signatory will be', 'identified for the approval of the study report. The investigator will be provided', 'reasonable access to statistical tables, figures, and relevant reports and will have the', 'opportunity to review the complete study results at a GSK Biologicals site or other', 'mutually-agreed location.', 'GSK Biologicals will also provide the investigator with the full summary of the study', 'results. The investigator is encouraged to share the summary results with the study', 'subjects, as appropriate.', '10.7.', 'Data Sharing', 'Under the framework of the SHARE initiative, results of GSK studies may be combined', 'with non- GSK studies, to investigate further about the study product(s) and other', 'product(s), and /or the disease/condition under investigation and related diseases and', 'conditions.', '11.', 'COUNTRY SPECIFIC REQUIREMENTS', 'Not applicable.', '19-OCT-2018', '74', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
74,page_75,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '12.', 'REFERENCES', 'Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of', 'chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106: 196-204.', 'Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials:', 'from lung function to biomarkers. Eur Respir J. 2008; 31: 416-69.', 'Charlson ES, Bittinger K, Haas AR et al. Topographical continuity of bacterial', 'populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;', '184: 957-63.', 'Curran T, Coyle PV, McManus TE et al. Evaluation of real-time PCR for the detection', 'and quantification of bacteria in chronic obstructive pulmonary disease. FEMS Immunol', 'Med Microbiol. 2007; 50: 112-8.', 'De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in', 'chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009; 46: 129-33.', 'Domenech A, Puig C, Mart√≠ S et al. Infectious etiology of acute exacerbations in severe', 'COPD patients. J Infect. 2013; 67: 516-23.', 'Erb-Downward JR, Thompson DL, Han MK et al. Analysis of the lung microbiome in', 'the ""healthy"" smoker and in COPD. PLoS One. 2011; 6: e16384.', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the', 'diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease,', 'updated 2013. Available from:', 'http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the', 'diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease,', 'updated 2017. Available from:', 'p://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/', 'Guoping Hu, MD, PhD; Yumin Zhou, MD et al. Risk of COPD from Exposure to', 'Biomass Smoke: A Metaanalysis. CHEST. 2010; 138(1):20-31', 'Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic', 'obstructive pulmonary disease. N Engl J Med. 2004; 350: 2645-53.', 'Hui DS, Ip M, Ling T et al. A multicentre surveillance study on the characteristics,', 'bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute', 'exacerbations of chronic bronchitis. Respirology. 2011; 16: 532-9.', 'Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive', 'pulmonary disease. N Engl J Med. 2010; 363: 1128-38.', '19-OCT-2018', '75', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
75,page_76,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Hutchinson AF, Ghimire AK, Thompson MA et al. A community-based, time-matched,', 'case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007;', '101: 2472-81.', 'Jones P, Miravitlles M, van der Molen T et al. Beyond FEV1 in COPD: a review of', 'patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis.', '2012; 7: 697-709.', 'Ko FW, Ip M, Chan PK et al. A 1-year prospective study of the infectious etiology in', 'patients hospitalized with acute exacerbations of COPD. Chest. 2007; 131: 44-52.', 'Ko FWS, Hui DSC, Lai CKW et al. Worldwide burden of COPD in high- and low-', 'income countries. Part III. Asia-Pacific studies. Int J Tuberc Lung Dis. 2008;12(7):713-', '717.', 'Leidy NK, Wilcox TK, Jones PW et al. Standardizing measurement of chronic', 'obstructive pulmonary disease exacerbations. Reliability and validity of a patient-', 'reported diary. Am J Respir Crit Care Med. 2011; 183: 323-9.', 'Lim Sam, Lam Chi-Leung David et al. Impact of chronic obstructive pulmonary disease', '(COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pacific', 'Family Medicine. 2015; 14:4', 'Mathers CD and Loncar D. Projections of global mortality and burden of disease from', '2002 to 2030. PLoS Med. 2006; 3: e442.', 'Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria', 'important? Eur Respir J Suppl. 2002; 36: 9s-19s.', 'Mohan A, Chandra S, Agarwal D et al. Prevalence of viral infection detected by PCR and', 'RT-PCR in patients with acute exacerbation of COPD: A systematic review. Respirology.', '2010;15(5):536.42.', 'Mons√≥ E, Ruiz J, Rosell A et al. Bacterial infection in chronic obstructive pulmonary', 'disease. A study of stable and exacerbated outpatients using the protected specimen', 'brush. Am J Respir Crit Care Med. 1995; 152: 1316-20.', 'Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic', 'obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;', '173: 1114-21.', 'Perotin JM, Dury S, Renois F et al. Detection of multiple viral and bacterial infections in', 'acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study. J', 'Med Virol. 2013; 85: 866-73.', 'Singh Richa, Mackay AJ et al. Inflammatory thresholds and the species-specific effects', 'of colonising bacteria in stable chronic obstructive pulmonary disease. Respiratory', 'Research. 2014; 15: 114.', '19-OCT-2018', '76', '75661ebdab2e949f7a1f1bc2071b9dec72acecc']"
76,page_77,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax. 2006; 61: 250-8.', 'Tan WC, Seale P, Ip M et al. Trends in COPD mortality and hospitalizations in countries', 'and regions of Asia-Pacific. Respirology. 2009; 14: 90-7.', 'Wedzicha JA and Seemungal TA. COPD exacerbations: defining their cause and', 'prevention. Lancet. 2007; 370: 786-96.', 'World Health Organization (WHO). Priority environment and health risks. 2013.', 'Available from: http://www.who.int/heli/risks/indoorair/indoorair/en/#. Accessed: 27 July', '2016.', 'World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD) Fact', 'Sheet. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/', 'Accessed: 20 October 2017.', 'Wilkinson TM, Hurst JR, Perera WR et al. Effect of interactions between lower airway', 'bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129: 317-24.', 'Ye F, He LX, Cai BQ et al. Spectrum and antimicrobial resistance of common pathogenic', 'bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary', 'disease in mainland of China. Chin Med J (Engl). 2013; 126: 2207-14.', '19-OCT-2018', '77', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
77,page_78,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'APPENDIX A', 'CLINICAL LABORATORIES (Amended 19', 'October 2018)', 'Table 14', ""GSK Biologicals' laboratories"", 'Laboratory', 'Address', 'GSK Biologicals Clinical', 'Biospecimen Reception - B7/44', 'Laboratory Sciences (CLS)', ""Rue de l'Institut, 89 - B-1330 Rixensart -"", 'Rixensart', 'Belgium', 'GSK Biologicals Clinical', 'Avenue Fleming, 20 - B-1300 Wavre - Belgium', 'Laboratory Sciences (CLS)', 'Wavre-Nord Noir Epine', 'Table 15', 'Outsourced Laboratories', 'Laboratory', 'Address', 'Q¬≤ Solutions Clinical Trials (US)', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Q¬≤ Solutions (Singapore)', 'Tan Tock Seng Hospital', 'Dept of Laboratory Medicine', 'Level 2, Podium Block', 'Tan Tock Seng Hospital', '11 Jalan Tan Tock Seng', 'Singapore 308433', 'DDL Diagnostic Laboratory B.V.', 'Fonteijnenburghlaan 7', 'Voorburg', 'Netherland', '19-OCT-2018', '78', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
78,page_79,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'APPENDIX B', 'AMENDMENT TO THE PROTOCOL', 'GlaxoSmithKline Biologicals', 'Vaccine Value & Health Science (VVHS)', 'Protocol Amendment 1', 'eTrack study number', '201112 (EPI-NTHI-001 BOD APA)', 'and Abbreviated Title', 'Amendment number:', 'Amendment 1', 'Amendment date:', '13 February 2017', 'PPD', 'Co-ordinating author:', 'Scientific Writer', 'Rationale/background for changes:', 'The protocol amendment has been issued to implement the following changes:', 'Alignment of the protocol to the updated GOLD consensus report of 2017 and the', 'COPD fact sheet.', 'Alignment of the study endpoints to the study objectives.', 'Overall update based on the scientific and operational experience gained from the', 'current COPD studies.', 'To update the new literature references.', 'To reflect the upgrade to new version for CRF, ICF, protocol, SPM and overall', 'changes in the functions due to reorganization.', 'To correct some typographical errors.', ""Update of the GSK laboratory's name."", 'Amended text has been included in bold italics and deleted text in strikethrough in the', 'following sections:', 'Title page:', 'Title', 'Occurrence of potential bacterial and viral pathogens', 'in stable chronic obstructive pulmonary disease', '(COPD) and during acute exacerbations of COPD', '(AECOPD), in Asia Pacific.', '19-OCT-2018', '79', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
79,page_80,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Contributing authors', 'PPD', 'Epidemiologist', 'PPD', 'Clinical Research', 'Development and Research Development Lead', 'PPD', 'Clinical', 'Research-Development and Research', 'Development Lead', 'PPD', 'Biostatistician', 'PPD', 'Lead', 'statistician', 'PPD', 'Project', 'Delivery Lead', 'PPD', 'Study Delivery Lead', 'PPD', 'Study Delivery Manager,', '(External Consultant [Freelance]for GSK', 'Biologicals)', 'PPD', 'Study Data', 'Manager (Business & Decision Life Sciences for', 'GSK Biologicals) Senior Manager, Oversight', 'Data Management', 'PPD', 'Study Data Manager', 'PPD', 'Vaccine Supply', 'Coordinator (CVO Europe, for GSK Biologicals)', 'PPD', 'Project Manager, GVCL', 'Clinical Readout Team Leader, Clinical', 'Laboratory Sciences', 'PPD', 'Study Manager, GVCL', '(Business & Decision Life sciences, for GSK', 'Biologicals)/', 'PPD', 'Study Manager,', 'Clinical Laboratory Sciences', 'PPD', 'Global', 'PPD', 'Regulatory Lead and', 'Technical', 'Global Regulatory Affairs representative', '19-OCT-2018', '80', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
80,page_81,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'Clinical Safety', 'Representatives', 'PPD', 'Expert Scientist, Clinical', 'Laboratory Sciences', 'PPD', 'Study Data Manager (Business', '& Decision Life Sciences, for GSK Biologicals)', 'P', 'P', 'Dr.', 'PPD', 'University of Sydney Head,', 'D', ',', 'Respiratory Trials, Contributing author from The', 'George Institute for Global Health, Australia', 'Contributing author from The George Institute for Global Health, Australia', 'Dr.', 'PPD', ',', 'University of Sydney Head, Respiratory Trials', 'Trademarks', 'Trademarks of the GlaxoSmithKline', 'Generic description', 'group of companies', 'EXACT-PROR', 'Exacerbations of Chronic Pulmonary', 'Disease Tool - Patient Reported Outcome', 'SGRQ-C', ""St. George's Respiratory Questionnaire"", 'for COPD patients', 'Background', 'Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable', 'disease characterised by persistent airflow obstruction which is not fully reversible and', 'which is usually progressive in the long term. The classification of COPD is done based', ""on the patient's spirometric classification according to GOLD, 2013. The airflow"", 'limitation in COPD patients can be classified into GOLD grades as shown in Table 1', '[GOLD, 2013]. In this study, additional parameters are going to be collected in order to', 'allow for a combined assessment that could be used for future evaluation, as detailed', 'in Figure 1 [GOLD, 2017].', '19-OCT-2018', '81', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
81,page_82,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Figure 1 The refined ABCD assessment tool', 'Spirometrically', 'Assessment of', 'Assessment of', 'confirmed', 'airflow limitation', 'symptoms/risk of', 'diagnosis', 'exacerbations', 'Exacerbation', 'history', 'FEV,', '2', '(% predicted)', 'or', 'Post-bronchodilator', 'GOLD 1', '80', '1 leading', 'c', 'D', 'FEV1/FVC < 0.7', 'to hospital', 'GOLD 2', '50-79', 'admission', 'GOLD 3', '30-49', '0 or 1', 'GOLD 4', '< 30', '(not leading', 'to hospital', 'A', 'B', 'admission)', 'mMRC 0-1', 'mMRC 2', 'CAT < 10', 'CAT 10', 'Symptoms', 'GOLD = Global Initiative for Chronic Obstructive Lung Disease; CAT = COPD assessment test; FEV1 = forced', 'expiratory volume in 1 second; FVC = forced vital capacity; mMRC = Modified British Medical Research', 'Council Questionnaire', 'The classification of severity of airflow limitation in COPD patients is provided', 'according to GOLD, 2017 as follows,', 'Patient Group A - Low Risk, Less Symptoms Typically GOLD 1 or GOLD 2 (Mild', 'or Moderate airflow limitation); and/or 0-1 exacerbation per year and no', 'hospitalization for exacerbation; and CAT score < 10 or mMRC grade 0-1', 'Patient Group B - Low Risk, More Symptoms Typically GOLD 1 or GOLD 2 (Mild', 'or Moderate airflow limitation); and/or 0-1 exacerbation per year and no', 'hospitalization for exacerbation; and CAT score > 10 or mMRC grade >2', 'Patient Group C - High Risk, Less Symptoms Typically GOLD 3 or GOLD 4', '(Severe or Very Severe airflow limitation); and/or > 2 exacerbations per year or >', '1 with hospitalization for exacerbation; and CAT score < 10 or mMRC grade 0-1', 'Patient Group D - High Risk, More Symptoms Typically GOLD 3 or GOLD 4', '(Severe or Very Severe airflow limitation); and/or > 2 exacerbations per year or', '>', '1 with hospitalization for exacerbation; and CAT score > 10 or mMRC grade > 2.', 'COPD is the fifth leading cause of mortality worldwide, accounting for 6% of all', 'deaths globally (WHO 2015]. A recent study reported high overall morbidity and', 'mortality rates due to COPD in the Asia Pacific region. The prevalence of moderate to', 'severe COPD in adults aged 30 years or above was estimated to be 5.9% in South Korea,', '5.4% in Taiwan, 4.7% in Australia and 3.5% in Hong Kong [Tan, 2009] The overall', 'estimated prevalence COPD in Asia-Pacific was estimated to be 6.2% with 19.1%', 'having severe COPD [Lim, 2015]. The prevalence and burden of COPD are projected to', 'continue to increase in the coming decades due to continued exposure to risk factors and', ""the changing age structure of the world's population [Mathers, 2006]. In Asia,"", '19-OCT-2018', '82', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
82,page_83,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'urbanisation is expected to play a major role in the increase of the number of prevalent', 'cases of COPD between 2010 and 2020 [Tan, 2009]. In terms of the number of deaths,', 'the burden of disease is higher in the Asia-Pacific region when compared to the', 'industrialised western countries. It was estimated through mathematical modelling that', '56.6 million people aged > 30 years had moderate to severe COPD with a prevalence rate', 'of 6.3% [Ko, 2008].', 'Synopsis and Section 1.2 Rationale for the study', 'Because the infectious aetiology-of AECOPD has been suggested to vary according to', 'geographical region, the primary purpose of this study (which will be conducted in', 'several countries in Asia Pacific) is to evaluate the occurrence of bacterial and viral', 'pathogens in the sputum of stable COPD patients and at the time of AECOPD. Given the', 'increasing and projected burden of COPD in the Asia Pacific region, this study will also', 'evaluate the frequency, severity and duration of AECOPD, as well as the impact of', 'AECOPD on health-related quality of life (HRQOL), healthcare utilisation, and lung', 'functionand on exercise capacity.', 'In addition, both PCR and bacteriological methods will be used for characterisation and', '(quantification in some cases) of bacteria in sputum. To date, identification of bacteria', 'and assessment of bacterial load is done in the vast majority of cases by culture.', 'However, the few studies that have compared culture with PCR demonstrated that PCR is', 'more discriminatory at detecting typical airway bacteria [Curran, 2007; Singh, 2014].', 'Moreover, in a multi-centre study, PCR has the advantage that it can be performed on', 'stored sputum samples, and can therefore be done centrally, whereas culture has to be', 'performed on fresh sputum samples, which can lead to variable results in case of due to', 'variability in testing methods between laboratories.', 'Synopsis and Section 2 Objectives', 'Primary objective', 'To estimate the proportion of bacterial and viral pathogens (overall and by species)', 'detected in sputum of stable COPD patients and during AECOPD.: To estimate the', 'proportion of potential bacterial and viral pathogens (overall and by species)', 'detected in sputum of stable COPD patients and during AECOPD, using', 'respectively bacteriological methods and viral PCR, over the course of 1 year.', '19-OCT-2018', '83', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
83,page_84,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Secondary objectives', 'To evaluate the concordance between PCR and bacteriological methods', 'databaeteriological culture with respect to their ability to characterise and (quantify', 'in some cases) bacterial pathogens in sputum in sputum for potential bacterial', 'pathogens.', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum of stable COPD patients, by GOLD grade.', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum during AECOPD, by severity of AECOPD.', 'To assess the impact of all cause AECOPD on exercise capacity.', 'Tertiary objectives', 'To estimate the difference in the presence of bacterial pathogens in sputum between', 'stable state and AECOPD.', 'To evaluate the load of bacterial and viral pathogen in stable COPD and during', 'AECOPD.', 'To collect biological specimens for future respiratory disease-related testing:', '-', 'Aliquots of sputum samples for assay development and microbiome analysis at', 'stable visits and during exacerbation.', '-', 'Blood sampling for potential biomarkers for identification/quantification of', 'biomarkers.', '-', 'Bacterial isolates for further strain characterisation.', '19-OCT-2018', '84', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
84,page_85,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 3 Study design overview', 'Moderate to very severe', 'COPD patients', '5', '40 years', 'Scheduled', 'Screening Visit', 'V1', 'V2', 'V3', '(stable) visits', '(Pre-month 0)', 'MO', 'M6', 'M12', '(V1,V2,V3)', '-', 'Spiro, Chest X-Ray,', 'e-DC, SP', 'SP', 'Spiro, SP', 'for all subjects', 'e -DC, SP, ATS-DLD-078,', 'CAT,SGRQ-O', 'CAT, SGRQ-C', 'CAT, SGRQ-C,', 'GMWT', 'GMWT', 'Biomass exposure', 'BS', 'BS', 'AECOPD visit during', 'AECOPD and follow-up', 'AECOPD', 'Follow -up', 'phone call(s)', 'visit', 'phone call(s)*', '-', 'SP ,CAT', 'for each AECOPD', 'Epoch 001', 'V = Visit; M = Month; SP = sputum sample; e-DC: Training and use of electronic Diary card; CAT= COPD', ""assessment test; SGRQ -C = St. George's Respiratory Questionnaire for COPD patients; spiro = spirometry;"", 'GMWT -6 -minutewalk test; BS = Blood Sampling; AECOPD= acute exacerbation of COPD;', '=', 'acute exacerbation of COPD; ATS-DLD-078 = American Thoracic Society and National Heart', 'and Lung Institute-Division of Lung Disease Respiratory Questionnaire', '* The sputum samples during AECOPD should preferably be obtained before administration of the first dose of', 'antibiotics to treat the AECOPD (if applicable). Self collection of the sputum sample will be allowedin specific', 'cases, where the first dose of antibiotics absolutely needs to be taken before an AECOPD visit can take place.', 'This is not-allowed at scheduled visits when subject should be in stable condition.', '**', 'Follow up phone calls will take place at least every 2 weeks, until the AECOPD has resolved', 'Note: Screening visit should ideally occur not more than be longer than 6 weeks before', 'visit 1 Study visits/contacts:', '- Screening visit.', '- 6 monthly Three scheduled (stable) study visits occurring at 6 month intervals.', '- For each AECOPD: AECOPD visit (within 96 hours of the onset of the', 'symptoms) and follow-up phone call(s) (at least every 2 weeks until the', 'AECOPD has resolved). Follow-up phone contacts will define end of AECOPD.', 'Biological samples:', '-', 'Blood samples for biomarker testing will be collected at Visit 1 (M0), Visit 3', '(M12).', '19-OCT-2018', '85', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
85,page_86,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Synopsis and Section 3.1 Discussion of study design', 'The primary objective of this study is to prospectively investigate the prevalence and', 'distribution of bacteria and viruses isolated from sputum samples from moderate to very', 'severe stable COPD patients (with moderate very severe COPD and at the time of', 'AECOPD, in Asian populations. In order to increase the chance that the patients will', 'exacerbate during the study, only patients with a documented history of at least 1', 'moderate or severe AECOPD in the previous year will be recruited, as this is known to be', 'the best predictor of AECOPD [Hurst, 2010]. Therefore, this study will permit an', 'estimation of incidence of AECOPD in a COPD population at increased risk of', 'exacerbation. It will not provide a true population-based incidence of AECOPD.', 'In order to study factors affecting disease progression in Asia Pacific, prospective data', 'from a relatively large cohort of COPD patients is essential. The use of electronic Diary', 'Cards to detect changes in the respiratory symptoms that define an AECOPD, the', 'standardised questionnaires and spirometry assessments,and exercise capacity tests will', 'allow robust conclusions to be drawn about the effects of exacerbations on decline in', 'lung function and HRQOL. Furthermore, the completeness of vital status information will', 'allow to determine the effects of exacerbations and hospitalizations on mortality to be', 'examined with confidence.', 'EXACT PRO will be used to assess breathlessness, cough and presence of sputum, chest', 'symptoms, difficulty bringing up sputum, feeling tired or weak, sleep disturbance, and', 'feeling scared or worried about their condition. Advantages to this approach include', 'standardised data, reduced recall bias, and the potential to identify events and determine', 'resolution based on a predefined scoring algorithm [Leidy, 2011]. Standardised', 'questionnaires completed during study visits include the SGRQ-C and the CAT. The', 'SGRQ-C is designed to assess HRQOL, current health and does not specify a recall', 'period. The CAT is a simple, short, patient-completed instrument to assess HRQOL and', 'symptom burden in patients with COPD. The CAT has good internal consistency and test-', 'retest reliability, correlates strongly with the SGRQ-C, and is able to distinguish between', 'stable patients and those undergoing an AECOPD [Jones, 2012].', 'Section 3.1.1 Detection of AECOPD', 'Note that:', 'Any symptom occurring on at least 5 consecutive days prior to a potential', 'exacerbation will not be taken into account to define an exacerbation.', 'Each time a potential AECOPD is detected via the electronic Diary Card, the device will', 'alert the subject to contact the study site, and at the same time an alert will be sent to the', 'site so that the site staff contacts the subject to determine if the alert is an AECOPD or', 'not, and if check whether an AECOPD visit is warranted. In addition, the site should', '19-OCT-2018', '86', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
86,page_87,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'proactively follow-up all data received via the electronic Diary Card and contact the', 'subject whenever deemed necessary.', 'During the contact with the subject, the site will determine whether the subject might', 'actually be experiencing an AECOPD (e.g. notifications that can be explained solely by', 'increased physical activity will not be considered):', 'If the site concludes that the subject is not experiencing an AECOPD, this should be', 'documented/ reported in the eCRF. Please refer to study procedures manual (SPM)', 'for more details on how to perform this.', 'If the site concludes that the subject may be experiencing an AECOPD, an AECOPD', 'visit will be scheduled as soon as possible after the onset of AECOPD symptoms as', 'recorded in the electronic Diary Card or confirmed by the subject (maximum', '96 hours after onset of symptoms and, if applicable, preferably before starting', 'treatment with antibiotics). The AECOPD onset date will be captured in the eCRF', 'and additional information about severity will be also collected.', '- In case the AECOPD is confirmed but no AECOPD visit can take place, the', 'site should record the information in the medical records subject files, and in', 'the CRF in medical records section and obtain all relevant information', 'regarding the AECOPD(hospital record, medical record etc) and record this in', 'the eCRF.', 'During the AECOPD visit, the investigator will confirm the occurrence of the AECOPD', 'based on clinical and medical judgement and based on the Anthonisen criteria, and will', 'record its date of onset. The end date of the AECOPD and its severity will be determined/', 'confirmed by the investigator/delegate during (a) follow-up phone call(s), which will take', 'place at least every 2 weeks until the AECOPD has resolved.', 'If an AECOPD occurs at the time when one of the scheduled [stable] study visits is', 'planned, it should be handled and recorded as an AECOPD visit, with all relevant', 'AECOPD visit study procedures performed and, if possible, the stable study visit should', 'be re-scheduled to a later date, when the subject is stable again and within the time', 'window specified in the protocol. However, in exceptional cases, in consultation with', 'GSK Biologicals, the concluding visit (Visit : 3, Month 12) may be exceptionally', 'conducted outside of the allowed interval, if deemed necessary by the investigator. The', 'reason for this should be documented in the eCRF.', 'The investigator/site must engage their best efforts to reach the patients, however, if the', 'site does not succeed in contacting the patient, the reason should be recorded and an', 'explanation given about what occurred. For example, the subject could be hospitalized', 'or could visit a different physician (and in that case medical record should be', 'obtained), or the subject is on holidays or not able to go the site.', '19-OCT-2018', '87', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
87,page_88,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 3.1.1.1 Date of onset and end date of AECOPD', 'The date of onset is the first day (of at least 2 consecutive days) of worsening symptoms', 'of COPD, as determined by the Investigator according to the Anthonisen criteria.', 'The end date should be based on when the investigator determines that the AECOPD', 'symptoms have resolved. In determining this end date, consideration should be given to', 'symptoms recorded in the electronic Diary Card and subject assessment during the', 'phone calls.', 'Section 4.1 Number of subjects/centres', 'The target is to enrol approximately 200 eligible moderate to very severe COPD patients.', 'All subjects should be recruited within the period of 1 year.', 'Section 4.2 Inclusion criteria for enrolment', 'Confirmed diagnosis of moderate to very severe COPD based on post-bronchodilator', 'spirometry (i.e. forced expiratory volume in 1 second [FEV1 over forced vital', 'capacity [FVC] ratio [FEV1/FVC] <0.7 AND and FEV1 < 80% predicted [GOLD', 'grades 2, 3 and 4].', 'Stable COPD patient* with documented history* (e.g. medical record verification)', 'of at least 1 moderate or severe AECOPD within the 12 months before study entry.', '* Patient for whom the last episode of AECOPD is resolved for at least 30 days at', 'the time of study entry. **Note: A documented history of a COPD exacerbation', '(e.g., medical record verification) is a medical record of worsening COPD', 'symptoms that required systemic/oral corticosteroids and/or antibiotics (for a', 'moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of', 'antibiotics alone does not qualify as an exacerbation history unless the use was', 'associated with treatment of worsening symptoms of COPD, such as increased', 'dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are', 'not acceptable.', 'Current or former tobacco smoker (cigarette) with a smoking history of > 10 pack-', 'years OR a subject exposed to biomass smoke for 20 years. [Guoping Hu 2010]', 'Section 4.3 Exclusion criteria for enrolment', 'Undergone or planning lung surgery within 12 months from study entry-Undergone', 'or has had lung surgery 12 months before, or plans to have lung surgery 12', 'months after, study entry.', 'Administration of antibiotics within 1 month of study entry OR continuous', 'administration of antibiotics (defined as more than 1 month-30 days in total) within', 'the three months 90 days before study entry.', 'Systemic administration of corticosteroids (PO/IV/IM) for more than 14', 'consecutive days within 90 days prior to informed consent.', '19-OCT-2018', '88', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
88,page_89,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Contraindication for spirometry testing (such as recent eye surgery, recent thoracic or', 'abdominal surgery procedures, unstable cardiovascular status, recent myocardial', 'infection infarction or pulmonary embolism).', 'Mentally impaired patients-Psychiatric illness or any other condition that interferes', 'with the ability to understand the study procedures.', 'Pregnant female with COPD.', 'Section 6.3 Outline of study procedures', 'Table 4', 'List of study procedures for scheduled [stable] visits', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Smoking exposure history (ATS-DLD-78A questionnaire)/', 'O', 'biomass exposure history', 'Urine Pregnancy test', 'Physical examination including vital signs', 'O', 'O', 'O', 'Record healthcare resource utilisation for COPD', 'Blood samples for biomarkers and haematology', '.', 'HRQOL questionnaires:', 'CAT', 'O', 'O', 'O', 'SGRQ-C', 'O', 'O', 'O', '6MWT', 'is used to indicate a study procedure that requires documentation in the individual eCRF.', 'O', 'is used to indicate a study procedure that does not require documentation in the individual eCRF.', 'a For non-eligible subjects, only informed consent, inclusion/ exclusion criteria, demographic data and SAEs related to', ""study participation that occurred after signing the informed consent pages need to be completed in the subject's eCRF."", 'For other activities, ""not done\' can be indicated.', 'b', 'Record both documented and self-reported, non-documented AECOPD. Subjects need documentation for at least', '1', 'moderate or severe AECOPD within the previous year to be eligible for study participation.', 'c Significant comorbidities include weight loss, cardiovascular disease, hypertension, gastro-oesophageal reflux', 'disease, osteoporosis/ osteopenia, skeletal muscle wasting and dysfunction, anxiety/ depression and diabetes.', ""d To be recorded in the 'Physical examination' section of the eCRF."", 'e Only study certified site staff can perform spirometry assessment.', 'f Only if no chest X-ray is taken within the previous 3 months.', 'g Sputum can be collected spontaneously or can be induced, as per investigator judgement. Sputum sampling should', 'only be done if, in the opinion of the investigator, it is safe for the subject.', '*', 'Non-serious AEs will be recorded in the eCRF and will not be entered into the safety database.', '19-OCT-2018', '89', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']"
89,page_90,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 5', 'List of study procedures for AECOPD visit', 'Type of contact', 'AECOPD Visit', 'End of AECOPD phone call(s)', 'Time point', 'within 96 hours of onset', 'at least every 2 weeks as of', 'AECOPD visit until AECOPD', 'symptoms', 'has resolvedh', 'Record date of visit', 'Physical examination', 'Urine Pregnancy Test', 'Chest X-rays/pneumonia confirmation', 'Confirm AECOPD and record its start date', 'Record current medication for COPD', 'Record healthcare resource utilisation', 'Record additional COPD treatments prescribed by', 'primary and secondary care physicians', 'Sputum sampling', 'HRQOL questionnaire:', 'CAT', 'O', 'Record AECOPD severity', 'Record AECOPD end date', 'Record Adverse Events (AEs) related to study', 'participation*', 'Record serious adverse events (SAEs)', 'is used to indicate a study procedure that requires documentation in the individual eCRF.', 'O is used to indicate a study procedure that does not require documentation in the individual eCRF.', 'h End of AECOPD phone calls/ visits should be scheduled at least every 2 weeks, until the AECOPD has resolved.', 'i Only the last phone call will be recorded in the eCRF as the end of the AECOPD phone call. All intermediate calls', 'should be recorded on source documentation.', 'jj Physical examination should be done only if necessary.', 'i', 'Only if clinically indicated to exclude another cause of worsening of symptoms (e.g. pneumonia). If a chest X-ray is', 'clinically indicated but a chest X-ray/ CT scan has already been taken for that AECOPD as part of medical care before', 'the study AECOPD visit takes places, the results of that chest X-ray/ CT scan can be used. All cases of pneumonia', '(including all signs and symptoms assessed to confirm pneumonia) should be documented in the eCRF.', 'j', 'Sputum can be collected spontaneously or can be induced, as per investigator judgement. Sputum sampling should', 'only be done if, in the opinion of the investigator, it is safe for the subject.', 'k AECOPD severity grading as indicated in Table 1.', '*', 'Non-serious AEs will be recorded in the eCRF and will not be entered into the safety database.', 'Table 6', 'Intervals between study visits', 'Interval', 'Optimal length of interval', 'Allowed interval¬π', 'Screening Visit', 'Screening Visit (pre-Month 0)', 'Visit 1', '+ 14 days', '<42 days before Visit 1', 'Scheduled study visits', 'Visit 1 (Month 0)', 'Visit 2 (Month 6)', '182 days', '175 203 days', 'Visit 2 (Month 6)', 'Visit 3 (Month 12)', '182 days', '175 203 days', 'AECOPD-driven study visit(s) and/ or phone contacts', 'Onset AECOPD symptoms', 'AECOPD Visit', '-', 'max 96 hours¬≤', '1', 'If an AECOPD occurs at the time one of the scheduled [stable] study visits is planned, the stable study visit should be', 're-scheduled to a later date, when the subject is stable again and within the time window specified. In consultation with', 'GSK, the concluding visit (Visit 3, Month 12) may however exceptionally be conducted outside of the allowed interval if', 'necessary by the investigator.', '2 AECOPD visits will be scheduled as soon as possible after the onset of AECOPD symptoms as recorded in the', 'electronic Diary Card or confirmed by the subject (maximum 96 hours after and, if applicable, preferably before starting', 'treatment with antibiotics).', '19-OCT-2018', '90', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
90,page_91,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.4.1.5 Record AECOPD history within the previous year', 'Documented, self-reported and non-documented AECOPD should be recorded in the', 'eCRF. However, for study participation the subject should have had at least one', 'documented moderate or severe AECOPD episode within the previous year.', 'Section 6.4.1.6 Smoking exposure history (ATS-DLD-78A questionnaire)/biomass', 'exposure history (At Sereening screening visit ONLY only)', 'The subject will be asked to complete the smoking history questionnaire (which is a', 'shortened version of the American Thoracic Society-Division of Lung Diseases-78A', '[ATS-DLD-78A] questionnaire) by himself/herself. This questionnaire will be provided', 'in paper. The subject will have to provide information about his/ her smoking history,', 'including duration (number of years) and number of cigarettes smoked. Subject years', 'exposed to biomass will be assessed from information obtained on indoor exposure to', 'fuels such as wood, crop waste and dung, or coal.', 'Section 6.4.1.9 Pregnancy test', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to', 'any study procedure. Note: The urine pregnancy test must be performed even if the', 'subject is menstruating at the time of the study visit. The test should be carried out', 'before performing chest x-ray. If the test is positive, the chest x- ray should not be', 'performed and the subject should be withdrawn from the study.', 'Section 6.4.1.13 Train subjects on the use of electronic Diary Card and assign', 'electronic dairy card to subject', 'The site staff will follow electronic Diary Card completion closely and should', 'provide timely input/guidance to ensure that the subject correctly completes the', 'eDiary Card both AM & PM as per protocol-reaches the targeted learning curve.', 'Section 6.4.1.14 Sputum sampling', ""Sputum-sample collected at subject's home (spontancous):At home, sputum"", 'collection will not be permitted. However, Sself-collection of the sputum sample', 'will be allowed only in specific cases, where the first dose of antibiotics absolutely', 'needs to be taken before an AECOPD visit can take place.', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing', 'Remaining DTT-sputum will be aliquoted as such and/or further diluted in STGG.', 'These samples will be kept at - -70/80¬∞C until shipment to GSK or GSK designated', 'lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', '19-OCT-2018', '91', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
91,page_92,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.4.2.1 Check inclusion and exclusion criteria', 'At visit 1, all applicable inclusion and exclusion criteria as described in Sections 4.2', 'and 4.3 will be checked before enrolment.', 'Section 6.4.2.10 Record healthcare utilisation for COPD', ""Healthcare use for each COPD patient will be obtained through review of the subject's"", 'medical record (aided by subject self-reporting). Healthcare utilisation includes primary,', 'secondary and tertiary care settings such as self care with over the counter [OTC] drugs,', 'general practitioner (GP) visits, emergency room (ER) visits, and hospital visits.', 'Healthcare utilisation includes all unscheduled visits to a physician office, visits to', 'urgent care, visits to emergency department, and hospitalizations. Healthcare use for the', 'COPD should be entered in the eCRF. Refer to the SPM for more details and guidance', 'on', 'recording of healthcare use.', 'Section 6.4.2.14 Sputum Sampling', 'Sputum samples will be collected during the scheduled stable-visits, if in the opinion', 'of the investigator, it is safe for the subject.', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing.', 'Remaining DTT-sputum will be aliquoted as such and/or further diluted in STGG.', 'These samples will be kept at - -70/80¬∞C until shipment to GSK or GSK designated', 'lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', 'Section 6.4.2.15 Blood Sampling', 'Blood samples for biomarker analysis will be taken at the scheduled visits; Visit', '1(M0) and Visit 3 (M12), including:', '-', 'Hematology profile, including differential cell counts', 'Approximately 2.0 mL of whole blood will be collected for hematology', 'assessment. These samples should be kept at room temperature and', 'shipped on the day of collection, ambient.', '-', 'Specific biomarkers will include serum hsCRP, CXCL10 (IP-10) and plasma', 'fibrinogen, may include other biomarkers based on results of ongoing disease', 'understanding research.', 'Approximately 8.5 mL of whole blood will be collected and processed to', 'serum for hsCRP & CXCL10 (IP-10) assessment. After processing, these', 'samples should be kept at - -70/-80¬∞C until shipment.', 'Approximately 4.5 mL of whole blood (Na Citrate) will be collected and', 'processed to plasma for fibrinogen assessment. After processing, these', 'samples should be kept at -70/-80¬∞C until shipment.', '19-OCT-2018', '92', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
92,page_93,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Approximately 6.0 mL of whole blood (EDTA) will be collected and', 'processed to plasma for other biomarker assessment. After processing,', 'these samples should be kept at - -70/-80¬∞C until shipment.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on the collection, handling, and processing of blood samples.', 'Sections 6.4.2.16MWT', 'The subject should perform the supervised, standardised 6MWT at Visit 1 and Visit', '3 -as presented in Table 4. The result of the test will be recorded in the eCRF.', 'Refer to the SPM for more details and guidance on the 6MWT.', 'Sections 6.4.3.3 Pregnancy Test', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to', 'any study procedure. Note: The urine pregnancy test must be performed even if the', 'subject is menstruating at the time of the study visit. The test should be carried out', 'before performing chest x-ray. If the test is positive, the chest x- ray should not be', 'performed and the subject should be withdrawn from the study.', 'Section 6.4.3.7 Record healthcare utilisation for AECOPD', ""Healthcare use for each AECOPD will be obtained through review of the subject's"", 'medical record (aided by subject self-reporting). Healthcare utilisation includes primary,', 'secondary and tertiary care settings such as self care with over the counter [OTC] drugs,', 'general practitioner (GP) visits, emergency room (ER) visits, and hospital visits. all', 'unscheduled visits to a physician office, visits to urgent care, visits to emergency', 'department, and hospitalizations. Healthcare use for the AECOPD should be entered in', 'the eCRF. Refer to the SPM for more details and guidance on recording of healthcare use.', 'Section 6.4.3.9 Sputum sampling', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing', 'Remaining DTT-sputum will be aliquoted as such and/or further diluted in STGG.', 'These samples will be kept at - -70/80¬∞C until shipment to GSK or GSK designated', 'lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', 'Section 6.4.4.1 Sputum sampling', 'Full details for obtaining sputum samples are provided in the Module on Biospecimen', 'Management in the SPM and in the Central Laboratory Investigator Manual', 'accompanying this protocol.', '19-OCT-2018', '93', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
93,page_94,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.5 Biological sample handling and analysis', 'Please refer to the SPM and the Central Laboratory Investigator Manual for details of', 'biospecimen management (handling, storage and shipment).', 'Section 6.5.1 Use of specified study materials', 'When materials are provided by GSK Biologicals or the central laboratory, it is', 'MANDATORY that all samples be collected and stored exclusively using those materials', 'in the appropriate manner. The use of other materials could result in the exclusion of the', 'subject from the PP analysis (See Section 9.3 for the definition of study cohorts/data sets', 'to be analysed). The investigator must ensure that his/her personnel and the', 'laboratory(ies) under his/her supervision comply with this requirement. However, when', 'GSK Biologicals or the central laboratory does not provide material for collecting and', ""storing samples, appropriate materials from the investigator's site must be used. Refer to"", 'the Module on Clinical Trial Supplies in the SPM and Central Laboratory investigator', 'manual.', 'Section 6.5.2 Biological samples', 'Table 7 Biological Samples', 'Time point', 'Sample type', 'Quantity', 'Unit', 'Screening', 'AECOPD', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Visit', 'Fresh/stored', 'Maximum', 'mL', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Within 96 hours', 'sputum', 'possible', 'of onset of', 'symptoms', 'Blood for', '21', 'mL', 'Month 0', 'Month 12', 'biomarkers', 'Section 6.5.3 Laboratory assays', ""The quality of sputum samples will be assessed at the investigator's institution and/ or"", 'at a laboratory designated by GSK Biologicals by gram staining.', 'Standard bacteriological methodsculture (and semi-quantitative counts) will be', ""performed on fresh sputum samples at the investigator's institution and/or at a"", 'laboratory designated by GSK Biologicals Identification of potential bacterial pathogens', 'will be performed according to agreed identification methods (potential pathogens', 'including, but not necessarily limited to, H. influenzae, S. pneumoniae, M. catarrhalis, S.', 'aureus, P. aeruginosa, K. pneumoniae and and A. baumannii). All results should be', 'entered in the eCRF.', 'Further bacterial characterization for H. influenzae isolates. Identified H. influenzae', ""isolates should be collected and stored in the investigator's institution and will undergo"", 'further species confirmation ((i.e. H. influenzae/ H. haemolyticus and when possible,', ""further differentiation (i.e., Hi/NTHi) at GSK Biologicals' laboratory or at a laboratory"", 'designated by GSK Biologicals using molecular techniques such as H. influenzael', 'Haemophilus haemolyticus (H. haemolyticus) differentiation PCR. Identified H.', '19-OCT-2018', '94', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
94,page_95,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', ""influenzae isolates might undergo further testing at GSK Biologicals' laboratory or at a"", ""laboratory designated by GSK Biologicals' using molecular techniques such as PCR"", 'and sequencing.', ""Identified M. catarrhalis isolates should be collected and stored in the investigator's"", 'institution and might undergo further species confirmation (and when possible, further', ""differentiation) at GSK Biologicals' laboratory or at a laboratory designated by GSK"", 'Biologicals using molecular techniques such as PCR and sequencing.', ""Identified P. aeruginosa isolates should be collected and stored in the investigator's"", ""institution for future testing at GSK Biologicals' laboratory or at a laboratory"", 'designated by GSK Biologicals.', 'Further bacterial pathogen identification (including, but not necessarily limited to, H.', 'influenzae, S. pneumoniae, M. catarrhalis, S. pyogenes, S. aureus and P. aeruginosa) and', 'quantification (for H. influenzae, S. pneumoniae, M. catarrhalis) on stored sputum', ""samples will be performed at GSK Biologicals' laboratory or a laboratory designated by"", 'GSK Biologicals using multiplex qualitative PCR and/or quantitative PCR.', 'Viral pathogen identification (including, but not necessarily limited to, RSV,', 'parainfluenza virus, enterovirus/ rhinovirus, metapneumovirus, influenza virus,', 'adenovirus, bocavirus and coronavirus) on stored sputum samples will be performed at', ""GSK Biologicals' laboratory or a laboratory designated by GSK Biologicals using"", 'multiplex reverse transcription polymerase chain reaction (RT-PCR).', 'In addition, some respiratory viral pathogens (such as rhinovirus) may be quantified in', ""stored sputum samples using RT-PCR at GSK Biologicals' laboratory or at a laboratory"", 'designated by GSK Biologicals.', '19-OCT-2018', '95', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
95,page_96,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 8', 'Microbiology', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution', 'Central Laboratory Manual', 'semi-', 'or GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', ""Investigator's institution"", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae', 'H. influenzael', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'H.haemolyticus', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'differentiation', 'as differentiation', 'laboratory', 'plates', 'PCR', 'M. catarrhalis', 'Sample collection for', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'isolate characterisation', 'techniques', 'laboratory* or', 'M. catarrhalis', 'designated laboratory', 'culture plates', 'P. aeruginosa', 'Sample collection for', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'isolate characterisation', 'techniques', 'laboratory* or', 'P. aeruginosa', 'designated laboratory', 'culture plates', 'Stored sputum', 'Respiratory bacterial', 'Multiplex', 'Qualitative', 'GSK Biologicals', 'pathogens', 'qualitative PCR', 'and/ or', 'laboratory * or designated', '(including H. influenzae,', 'and/or', 'quantitative', 'laboratory', 'S. pneumoniae,', 'quantitative-PCR', 'M. catarrhalis, S. aureus and', 'P. aeruginosa,', 'Streptococcus pyogenes)', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'and/or', 'laboratory * or designated', 'parainfluenza virus,', 'quantitative', 'laboratory', 'enterovirus/ rhinovirus,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', 'Respiratory viral', 'RT-PCR', 'Quantitative', 'GSK Biologicals', 'pathogens (such as', 'laboratory* or', 'rhinovirus)', 'designated laboratory', '* GSK Biologicals laboratory refers to the Clinical Laboratory Sciences (CLS) Global Vaccines Clinical Laboratories', '(GVCL) in Wavre, Belgium; Rixensart, Belgium.', 'Stored frozen sputum samples (either in dithiothreitol [DTT] and/or in DTT', 'supplemented with skim milk, tryptone, glucose, and glycerine [STGG] medium) might', 'be used for assay development, such as assays for diagnostic purpose or for microbiome', 'analysis and/or for assay validation/characterization purpose and/or quality control.', '19-OCT-2018', '96', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
96,page_97,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Additional testing on stored sputum samples (such as, but not limited to, K. pneumoniae', 'and A. baumannii PCR detection, quantitative PCR for other bacterial and/or viral', 'pathogens, further characterisation of virus such as rhinovirus typing, pathogen', 'genome/gene sequencing, quantitative/qualitative serotype-specific PCR, multilocus', 'sequence typing, microarray typing, 16sRNA analysis) or on H. influenzae, M.', 'catarrhalis and P. aeruginosa H. influenzae isolates (such as further strain', 'characterisation using new molecular biology tools) may be done during the study or after', 'study completion, should these data be required for accurate interpretation of the study', 'data and/ or for further research related to respiratory diseases COPD and/ or should such', ""test(s) become available at GSK Biologicals' laboratory or a laboratory designated by"", 'GSK.', 'Table 9', 'Planned assays on serological samples', 'Sample type', 'Component', 'Method', 'Scale', 'Laboratory', 'Plasma', 'Fibrinogen', ""Per contract laboratory's"", 'Quantitative', 'GSK', 'procedures', 'Biologicals', 'Serum', 'hsCRP', ""Per contract laboratory's"", 'Quantitative', 'or GSK', 'procedures', 'designated', 'Serum', 'CXCL10 (IP-10)', ""Per contract laboratory's"", 'Quantitative', 'lab', 'procedures', 'Leukocytes (White', ""Per contract laboratory's"", 'Quantitative', 'Blood Cells)', 'procedures', 'Neutrophils *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Lymphocytes *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Eosinophils *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Whole blood', 'Basophils *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Monocytes *', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Erythrocyte (Red', ""Per contract laboratory's"", 'Quantitative', 'Blood Cells)', 'procedures', 'Haemoglobin', ""Per contract laboratory's"", 'Quantitative', 'procedures', 'Platelets', ""Per contract laboratory's"", 'Quantitative', 'procedures', '*For white blood cell differential counts', 'Additional testing for biomarkers on stored serum/plasma may be done during the', 'study or after study completion, should these data be required for accurate', 'interpretation of the study data and/ or for further research related to respiratory', ""diseases available at GSK Biologicals' laboratory or a laboratory designated by GSK."", 'Section 7.2.1 Time periods for detecting and recording AEs and SAEs', 'AEs and SAEs related to study participation will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', '19-OCT-2018', '97', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
97,page_98,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'AEs leading to withdrawal from the study will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', 'An overview of the protocol-required reporting periods for SAEs and AEs leading to', 'withdrawal is given in Table 9.', 'Table 10', 'Reporting period for SAE', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month', 'M 0', 'M 6', 'M 12', 'Within 96', '0', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'leading to', 'withdrawal', 'from the', 'study', 'Synopsis and Section 9 Statistical endpoints', 'Primary endpoint', 'Occurrence of potential bacterial and viral pathogens in sputum of stable COPD', 'patients and during AECOPD, over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological culture methods, including', '(but not necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S.', 'aureus, P. aeruginosa, K. pneumoniae and A. baumannii.', '-', 'Viral pathogens, as identified by multiplex RT PCR, including (but not', 'necessarily limited to) RSV, parainfluenza virus, enterovirus/ rhinovirus,', 'metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus and', 'by rhinovirus quantitative RT-PCR.', 'Secondary endpoints', 'Occurrence of potential bacterial pathogens in sputum of stable COPD patients and', 'during AECOPD, as measured by multiplex real-time qualitative PCR/ quantitative', 'PCR and compared to data from bacteriological methods, over the course of 1 year:', '-', 'Including (but not necessarily limited to) H. influenzae, M. catarrhalis, S.', 'pneumoniae, S. aureus and P. aeruginosa.', 'Occurrence of potential bacterial and viral pathogens (overall and by species) in', 'sputum of stable COPD patients by GOLD grade, over the course of 1 year.', 'Occurrence of potential bacterial and viral pathogens (overall and by species) in', 'sputum during AECOPD by severity of AECOPD, over the course of 1 year.', 'Number Incident rate (per subject per year) of AECOPD, overall and by GOLD', 'grade, over the course of 1 year.', '19-OCT-2018', '98', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
98,page_99,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Severity of AECOPD, overall and by GOLD grade, over the course of 1 year.', 'Duration of AECOPD, overall and by AECOPD severity, over the course of 1 year.', 'FEV1% of predicted normal value in stable COPD patients, at Pre-Month 0 and', 'Month 12.', 'Healthcare utilisation for COPD, over the course of 1 year.', 'Tertiary endpoints', 'Bacterial load measured by both culture and PCR in COPD and during AECOPD.', 'Viral load measured by PCR in COPD and during AECOPD.', 'Section 9.5 Analysis of primary objective', 'The proportion of sputum samples obtained at each visit (confirmed stable visits and', 'AECOPD visits [any severity, mild, moderate and severe]) and positive for specific', 'bacterial/viral pathogens by bacteriological culture-methods and PCR, respectively', '(overall and by bacterial/viral species) will be computed with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled [stable] study visit for which', 'the investigator confirms in the eCRF that the subject is stable/ has recovered from a', 'previous exacerbation.', 'Section 9.6 Analysis of secondary objectives', 'The proportion of sputum samples obtained at each visit (confirmed stable visits* and', 'AECOPD visits [any severity, mild, moderate and severe]) and positive for specific', 'bacterial pathogens by both bacteriological methods and PCR (overall and by bacterial', 'species) will be computed with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled [stable]study visit for which', 'the investigator confirms in the eCRF that the subject is stable/has recovered from', 'a previous exacerbation.', 'The proportion of sputum samples obtained at each stable visit and positive for specific', 'bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and', 'by bacterial/viral species) will be computed with 95% confidence intervals, by GOLD', 'grade at enrolment.', 'The proportion of sputum samples obtained at each AECOPD visits and positive for', 'specific bacterial/ viral pathogens by bacteriological methods and PCR, respectively', '(overall and by bacterial/viral species) will be computed with 95% confidence intervals,', 'by AECOPD severity.', 'Those proportions will be also presented by GOLD grade at enrolment.', '19-OCT-2018', '99', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
99,page_100,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'The following incidence rates will be computed, with 95% confidence intervals (CI):', 'All-cause AECOPD.', 'AECOPD having sputum containing bacterial pathogens found by PCR and or by', 'bacteriological methods or by both methods overall and by, but not limited to, the', 'following bacterial species: H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'and P. aeruginosa).', 'The 95% CI of the incidence rate will be computed using a model which accounts for', 'repeated events. The Generalised linear model assuming the Negative Binomial', 'distribution for the response variable with logarithm as link function, and the logarithm of', 'time for follow-up as an offset variable will be used. The incidence rates described above', 'will also be computed for mild, moderate AECOPD and for severe AECOPD and by', 'GOLD grade at enrolment and will be estimated by country.', 'Descriptive statistics (median, mean, range, standard deviation, first and third quartiles)', 'on the CAT and SGRQ-C scores will be tabulated at each respective visit.', 'Descriptive summaries on healthcare use for COPD will be provided.', 'Section 9.6 Analysis of tertiary objectives', 'Descriptive summaries of the quantity of specific bacteria at each scheduled [stable]', 'and exacerbation visit will be provided for both culture and PCR analysis.', 'Descriptive summaries of the quantity of specific viruses at each scheduled [stable] and', 'exacerbation visit will be provided for PCR analysis.', 'Section 9.8.1 Sequence of analyses', 'An interim analysis of the bacterial primary objective will be performed when by the', 'time of country allocation for the Phase 2 vaccine trial (provided that at least 4050', 'AECOPD sputum samples are available). The rate of positive samples will be', 'computed for Hi, NTHi and Mcat together and per pathogen. No study report will', 'be written at this stage.', 'A final analysis of all objectives will be performed after the last subject last visit of', 'the entire study. A final study report will be written at this stage.', 'Section 12 References', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for', 'the diagnosis, management, and prevention of Chronic Obstructive Pulmonary', 'Disease, updated 2017. Available from:', 'http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/', 'Guoping Hu, MD, PhD; Yumin Zhou, MD et al. Risk of COPD from Exposure to', 'Biomass Smoke: A Metaanalysis. CHEST. 2010; 138(1):20-31', '19-OCT-2018', '100', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
100,page_101,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Lim Sam, Lam Chi-Leung David et al. Impact of chronic obstructive pulmonary', 'disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey.', 'Asia Pacific Family Medicine. 2015; 14:4', 'Singh Richa, Mackay AJ et al. Inflammatory thresholds and the species-specific effects', 'of colonising bacteria in stable chronic obstructive pulmonary disease. Respiratory', 'Research. 2014; 15: 114', 'World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD)', 'Fact Sheet. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/', 'Accessed: 13 February 2017', 'Appendix A Clinical Laboratories', 'Table 14', ""GSK Biologicals' laboratories"", 'Laboratory', 'Address', 'GSK Biologicals Clinical', 'Biospecimen Reception - B7/44', 'Laboratory Sciences (CLS),', ""Rue de l'Institut, 89 - B-1330 Rixensart - Belgium"", 'Global Vaccine Clinical Laboratory,', 'Rixensart', 'GSK Biologicals Clinical', 'Avenue Fleming, 20 - B-1300 Wavre - Belgium', 'Laboratory Sciences (CLS),', 'Global Vaccine Clinica Laboratory,', 'Wavre-Nord Noir Epine', 'Table 15', 'Outsourced Laboratories', 'Laboratory', 'Address', 'Q Solutions Clinical Trials (US)', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Q¬≤ Solutions (Singapore)', 'Tan Tock Seng Hospital', 'Dept of Laboratory Medicine', 'Level 2, Podium Block', 'Tan Tock Seng Hospital', '11 Jalan Tan Tock Seng', 'Singapore 308433', '19-OCT-2018', '101', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']"
101,page_102,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'GlaxoSmithKline Biologicals', 'Vaccine Value & Health Science (VVHS)', 'Protocol Amendment 2', 'eTrack study number', '201112 (EPI-NTHI-001 BOD APA)', 'and Abbreviated Title', 'Amendment number:', 'Amendment 2', 'Amendment date:', '20 October 2017', 'PPD', 'Co-ordinating author:', 'Scientific Writer', 'Rationale/background for changes:', 'The protocol has been amended to implement the following changes:', 'The study procedure with respect to pre- and post-bronchodilator spirometry', 'during the screening visit has been amended in order to clarify that if a good', 'quality spirometry was not obtained, the test can be repeated (preferably within', '7', ""days of the previous spirometry) as per investigator's medical judgement."", 'Update of the laboratory section to better clarify that:', '-', 'The PCR on H. influenzae isolate samples allows discrimination of Hi from', 'non-Hi & identification of NTHi. Furthermore, reference to H. haemolyticus', 'has been deleted from the protocol as the PCR that will be performed on', 'bacterial Hi isolates is designed to identify H. influenzae and not', 'H. haemolyticus.', 'The cohorts for analyses have been updated as the PP analysis is not applicable to', 'this specific study design, as all patients will be included in the analysis.', 'Furthermore, according to ICH E9 recommendation a Full Analysis Set (FAS),', 'All Screened set and All Enrolled Set have been added.', 'To correct some typographical errors.', 'Removal of the R and symbols in the document and simplification of the copyright', 'TM', ""statement as per GSK Legal Global Trade Marks (LGTM) department's"", 'recommendation.', 'Amended text has been included in bold italics and deleted text in strikethrough in the', 'following sections:', 'Contributing authors', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', ',', 'Clinical Safety Representatives', '19-OCT-2018', '102', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
102,page_103,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'C', '[2017] GSK group of companies or its licensor. Copyright 2014-2017 of the GlaxoSmithKline', 'group of companies. All rights reserved. Unauthorised copying or use of this information is', 'prohibited.', 'List of Abbreviations', 'FAS', 'Full Analysis Set', 'DTT', 'Dithiothreitol', 'HRV', 'Human Rhinovirus', 'STGG', 'Skim Milk-Tryptone-Glucose-Glycerol', 'H. haemolyticus', 'Haemophilus haemolyticus', 'PP', 'Per Protocol', 'Glossary of terms', 'Evaluable:', 'Meeting all eligibility criteria, complying with the', 'procedures defined in the protocol, and, therefore,', 'included in the per protocol (PP) analysis (see Section 9.3', 'for details on criteria or evaluability).', 'Trademarks', 'Note: In the body of the protocol (including the synopsis), the names of the products', 'will be written without the superscript symbol TM or R and in italies.', 'Trademarks of the GlaxoSmithKline GSK', 'Generic description', 'group of companies', 'COPD Assessment test (CAT)', 'Questionnaire to measure the impact of', 'COPD on wellbeing and daily life', 'EXACT-PRO¬Æ', 'Exacerbations of Chronic Pulmonary', 'Disease Tool - Patient Reported Outcome', 'SGRQ-C', ""St. George's Respiratory Questionnaire for"", 'COPD patients', 'Synopsis and Section 1.2 Rationale for the study', 'Because the infectious aetiology of AECOPD has been suggested to vary according to', 'geographical region, the primary purpose of this study (which will be conducted in', 'several countries in Asia Pacific) is to evaluate the occurrence of potential bacterial and', 'viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.', '19-OCT-2018', '103', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
103,page_104,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Given the increasing and projected burden of COPD in the Asia Pacific region, this study', 'will also evaluate the frequency, severity and duration of AECOPD, as well as the impact', 'of AECOPD on health-related quality of life (HRQOL), healthcare utilisation and lung', 'function.', 'Synopsis and Section 3 Study design overview', 'COPD symptoms', 'Subjects will be asked to record their COPD symptoms in an electronic Diary Card', 'on a daily basis:', '- Daily in the morning throughout the study: Morning symptoms questionnaire.', '- Daily at bedtime throughout the study: EXACT-PRO (EXAcerbations of Chronic', 'Pulmonary Disease Tool - Patient Reported Outcome) questionnaire.', 'Biological samples:', '- Sputum samples collected at site (spontaneous or induced, as per investigator', 'judgement) will be collected at each study visit at the site (scheduled [stable]', 'visits and AECOPD visits) if, in the opinion of the investigator, it is safe for the', 'subject.', 'Synopsis and Section 2.3 Tertiary objectives', 'Blood sampling for potential biomarkers for identification/quantification of biomarkers at', 'Visit 1 and Visit 3.', 'Section 3.1.1 Detection of AECOPD', 'Each time a potential AECOPD is detected via the electronic Diary Card, the device will', 'alert the subject to contact the study site, and at the same time an alert will be sent to the', 'site so that the site staff investigator or medically qualified individual contacts the', 'subject to determine if the alert is an AECOPD or not, and if an AECOPD visit is', 'warranted. In addition, the site should proactively follow-up all data received via the', 'electronic Diary Card and contact the subject whenever deemed necessary.', 'During the contact with the subject, the site investigator or medically qualified', 'individual will determine whether the subject might actually be experiencing an', 'AECOPD (e.g. notifications that can be explained solely by increased physical activity', 'will not be considered):', 'If the investigator or medically qualified individual site concludes that the subject is', 'not experiencing an AECOPD, this should be documented/reported in the cCRF in', 'the electronic Diary website (StudyWorks). Please refer to study procedures manual', '(SPM) for more details on how to perform this.', 'If the investigator or medically qualified individual site concludes that the subject', 'may be experiencing an AECOPD, an AECOPD visit will be scheduled as soon as', 'possible after the onset of AECOPD symptoms as recorded in the electronic Diary', 'Card or confirmed by the subject (maximum 96 hours after onset of symptoms and,', 'if applicable, preferably before starting treatment with antibiotics). The AECOPD', 'onset date will be captured in the eCRF and additional information about severity', 'will be also collected.', '19-OCT-2018', '104', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
104,page_105,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 5.1 Regulatory and ethical considerations, including the informed consent', 'process', 'Freely given and written or witnessed, thumb printed informed consent must be obtained', 'from each subject, as appropriate, prior to participation in the study.', 'Section 6.3 Outline of study procedures', 'Table 16', 'List of study procedures for scheduled visits', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Smoking exposure history (ATS-DLD-78A questionnaire)/', 'O', 'biomass exposure history (Biomass Exposure', 'questionnaire)', 'Record additional COPD treatments prescribed by', 'primary and secondary care physicians', 'Record Adverse Events (AEs) related to study', 'participation*', 'Record serious adverse events (SAEs) related to study', 'participation', 'h Physical examination should be done only if necessary by the investigator or delegate.', 'Table 5 List of study procedures for AECOPD visits', 'Type of contact', 'AECOPD Visit', 'End of AECOPD phone call(s)', 'Time point', 'within 96 hours of onset', 'at least every 2 weeks as of', 'AECOPD visit until AECOPD', 'symptoms', 'has resolvedi', 'Record date of visit', 'Physical examination', 'Urine Pregnancy Test', 'I Physical examination should be done only if necessary by the investigator or delegate.', 'Section 6.4.1.1 Informed consent', 'The signed/thumb printed informed consent of the subject must be obtained before study', 'participation during the screening visit. Refer to Section 5.1 for the requirements on how', 'to obtain informed consent and assent, as appropriate.', 'Section 6.4.1.11 Pre and post-bronchodilator spirometry', 'Pre- and post-bronchodilator spirometry should be performed during the screening visit.', 'Only study-certified staff can perform spirometry assessment for this study. Spirometry', 'will be performed using following the eResearch Technology (ERT) instructions for use', 'FlowScreen manual techniques that meet published standards [ATS/ERS, 2005] and', 'following all safety requirements.', 'A good quality spirometry should be obtained, and will be confirmed by the spirometry', 'provider. If during the Screening Visit a good quality spirometry was not obtained, the', ""spirometry can be repeated, as per investigator's medical judgement. If a repeat"", 'spirometry is elected, the site should make all possible efforts to repeat the spirometry', '19-OCT-2018', '105', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
105,page_106,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'preferably within 7 days of the previous spirometry. The data will be directly transferred', 'from the provider to GSK Biologicals.', 'Section 6.4.1.14 Sputum sampling', 'Sputum samples will be collected during the screening visit if, in the opinion of the', 'investigator, it is safe for the subject. If it is not safe, the sputum sample will not be', 'collected and the subject will not be included in the study.', 'At home, sputum collection will not be permitted. However, self collection of the', 'sputum sample will be allowed only in specific cases, where the first dose of', 'antibiotics absolutely needs to be taken before an AECOPD visit can take place.', 'Section 6.4.2.7 Pre- and post-bronchodilator spirometry', 'Pre- and post-bronchodilator spirometry should be performed during Visit 3 as detailed in', 'Table 4. Only study-certified staff can perform spirometry assessment for this study.', 'Spirometry will be performed using techniques that meet published standards', '[ATS/ERS, 2005] following the eResearch Technology (ERT) instructions for use', 'FlowScreen manual and following all safety requirements. The data will be directly', 'transferred from the provider to GSK Biologicals.', 'Section 6.4.2.7 Pre- and post-bronchodilator spirometry', 'Pre- and post-bronchodilator spirometry should be performed during Visit 3 as detailed in', 'Table 4. Only study-certified staff can perform spirometry assessment for this study.', 'Spirometry will be performed following the eResearchTechnology e (ERT) instructions', 'for use FlowScreen manual and following all safety requirements.', 'A good quality spirometry should be obtained, and will be confirmed by the spirometry', 'provider. If during Visit 3 a good quality spirometry was not obtained, the spirometry', ""can be repeated, as per investigator's medical judgement. If a repeat spirometry is"", 'elected, the site should make all possible efforts to repeat the spirometry preferably', 'within 7 days of the previous spirometry. The data will be directly transferred from the', 'provider to GSK Biologicals.', 'Section 6.4.2.10 Record healthcare resource utilisation', ""Healthcare use will be obtained through review of the subject's medical record (aided by"", 'subject self-reporting). Healthcare utilisation includes all unscheduled visits to a', 'physician office, visits to urgent care, visits to emergency department, and', 'hospitalizations. Healthcare use should be recorded in eDiary Card and reported in the', 'eCRF at study visit entered in the eCRF. Refer to the SPM for more details and guidance', 'on recording of healthcare use.', '19-OCT-2018', '106', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
106,page_107,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.4.2.11 Additional COPD treatments prescribed by primary and secondary', 'care physician', 'Section 6.4.2.14 Sputum sampling', 'At home, sputum collection will not be permitted.', ""Sputum sample collected at subject' s home (spontaneous): Self collection of the"", 'sputum sample will be allowed in specifie cases, where the first dose of antibiotics', 'absolutely needs to be taken before an AECOPD visit can take place. This is not', 'allowed at scheduled visits when subject should be in stable condition.', 'Remaining DTT-sputum will be aliquoted as such and/or when possible further', 'diluted in STGG. These samples will be kept at - -70/80¬∞C until shipment to GSK or', 'GSK designated lab for testing.', 'Section 6.4.2.16 HRQOL questionnaires', 'The subject will be asked to complete the questionnaires on HRQOL questionnaires', 'by himself/herself, during specified study visits directly in the electronic Diary Card', 'as detailed in Table 4 and Table 5.', 'Section 6.4.3.4 Chest X-rays/pneumonia confirmation', 'Fever (oral temperature >> 37.5 ¬∞C),', 'All incidences of pneumonia must be captured on the pneumonia page of the eCRF.', 'All pneumonias must be captured on the AE/SAE page of the eCRF and on the', 'pnoumonia page of the eCRF.', 'The investigators and site staff should remain vigilant for the possible development of', 'pneumonia in patients with COPD as the clinical features of such infections overlap with', 'the symptoms of COPD exacerbations. For all suspected cases of pneumonia,', 'investigators are strongly encouraged to confirm the diagnosis (this includes obtaining a', 'chest x-ray) and to initiate appropriate therapy as promptly as possible. All diagnoses of', 'pneumonia (radiographically confirmed or unconfirmed) must be reported as an AE or', 'SAE (if applicable) as detailed in Section 7.2 and Section 7.3.', 'Section 6.4.3.7 Record healthcare resource utilisation', ""Healthcare use will be obtained through review of the subject's medical record (aided by"", 'subject self-reporting). Healthcare utilisation includes all unscheduled visits to a', 'physician office, visits to urgent care, visits to emergency department, and', 'hospitalizations. Healthcare use should be recorded in the eDiary Card and reported in', 'the eCRF at study visit entered in the eCRF. Refer to the SPM for more details and', 'guidance on recording of healthcare use.', '19-OCT-2018', '107', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
107,page_108,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.4.3.10 HRQOL questionnaires', 'The subject will be asked to complete the HRQOL questionnaire (CAT only) by', 'himself/herself directly in the electronic Diary Card, during the AECOPD visit as', 'detailed in Table 5.', 'Section 6.4.5 Health related quality of life questionnaires', 'Refer to section 6.4.2 for description of the Quality of Life (QoL) questionnaire. The', 'subject will be asked to complete the HRQOL questionnaires by himself/herself, during', 'specified study visits directly in the electronic Diary Card.', 'The investigator will provide the Quality of Life (QoL) questionnaire to the subject to', 'record his/her condition until the next visit. The subjects will be instructed to return the', 'completed QoL questionnaire to the investigator at the next visit/contact.', 'Collection and verification of the completed diary card/QoL questionnaire will take place', 'during discussion with the subject at the subsequent visit. Any unreturned diary', 'cards/QoL questionnaires will be solicited from the subjects through telephone call(s) or', 'any other convenient procedure. The investigator will transcribe the collected information', 'into the eCRF in English.', 'Section 6.5.1 Use of specified study materials', 'When materials are provided by GSK Biologicals or the central laboratory, it is', 'MANDATORY that all samples be collected and stored exclusively using those materials', 'in the appropriate manner. The use of other materials could result in the exclusion of the', 'subject from the per protocol analysis (See Section 9.3 for the definition of study', 'cohorts/data sets to be analysed).- The investigator must ensure that his/her personnel and', 'the laboratory(ies) under his/her supervision comply with this requirement. However,', 'when GSK Biologicals or the central laboratory does not provide material for collecting', ""and storing samples, appropriate materials from the investigator's site must be used."", 'Refer to the Module on Clinical Trial Supplies in the SPM and Central Laboratory', 'investigator manual.', 'Section 6.5.3 Laboratory assays', 'Further bacterial characterization for H. influenzae isolates: Identified H. influenzae', ""isolates should be collected and stored in the investigator's institution and will undergo"", 'further species confirmation (i.e. confirmed H. influenzae/H. haemolyticus) and when', ""possible, further differentiation (i.e., Hi/NTHi) at GSK Biologicals' laboratory or at a"", 'laboratory designated by GSK Biologicals using molecular techniques such as', 'H. influenzael Haemophilus haemolyticus (H. haemolyticus) differentiation PCR.', ""Identified H. influenzae isolates might undergo further testing at GSK Biologicals'"", ""laboratory or at a laboratory designated by GSK Biologicals' using other molecular"", 'techniques such as PCR and sequencing.', '19-OCT-2018', '108', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
108,page_109,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', ""Identified P. aeruginosa isolates should be collected and stored in the investigator's"", ""institution and might potentially undergo further for future testing at GSK Biologicals'"", 'laboratory or at a laboratory designated by GSK Biologicals.', 'In addition, some respiratory viral pathogens (such as HRVthinovirus) may will be', ""quantified in stored sputum samples (or subset) using RT-PCR at GSK Biologicals'"", 'laboratory or at a laboratory designated by GSK Biologicals.', 'Table 8 Microbiology', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution or', 'Central Laboratory Manual', 'semi-', 'GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', ""Investigator's institution"", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae isolates', 'H. influenzae species', 'Molecular', 'Qualitative', 'GSK Biologicals', 'of positive', 'confirmation and when', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'possible Hi/NTHi', 'as differentiation', 'laboratory', 'plates', 'differentiation', 'PCR', 'Sample collection for', 'potential further', 'characterisation', 'H. influenzael', 'H.haomolyticus', 'differentiation', 'M.catarrhalis', 'Sample collection forisolate', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'characterisation', 'techniques', 'laboratory*or', 'M.catarrhalis', 'designated-laboratory', 'culture plates', 'P.aeruginosa', 'Sample collection for isolate', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'characterisation', 'techniques', 'laboratory*or', 'Paeruginosa-culture', 'designated-laboratory', 'plates', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex-PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'and/or', 'laboratory or designated', 'parainfluenza virus,', 'quantitative', 'laboratory', 'enterovirus/ HRV/hinovirus,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', '* GSK Biologicals laboratory refers to the Clinical Laboratory Sciences (CLS) in Wavre, Belgium; Rixensart, Belgium;', 'Marburg, Germany.', '19-OCT-2018', '109', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
109,page_110,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Stored frozen sputum samples (either in dithiothreitol [DTT] and/or in DTT', 'supplemented with skim milk, tryptone, glucose, and glycerine [STGG] medium) might', 'be used for assay development, such as assays for diagnostic purpose or for microbiome', 'analysis and/or for assay validation/characterization purpose and/or quality control.', 'Stored frozen sputum samples (in DTT supplemented with skim milk, tryptone, glucose,', 'and glycerine [STGG] medium) might be collected when possible for potential assay', 'development/validation purpose.', 'Additional testing on stored sputum samples (such as, but not limited to, K. pneumoniae', 'and A. baumannii PCR detection, quantitative PCR for other bacterial and/or viral', 'pathogens, further characterisation of virus such as rhinovirus typing, pathogen', 'genome/gene sequencing, pathogen quantitative/qualitative serotype-specific PCR,', 'multilocus sequence typing, microarray typing, 16sRNA analysis) or on H. influenzae, M.', 'catarrhalis and P. aeruginosa bacterial isolates (such as agglutination assays, further', 'strain characterisation using new molecular biology tools) may be done during the study', 'or after study completion, should these data be required for accurate interpretation of the', 'study data and/ or for further research related to respiratory diseases and/ or should such', ""test(s) become available at GSK Biologicals' laboratory or a laboratory designated by"", 'GSK.', 'Section 7.2.1 Time periods for detecting and recording AEs and SAEs', 'Table 10 Reporting period for SAE and AEs leading to withdrawal', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month 0', 'M 0', 'M 6', 'M 12', 'Within 96', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'related to', 'study', 'participation*', 'AEs leading to', 'withdrawal', 'from the study', '*Study participation: Specific procedures required by study participation.', 'Synopsis and Section 9.1.3', 'Human Rhinovirus (HRV) Viral-load measured by PCR in COPD and during', 'AECOPD.', '19-OCT-2018', '110', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
110,page_111,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 9.2 Determination of sample size', 'Assuming around 90% of the All Enrolled Set participated in the study population is in', 'the PP cohort, on average 1 AECOPD visit per subject and 80% of the above population', 'setsubjects in the PP cohort can provide an evaluable sputum sample at AECOPD, for', '240, 200, 160, and 50 enrolled subjects, one may expect around 180, 140, 120, 40 sputum', 'samples in the exacerbation category of the PP analysis, respectively. Assuming that', 'results from these sputum samples are independent and that the between country', 'variability is much smaller than the within country variability, we would have the', 'following 95% exact confidence interval for different incidences in sputum samples from', 'exacerbations (see Table 12).', 'Assuming around 8090% of the all enrolled set population is in the PP cohort, from', 'which around 90% of the subjeets-completed the study the one year follow up, for 240,', '200, 160 and 50 subjects enrolled, one would have at least 190, 160, 130 and 40 subjects', 'evaluable respectively. Assuming further that around 80% of the subjects can provide an', 'evaluable sputum sample at AECOPD, this would lead to around 150, 130, 100, 30', 'subjects (see Table 13).', 'Section 9.3.1 All screened set', 'The all screened set will include all screened patients.', 'Section 9.3.2 Total All Enrolled cohort-Set', 'The all enrolled set will include all successfully screened subjects in the study- The total', 'enrolled cohort will include all subjects enrolled in the study.', 'Section 9.3.3 Full Analysis Set', 'The Full Analysis Set (FAS) will include all enrolled patients except for those who', 'discontinued the study during Visit 1.', 'Study objectives will be assessed on the FAS. The population set for each analysis will', 'change according to the subjects evaluable for the specific endpoint.', 'The PP cohort will include all evaluable subjects (i.e. those meeting all eligibility criteria', 'and complying with procedures described in the protocol) who did not receive a', 'concomitant medication/ vaccination leading to elimination from the PP cohort.', 'Missed study visits and intervals between study visits will not be considered as criteria', 'for exclusion from the PP cohort.', 'Note: Subjects using antibiotics on a continual basis (defined as more than 1 month in', 'total) will be allowed to continue study participation, but may be eliminated from the per', 'protocol (PP) cohort-analyses.', '19-OCT-2018', '111', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
111,page_112,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 9.4 Analysis of demographics', 'Withdrawal status will be summarised according to the reason for withdrawal. The', 'number of withdrawn patients will be tabulated by study visit and overall.', 'Withdrawal status will be summarised using descriptive statistics:', 'The numbers of withdrawn subjects will be tabulated according to the reason for', 'withdrawal.', 'The number of subjects enrolled into the study as well as the number of subjects', 'excluded from PP analyses will be tabulated.', 'Section 12 References', 'M.R. Miller, J. Hankinson, V. Brusasco et al. Standardisation of spirometry. Eur Respir', 'J. 2005;26:319 38. Series ""ATS/ERS task force: standardisation of lung function', 'testing"".', '19-OCT-2018', '112', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
112,page_113,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'GlaxoSmithKline Biologicals', 'Vaccine Value & Health Science (VVHS)', 'Protocol Amendment 3', 'eTrack study number', '201112 (EPI-NTHI-001 BOD APA)', 'and Abbreviated Title', 'Amendment number:', 'Amendment 3', 'Amendment date:', '19 October 2018', 'PPD', 'Co-ordinating author:', 'Scientific Writer', 'Rationale/background for changes:', 'Removal of all STGG (Skim Milk-Tryptone-Glucose-Glycerol) wording', 'throughout the protocol. STGG product not being available, it has been decided', 'to replace it with cryobeads for storage of bacterial isolates. PCR testing on', 'samples stored in cryobeads was shown to be as efficient as for samples stored in', 'STGG. Besides, this decision has been taken for alignment with other COPD', 'studies, where STGG solutions are no longer used.', 'Clarification of technique used for target identification. For the primary endpoint,', 'various viral pathogens will be identified but not quantified. Along this line, the', 'wording ""and by HRV quantitative RT-PCR"" has been removed from primary', 'endpoint to avoid confusion as HRV viral load data will be reported as part of the', 'tertiary endpoints.', 'Clarification in exclusion criteria section (4.3). Administration of antibiotics', 'before study entry, where study entry is meant to be Visit 1.', 'Clarification in study procedure section (6.3) and in the section for recording', 'current medication (6.4.2.10) during scheduled visits, where it has been specified', 'that recording of any current medication is applicable for any disease not only', 'COPD-related. Moreover, a footnote referring to Table 10 ""Reporting period for', 'SAE and AEs leading to withdrawal"" has been added for further clarification,', 'both in Table 4 and 5.', 'Addition of a section (actual 6.4.2.6) for Pregnancy test for Visit 1, Visit 2 and', 'Visit 3. A Pregnancy test section for Screening Visit was included during', 'Protocol Amendment 1: to be consistent, same wording has been included for the', 'subsequent visits.', '19-OCT-2018', '113', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
113,page_114,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Clarification of reporting of severe AECOPDs. Two sentences have been added', 'in sections 7.1.1 and 7.2.2.1 for making clear that severe AECOPD events are not', 'to be reported as SAE as they are meant as disease-related outcomes.', 'Rewording in the table concerning reporting period for SAE and AEs leading to', 'withdrawal for better clarification (Table 10).', 'Addition of a new outsourced laboratory (DDL).', 'To correct some typographical errors.', 'Amended text has been included in bold italics and deleted text in strikethrough in the', 'following sections:', 'List of Abbreviations', 'STGG', 'Skim Milk Tryptone Glucose Glycerol', 'Section 4.3 Exclusion criteria for enrolment', 'Administration of antibiotics within 1 month of study entry OR continuous', 'administration of antibiotics (defined as more than 30 days in total) within 90 days', 'before study entry.', '* Study entry is Visit 1. If this exclusion criteria is met during Screening Visit the', 'patient can enter the study and this exclusion criteria will be reassessed during Visit', '1.', '19-OCT-2018', '114', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
114,page_115,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.3 Outline of study procedures', 'Table 4 List of study procedures for scheduled visits', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Informed consenta', 'Check inclusion/exclusion criteriaa', 'O', 'Record demographic data', 'Record medical history', 'Record history of AECOPD within the previous yearb', 'Record intercurrent comorbidities', 'O', 'Record history of pneumococcal and influenza', 'O', 'vaccination', 'Smoking exposure history (ATS-DLD-78A questionnaire)/', 'biomass exposure history (Biomass Exposure', 'O', 'questionnaire)', 'Smoking status', 'Physical examination including vital signsh', 'O', 'O', 'O', 'Urine Pregnancy Test', 'Measure/ record height and weightd', 'Pre- and post-bronchodilator spirometrye', 'Chest X-rayf', ""Record subject's COPD status (stable, recovered or not"", 'recovered)', 'Record current medication for COPD', 'Record healthcare resource utilisation', 'Record additional treatments prescribed by primary and', 'secondary care physicians', 'Train subject on use of electronic Diary Card and assign', 'O', 'O', 'electronic Diary Card to the subject', 'Return electronic Diary Card', 'O', 'Sputum samplingg', 'Blood samples for biomarkers', 'Record Adverse Events (AEs)* related to stud', 'participation', 'Record serious adverse events (SAEs)^ related to study', 'participation', 'Screening conclusion', 'Study conclusion', 'HRQOL questionnaires:', 'CAT', 'O', 'O', 'O', 'SGRQ-C', 'O', 'O', 'O', 'A Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'h Physical examination (Visit1-3) should be done only if necessary by the investigator or delegate.', '19-OCT-2018', '115', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
115,page_116,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 5 List of study procedures for AECOPD visits', 'Type of contact', 'AECOPD Visit', 'End of AECOPD phone call(s)', 'Time point', 'at least every 2 weeks as of', 'within 96 hours of onset', 'AECOPD visit until AECOPD', 'symptoms', 'has resolvedi', 'Record date of visit', 'Physical examination', 'Urine Pregnancy Test', 'Chest X-rays/pneumonia confirmationi', 'Confirm AECOPD and record its start date', 'Record current medication for AECOPD', 'Record healthcare resource utilisation', 'Record additional COPD treatments prescribed by', 'primary and secondary care physicians', 'Sputum samplingk', 'HRQOL questionnaire:', 'CAT', 'O', 'Record AECOPD severitym', '.', 'Record AECOPD end date', 'Record Adverse Events (AEs)*/ related to study', 'participation', 'Record serious adverse events (SAEs) related to', 'study participation', '^ Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'Section 6.4 Detailed description of study procedure', 'Sputucm sampling at sub-sections 6.4.1.14 - 6.4.2.15 - 6.4.3.9:', 'Remaining DTT-sputum will be aliquoted as such and/or further diluted in STGG. These', 'samples will be kept at - -70/80¬∞C until shipment to GSK or GSK designated lab for', 'testing.', 'Section 6.4.2.6 Pregnancy test', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to', 'any study procedure. Note: The urine pregnancy test must be performed even if the', 'subject is menstruating at the time of the study visit.', 'Section 6.4.2.10 Record current medication for COPD', 'At each study visit/contact, the investigator should question the subject about any', 'medications taken. administered for treatment of COPD.', 'All medications administered for treatment of COPD will be recorded in the eCRF.', '19-OCT-2018', '116', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']"
116,page_117,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.5.3 Laboratory assays', 'Table 8 Microbiology', 'Further bacterial pathogens identification', 'Viral pathogens identification', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution or', 'Central Laboratory Manual', 'semi-', 'GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', ""Investigator's institution"", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae', 'H. influenzae species', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'confirmation and when', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'possible Hi/NTHi', 'as differentiation', 'laboratory', 'plates', 'differentiation', 'PCR', 'Sample collection for', 'potential further', 'characterisation', 'Stored sputum', 'Respiratory bacterial', 'Multiplex PCR', 'Qualitative', 'GSK Biologicals', 'pathogens', 'and/ or quant', 'laboratory or', '(including H. influenzae,', 'itative', 'designated laboratory', 'S. pneumoniae,', 'M. catarrhalis, S. aureus and', 'P. aeruginosa,', 'Streptococcus pyogenes))', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex-PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'laboratory * or', 'parainfluenza virus,', 'designated laboratory', 'enterovirus/ HRV,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', 'Respiratory viral pathogens', 'RT-PCR', 'Quantitative', 'GSK Biologicals', '(such as HRV)', 'laboratory* or designated', 'laboratory', 'Stored frozen sputum samples (in DTT supplemented with skim milk, tryptone, glucose,', 'and glycerine [STGG] medium) might be collected when possible for potential assay', 'development validation purpose.', '19-OCT-2018', '117', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
117,page_118,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Synopsis Primary endpoints and Section 9.1.1 Primary endpoint', 'Occurrence of potential bacterial and viral pathogens in sputum of stable COPD', 'patients and during AECOPD, over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological methods, including (but not', 'necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii.', 'Viral pathogens, as identified by RT PCR, including (but not necessarily limited', 'to) RSV, parainfluenza virus, enterovirus/ Human Rhinovirus (HRV),', 'metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus-and', 'by HRV quantitative RT PCR.', 'Section 7.1.1 Definition of an adverse event', 'An AE is any untoward medical occurrence in a subject, temporally associated with the', 'use of a medicinal product, whether or not considered related to the medicinal product, or', 'temporally associated with a study procedure.', 'Examples of an AE include', 'Signs, symptoms, or the clinical sequelae of a suspected interaction.', 'Examples of an AE DO NOT include:', 'Medical or surgical procedures (e.g., endoscopy, appendectomy); the condition that', 'leads to the procedure is an AE.', 'Situations where an untoward medical occurrence did not occur (e.g., social and/or', 'convenience admission to a hospital, admission for routine examination).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Occurrence of a severe AECOPD, unless in the opinion of the Investigator this is', 'related to study procedure.', '19-OCT-2018', '118', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
118,page_119,"['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 7.2.1 Time periods for detecting and recording AEs and SAEs - Table 10', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month', 'M 0', 'M 6', 'M 12', 'Within 96', '0', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'related to', 'study', 'participation*', 'AEs/SAEs', 'leading to', 'withdrawal', 'from the', 'study', 'Section 7.2.2.1 Active questioning to detect SAEs', 'Each subject/ will be instructed to contact the investigator immediately should the subject', 'manifest any signs and symptoms (s)he perceives/ they perceive as serious. However, an', 'occurrence of severe AECOPD is not defined as an SAE and therefore does not need to', 'be reported as such, unless in the opinion of the Investigator this is related to a study', 'procedure.', 'Appendix A', 'Table 15 Outsourced Laboratories', 'Laboratory', 'Address', 'Q¬≤ Solutions Clinical Trials (US)', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Q¬≤ Solutions (Singapore)', 'Tan Tock Seng Hospital', 'Dept of Laboratory Medicine', 'Level 2, Podium Block', 'Tan Tock Seng Hospital', '11 Jalan Tan Tock Seng', 'Singapore 308433', 'DDL Diagnostic Laboratory B.V.', 'Fonteijnenburghlaan 7', 'Voorburg', 'Netherland', '19-OCT-2018', '119', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']"
